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Schizophrenia-Relevant DISC1 Interruption Alters Wnt Signaling and Cell Fate in 
Human iPSC-Derived Neurons 
 
Abstract 
 
The advent of human induced pluripotent stem cell (iPSC) technology has allowed for 
unprecedented investigation into the pathophysiology of human neurological and psychiatric 
diseases. Use of human iPSC-derived neural cells to study disease is complicated by the 
genetic heterogeneity of cell lines and diversity of differentiation protocols. Here, I address 
issues surrounding neuropsychiatric disease modeling with human iPSCs. 
Dozens of published protocols exist to differentiate iPSCs into forebrain neuronal 
cultures. Among the factors that distinguish these methods are: use of small molecules, 
monolayer vs. aggregate culture, choice of plating substrates, method of NPC isolation, and 
glial co-culture. Each of these factors is evaluated here, creating a resource that directly 
compares a variety of differentiation procedures. The most efficient and reproducible method 
was an embryoid aggregate differentiation protocol, including aggregate plating onto a Matrigel 
substrate, enzymatic neural rosette selection, and neuronal dissociation and plating onto 
Matrigel. 
This optimized protocol is used to model a schizophrenia-relevant mutation in human 
neural cells. Genetic and clinical association studies have identified disrupted-in-schizophrenia 
1 (DISC1) as a strong candidate risk gene for major mental illness. DISC1 was initially 
associated with mental illness upon the discovery that its coding sequence is interrupted by a 
balanced chr(1;11) translocation in a Scottish family, in which the translocation cosegregates 
with psychiatric disorders. I investigate the functional and biochemical consequences of DISC1 
interruption in human neurons using TALENs or CRISPR-Cas9 to introduce DISC1 frameshift 
mutations into iPSCs. I show that disease-relevant DISC1 targeting results in decreased DISC1 
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protein expression by nonsense-mediated decay, increases baseline Wnt signaling in neural 
progenitor cells, and causes a shift in neural cell fate. DISC1-dependent Wnt signaling and cell 
fate changes can be reversed by antagonizing the Wnt pathway during a critical window in 
neural progenitor development. These experiments suggest that DISC1-disruption increases 
Wnt signaling, which alters the balance and identity of neural progenitors, thereby subtly 
modifying cell fate. 
These studies evaluate the use of multiple differentiation procedures in neural disease 
modeling, shed light on the roles of DISC1 during human brain development, and further our 
understanding of the pathogenesis of major mental illness. 
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Chapter I. 
Introduction 
 
Modeling neurodevelopmental and neurodegenerative 
diseases using human iPSCs  
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Srikanth P, Young-Pearse TL. Stem cells on the brain: modeling neurodevelopmental and 
neurodegenerative diseases using human induced pluripotent stem cells. J Neurogenet. 2014 
Mar-Jun; 28(0): 5–29. PMID: 24628482 
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INTRODUCTION 
 The alleviation of human suffering through the prevention and treatment of disease is the 
ultimate goal of biomedical research. In order to target the causes of a particular disease, it is 
beneficial to first understand the molecular mechanisms that underlie the pathology. Studying 
diseases of the nervous system comes with certain unique challenges due to the complexity of 
the systems involved and the lack of accessibility of the human brain to direct observation. 
Recent advances in stem cell technology have allowed researchers to establish human induced 
pluripotent stem cell (hiPSC) lines from patients1-3 and direct the differentiation of these cells to 
various neuronal and glial fates of the nervous system. The hope is that these advancements 
will allow researchers to model neurological diseases at a cellular level in a dish, providing an 
opportunity to both study disease mechanisms and test therapeutic strategies in the cell types 
most affected in these diseases. 
 As these cells can be maintained and expanded in culture, human iPSCs provide a 
theoretically unlimited source of disease-relevant human cells for experimentation. Since the 
initial description of the technology, researchers in the field of neuroscience have established 
dozens of lines from patients with neurodegenerative and neurodevelopmental diseases, and 
have modified and expanded neuronal differentiation protocols used with embryonic stem cells 
(ESCs) to be used with iPSCs. Here, we review the progress in the field in modeling neurologic 
and psychiatric diseases, providing an overview of the lines created for different diseases and 
disorders, the cell fates examined for each, and the cell and molecular phenotypes observed. 
We highlight the challenges involved in studying phenotypes associated with different 
categories of genetic alterations, and the potential pitfalls in the interpretations of results 
obtained with hiPSC models. Finally, we discuss the possibilities for expanding the utility of 
hiPSCs through manipulations of the in vitro environment to generate more physiological 
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models of brain development and aging. As this review focuses on the analysis of stem cells, 
we will use the term “phenotype” to refer to specific assay outcomes such as gene expression, 
protein cleavage or phosphorylation, or electrophysiological measures, rather than organismal-
level observations. As such, each cell line may display an array of phenotypes that are either a 
direct result of the genetic lesion (i.e. a truncated protein resulting directly from a nonsense 
mutation) or are progressively more distantly related to the genetic lesion. We will refer to the 
former as “proximal” phenotypes, and the latter as “distal” phenotypes. Finally, we include three 
tables describing published patient-derived iPSC lines and protocols for differentiation to neural 
fates. While these were meant to be an all-inclusive resource for the community, the rapidly 
growing literature of the iPSC field makes this challenging. We apologize for any unintentional 
omissions in these tables. For additional information regarding iPSC usage, we direct the reader 
to reviews pertaining to the careful modeling of disease-associated genetic variants with stem 
cells4,5, direct induction as an alternative to iPSC generation6, drug screening using stem cells7, 
genomic variation between stem cell lines8, methods of iPSC derivation6,8, and the study of 
aging-related disorders using iPSCs9. 
EXAMINING EFFECTS OF GENETIC MUTATIONS AND MODIFIERS USING HUMAN IPSCS 
 The identification of genetic variants that predispose to disease is of tremendous 
importance when attempting to identify the molecular and cellular underpinnings of a 
pathological process. Genetic modifiers of various strengths and prevalence have been found 
for a variety of diseases (Fig 1.1a). Different strategies can be (and perhaps should be) used to 
model disease based upon each of these kinds of variants. The influence of genomic variants 
on cellular phenotypes in question depends on a number of factors, including: (1) the 
penetrance of the mutation/variant, (2) the proximity of the phenotype to be studied to the 
mutation of interest, and (3) the technical and biological reproducibility of the phenotype. For 
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Figure 1.1. Relationship of allele frequency, variant strength, and number of iPSC lines 
needed to study disease processes. (A) Distributions of disease-predisposing genetic 
variants and allele frequency. Nearly all identified rare variants that confer an increased 
disease risk are high in penetrance, such as autosomal dominant mutations causing early-
onset familial Parkinson’s disease (e.g. in SCNA), early-onset familial Alzheimer’s disease 
(e.g. in APP or PSEN1/2), or familial ALS (e.g. in SOD1). There also are low frequency 
variants, with lower penetrance than the aforementioned rare alleles, which greatly increase 
disease risk, such as LRRK2 mutation in Parkinson’s disease. Relatively common alleles 
have been identified that carry a substantially increased risk, such as the APOE ε4 allele, 
with an allelic odds ratio of ~4 for Alzheimer’s disease10. Many genome-wide association 
study (GWAS)-identified loci mark common variants of weak effect, as is the case for most 
SNPs associated with neuropsychiatric disease. Finally, there almost certainly exist rarer 
variants than those currently known, which confer a small increase in disease risk. However, 
current methods are unable to discern such genetic variants due to lack of statistical power. 
(B) Estimate of the number of disease and control-derived iPSC lines needed to attribute a 
phenotype to the genotype under examination. For strong genetic variants with high 
increased disease risk and penetrance, fewer lines will generally be needed. Similarly, when 
analyzing phenotypes that are closer functionally to the genetic alteration of interest, fewer 
lines will be required. The graph above relays an estimate of how the variables of variant 
strength and phenotypic ‘distance’ might combine to achieve statistically significant results, 
based upon published studies. Example phenotypes listed pertain to the study of a familial 
Alzheimer’s disease mutation, i.e. APP mutation. 
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 these reasons, the widespread genetic variation that exists between iPSC lines derived from 
unrelated individuals is likely to affect analyses of weaker disease-predisposing mutations and 
phenotypes more distant from the mutation. Thus, when studying genetic variants that only 
mildly increase disease risk or phenotypes far removed from the genetic alteration, it is 
especially important to control for other genetic variation. Using genetically related, unaffected 
family-derived control lines would lessen genomic variability, but this is ideally done using gene 
correction methods (outlined below). On the other hand, rare but highly penetrant variants may 
be capable of recapitulating disease phenotypes even in the presence of other genomic 
variation, especially when examining phenotypes proximal to the disease-causing mutation. 
 For example, fully penetrant mutations have been identified that cause early-onset familial 
Alzheimer’s disease (fAD). Hundreds of such mutations have been identified in Amyloid 
Precursor Protein (APP) and Presenilin 1 or 2 (PSEN1/2) (reviewed here10). APP encodes the 
precursor protein for β-amyloid (Aβ), and presenilins encode the active site of the enzyme that 
cleaves APP to generate Aβ of differing lengths. An example of a so-called “proximal” 
phenotype to these mutations would be the generation of different lengths of Aβ. Based upon 
pathological findings in fAD patients and animal models, progressively more “distal” phenotypes 
may include tau phosphorylation, gliosis, neuritic dystrophy, synaptic failure, and ultimately, cell 
death. Alzheimer’s disease genetics also provide an example of a relatively common allelic 
variant of strong effect. The APOE ε4 allele increases risk for AD 3-12 fold, depending on allele 
dosage, and is present in ~15% of subjects of European ancestry11,12. A proximal phenotype of 
APOE allelic variation may be expression, secretion, or cholesterol-binding abilities of APOE 
variants, while more distal phenotypes may overlap with those of APP and PSEN mutations. In 
order to achieve sufficient statistical power using iPSC modeling, the number of lines required 
for analysis would vary based upon these variables of penetrance/strength of genetic variant 
and the proximity of the phenotype to the genetic alteration (schematized in Fig 1.1b). 
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 Investigating the proximal effects of strong genetic variants in neurological disease are the 
“low hanging fruit” that most iPSC studies published to date have presented. Many of these 
have confirmed the findings from animal models, heterologous cell lines (such as CHO, HEK, 
HELA, and others) and postmortem studies (see Tables 1.1 and 1.2). While it is valuable to re-
examine these phenotypes in living human neuronal and glial cells, it will be important to 
examine additional phenotypes that may or may not be specific to cell type, and identify sites of 
convergence of multiple predisposing genetic variants (Fig 1.2). However, other genetic loci are 
more likely to impact these phenotypes the further removed they are from the mutation of 
interest, which underlies the predicted requirement for increased numbers of iPSC lines to study 
such phenotypes (Fig 1.1b). Known genetic variants can be modeled with “isogenic” cell lines, 
where a patient-derived iPSC line has been gene-corrected (e.g. using zinc-finger nucleases 
[ZFNs], transcription-activator-like effector nucleases [TALENs], clustered regularly interspaced 
short palindromic repeat [CRISPR]-Cas9, or other methods), reverting a mutant line to the wild-
type genotype or vice-versa. It may be more desirable to correct a mutant line than to induce 
mutation in a wild-type line, as beginning with an iPSC line from a patient manifesting disease 
ensures that the genetic background is permissive to disease progression in the presence of the 
mutation in question. 
 The recent expansion of gene-editing nuclease technologies has greatly enhanced the 
possibilities for genomic editing in iPSCs. TALENs and ZFNs are similar in action, in that they 
both involve a custom DNA binding domain conjugated to FokI nuclease, which induces a DNA 
break upon dimerization with another FokI nuclease within a certain spacer distance. The 
identification of a simple DNA recognition “code” for TALENs has made TALEN design far 
simpler and more predictable than ZFN design, which was largely based on testing many 
nucleases for activity at the target site86. For all cleavage-based methods, DNA-binding and 
cleavage specificity is a concern, as off-target mutations may induce aberrant phenotypes or
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Table 1.1. Human iPS cell lines created to study neurodegenerative diseases 
This table outlines published studies that generated novel hiPSC lines to study a subset of 
neurodegenerative diseases. The number of lines listed indicates the number of distinct 
subjects from whom iPSC lines were derived (i.e. “1x” may represent a single line or multiple 
clonal lines derived from a single subject). All mutations are heterozygous unless otherwise 
indicated (het: heterozygous, homo: homozygous). The differentiated cell types are listed as 
identified in the original paper. A-T: ataxia telangiectasia, AD: Alzheimer’s disease, ALS: 
amyotrophic lateral sclerosis, ER: endoplasmic reticulum, FA: Friedreich’s ataxia, FD: familial 
dysautonomia, FTD: frontotemporal dementia, HD: Huntington’s disease, MMR: mismatch 
repair, NCL: neuronal ceroid lipofuscinosis, ND: no data, NMJ: neuromuscular junction, NPC: 
neural progenitor cell, PD: Parkinson’s disease, ROS: reactive oxygen species, RP: retinitis 
pigmentosa, RPE: retinal pigment epithelium, SMA: spinal muscular atrophy, TH: tyrosine 
hydroxylase, wt: wild-type. 
 
Year 
Novel iPSC lines 
generated (# of subjects 
per genotype/phenotype) 
Differentiated 
cell type(s) 
identified and 
analyzed 
Phenotypes described Reference 
Alzheimer's disease 
2011 1x PSEN1 A246E, 1x PSEN2 N141I Neurons Aβ generation 13 
2012 2x sporadic AD, 2x APP duplication, 1x wt 
Neurons, co-
culture with 
astrocytes 
Aβ generation, Tau 
phosphorylation, GSK3b 
phosphorylation, endosome 
size 
14 
2013 
1x APP homo E693Δ, 1x 
APP V717L, 2x sporadic AD, 
3x wt 
Cortical neurons 
Aβ generation, localization, 
and oligomerization state, 
levels of cellular stress  
15 
2014 2x APP V717I Cortical neurons 
Aβ and sAPPα/β generation, 
APP & Tau levels, Tau 
phosphorylation, APP early 
endosomal localization 
16 
Amyotrophic lateral sclerosis 
2008 2x SOD1 L144F Motor neurons and astrocytes ND 17 
2010 16x idiopathic ALS, 10x wt 
Cortical neurons, 
motor neurons, 
co-cultured with 
astrocytes 
TDP-43 aggregation 18 
2011 4x VAPB P56S, 3x wt Motor neurons VAPB protein levels, VAPB aggregates 19 
2012 1x TARDBP M337V, 2x wt Motor neurons TDP-43 protein levels, cell death 20 
2013 
4x C9ORF72 GGGGCC 
expansion (3x ALS, 1x 
ALS/FTLD, 1x >70, 3x >800 
repeats), 4x wt 
Motor neurons 
C9ORF72 GGGGCC repeat 
stability, C9ORF72 
expression, RNA foci, RNA 
binding protein 
sequestration, gene 
expression, motor neuron 
survival 
21 
Table 1.1 (Continued) 
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2013 
4x C9ORF72 GGGGCC 
expansion (1x >620, 2x 
>850, 1x >1150 repeats), 2x 
SOD1 A4V, 2x SOD1 D90A, 
5x wt 
Motor neurons 
C9ORF72 expression, 
C9ORF72 GGGGCC repeat 
stability, RNA foci, gene 
expression, RNA binding 
protein sequestration, 
C9ORF72 RAN translation, 
excitotoxicity 
22 
Ataxia telangiectasia 
2012 
1x ATM het, 1x ATM homo 
(ATM c.7004delCA and/or 
ATM c.7886delTATTA) 
Neurons 
Radiation-induced signaling, 
radiosensitivity, DNA 
damage signaling pathways, 
mitochondrial and pentose 
phosphate pathways 
23 
2013 
1x ATM homo c.103C>T, 1x 
ATM compound het 
c.967A>G;c.3802delG, 1x wt 
NPCs and 
neurons 
Activation of ATM activity, 
DNA repair, mitochondrial 
function 
24 
Best vitelliform macular dystrophy   
2013 1x BEST1 A146K, 1x BEST1 N296H, 2x wt 
RPE, co-cultured 
with 
photoreceptor 
outer segments 
Fluid flux, rhodopsin 
degradation, stimulated 
calcium responses, oxidative 
stress measures 
25 
Familial dysautonomia 
2009 3x IKBKAP homo c.2507+6T>C, 1x wt 
Neural crest, 
NPCs IKBKAP splicing, cell motility 26 
Friedreich’s ataxia 
2010 2x FXN homo GAA (330;380 and 541;420) 
No neurons 
created 
Global gene expression, 
FXN expression, FXN GAA 
repeat instability, MMR 
enzyme expression and 
localization to FXN gene 
27 
2011 
2x FXN homo GAA 
expansion (527;1058 and 
751;1027) 
Neurons, neural 
crest, peripheral 
sensory neurons, 
cardiomyocytes 
FXN expression, FXN GAA 
repeat instability 28 
2013 
2x FXN homo GAA 
expansion (800;600 and 
900;400), 2x wt (<20 FXN 
GAA) 
Neurons, 
cardiomyocytes 
FXN expression, FXN GAA 
repeat stability, morphology, 
viability, electrophysiological 
properties, mitochondrial 
structure and membrane 
potential, MMR enzyme 
levels 
29 
2013 
2x FXN homo GAA 
expansion (500;750 and 
580;620) 
Neural crest, 
peripheral 
sensory neurons  
FXN expression 30 
Frontotemporal dementia 
2012 1x FTD sporadic, 1x GRN S116X, 1x wt 
Neurons (majority 
glutamatergic, 
some 
GABAergic) 
GRN/PGRN expression, 
sensitivity to cellular stress, 
S6K2 expression 
31 
Table 1.1 (Continued) 
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2013 2x C9ORF72 >1,000 GGGGCC 
Neurons (majority 
glutamatergic, 
some 
GABAergic), 
some astrocytes 
C9ORF72 expression, 
C9ORF72 GGGGCC repeat 
stability, RNA foci, RNA 
binding protein 
sequestration, C9ORF72 
RAN translation, viability in 
response to inhibitors of 
autophagy 
32 
Gaucher's disease 
2013 
1x GBA1 compound het 
L444P;G202R (acute 
neuronopathic [type 2] 
Gaucher's disease) 
Dopaminergic 
neurons, 
macrophages 
Acid-β-glucosidase activity 33 
Gyrate atrophy 
2011 1x OAT homo A226V RPE OAT activity 34 
Hereditary spastic paraplegia 
2013 1x SPAST c.683-1G>T, ≥1x wt 
Telencephalic 
glutamatergic 
neurons 
Axonal swellings, 
mitochondrial transport, 
spastin protein levels, tubulin 
acetylation 
35 
Huntington's disease 
2012 
3x HTT CAG expansion 
(180;18, 109;19, 60;18), 3x 
wt (HTT 33;18, 28;21, 21;17 
CAG). 
NPCs, forebrain 
neurons, striatal 
neurons  
Adhesion, cytoskeletal 
properties, 
electrophysiological activity, 
gene expression profiles, 
ATP levels, susceptibility to 
glutamate toxicity and other 
stressors 
36 
2012 
1x HTT 73;19 CAG 
expansion, corrected to HTT 
21;20 CAG 
NPCs, striatal 
neurons  
Gene expression, cell death 
following growth factor 
withdrawal, mitochondrial 
bioenergetics, xenografting 
into striatum 
37 
2012 
2x HTT  CAG expansion 
(50;ND, 109;ND CAG), 1x wt 
(HTT 28;ND CAG) 
Neurons, 
astrocytes 
Clear cytoplasmic vacuole 
formation 38 
2012 
3x HTT CAG expansion 
(42;44, 39;42, 17;45), 2x wt 
(HTT 15;17, 15;18 CAG) 
Neurons Lysosomal activity 39 
Neuronal ceroid lipofuscinosis 
2013 
2x CLN2 compound het 
c.509-1G>C;R208X (late-
infantile NCL), 3x CLN3 
homo 1.02 kb del (juvenile 
NCL), 1x CLN3 compound 
het c.1056+3 A>C;D416G 
(juvenile NCL), 1x CLN3 het 
1.02 kb del, 1x wt 
NPCs, neurons Organelle morphology, lysosomal storage material 40 
Table 1.1 (Continued) 
 10 
Niemann-Pick type C1 disease 
2013 1x NPC1 compound het c.1628delC;E612D, 1x wt NPCs, neurons 
Electrophysiological 
properties, cholesterol 
accumulation 
41 
Parkinson's disease 
2009 5x idiopathic PD, 3x non-PD Dopaminergic neurons ND 42 
2011 1x LRRK2 homo G2019S, 1x wt 
Dopaminergic 
neurons and 
other midbrain 
neuronal types 
α-synuclein accumulation, 
measures of oxidative 
stress, cell death in 
response to stressors 
43  
2011 2x PINK1 homo Q456X, 1x PINK1 homo V170G, 1x wt  
Dopaminergic 
neurons  
Stress-induced Parkin 
mitochondrial translocation, 
mitochondrial copy number, 
and PGC-1a expression 
44 
2011 1x SCNA A53T with gene correction  
Dopaminergic 
neurons  ND 45 
2011 1x SCNA triplication, 1x wt Dopaminergic neurons 
Expression of a-synuclein 
and other triplicated genes 46 
2011 1x SCNA triplication, 1x wt Dopaminergic neurons 
a-synuclein expression, 
oxidative stress, peroxide-
induced cell death 
47 
2012 7x idiopathic PD, 4x LRRK2 G2019S, 4x wt 
Ventral midbrain 
dopaminergic 
neurons  
a-synuclein accumulation, 
cell death, autophagy 48  
2012 
2x PINK1 homo Q456X, 1x 
LRRK2 homo G2019S, 2x 
LRRK2 R1441C, 2x wt 
Neurons, 
dopaminergic 
neurons 
Response to stressors as 
measured by, mitochondrial 
respiration, proton leakage, 
mitochondrial mobility 
49 
2012 1x PARK2 homo ex2-4 del, 1x PARK2 homo ex6-7 del 
Dopaminergic 
neurons  
Oxidative stress, 
mitochondrial morphology 
and homeostasis, changes 
in Nrf2 pathway, a-synuclein 
accumulation 
50  
2012 1x LRRK2 G2019S with gene correction NPCs, neurons 
LRRK2 activity, nuclear 
morphology, susceptibility to 
proteosomal stress, 
neuronal differentiation 
51  
2013 2x LRRK2 G2019S with gene correction, 4x wt 
Dopaminergic 
neurons 
Neurite outgrowth, cell death 
in response to certain toxins, 
tau and a-synuclein 
expression 
52  
2013 1x LRRK2 homo G2019S, 1x wt 
Dopaminergic 
neurons  
Mitochondrial morphology, 
ATP levels, mitochondrial 
ROS generation, lysosomal 
activity 
53 
2013 3x LRRK2 G2019S with gene correction, 1x wt 
NPCs, 
dopaminergic 
neurons 
Mitochondrial DNA damage  54 
2013 1x PINK1 homo Q456X, 1x PARK2 homo c.1072delT, 
Dopaminergic 
neurons, 
Age-associated markers, 
dendritic length, gene 55 
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1x PARK2 R275W, 2x wt fibroblasts expression, xenografting into 
striatum, cell death, 
neuromelanin accumulation, 
mitochondrial size & ROS, 
Lewy body-precursor 
inclusions 
Retinitis pigmentosa 
2011 
1x RP1 c.2161insC, 2x RP9 
H137L, 1x PRPH2 W316G, 
1x RHO G188R 
Rod 
photoreceptor 
cells 
Cell degeneration, oxidative 
stress, ER stress, response 
to antioxidants 
56 
2011 
 1x MAK homo ex 9 353bp 
Alu repeat ins, 1x non-MAK 
RP 
Postmitotic retinal 
cells MAK expression 57 
2012 1x RHO G188R 
Rod 
photoreceptor 
cells 
RHO protein distribution, ER 
stress, cell degeneration 58 
Spinal muscular atrophy 
2012 
2x type I SMA (1x homo 
SMN1 del, 1x unknown 
genotype) with targeted 
conversion of SMN2 to 
SMN1, 1x SMN1 het del, 1x 
wt 
Spinal motor 
neurons, co-
cultured with 
myotubes 
Motor neuron number and 
size, axon length, endplate 
size and number (NMJ) 
when co-cultured with 
myotubes, number of 
nuclear gems, xenografting 
into spinal cord 
59 
Tauopathy 
2013 
1x MAPT A152T with gene 
correction to wt or MAPT 
homo A152T 
Neurons 
Tau fragmentation, 
phosphorylation, axonal 
degeneration, cell death 
60 
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Table 1.2. Human iPS cell lines created to study neurodevelopmental and 
neuropsychiatric diseases 
This table outlines published studies that generated novel hiPSC lines to study a subset of 
neurodevelopmental and neuropsychiatric disorders. The number of lines listed indicates the 
number of distinct subjects from whom iPSC lines were derived (i.e. “1x” may represent a single 
line or multiple clonal lines derived from a single subject). All mutations are heterozygous unless 
otherwise indicated (het: heterozygous, homo: homozygous). The differentiated cell types are 
listed as identified in the original paper. AS: Angelman’s syndrome, F: female, FXS: fragile X 
syndrome, ND: no data, NPC: neural progenitor cell, pre-FXS: FMR1 premutation carrier, M: 
male, PWS: Prader-Willi syndrome, RG: radial glia, ROS: reactive oxygen species, SCZ: 
schizophrenia, SCZoid: schizoid, sE/IPSCs: spontaneous excitatory/inhibitory post-synaptic 
currents, wt: wild-type. 
 
Year 
Novel iPSC lines 
generated (# of subjects 
per genotype/phenotype) 
Differentiated 
cell type(s) 
identified and 
analyzed 
Phenotypes described Reference 
Angelman/Prader-Willi syndromes 
2010 
2x AS maternal 15q11-13 
del, 1x PWS paternal 15q11-
13 del, 1x wt 
Neurons, 
astrocytes 
Methylation imprint, UBE3A 
and UBE3A-ATS 
expression 
61 
Dravet syndrome 
2013 1x SCN1A c.IVS14+3A>T, 1x SCN1A Y325X, 3x wt 
Forebrain neurons 
(primarily 
GABAergic) 
SCN1A expression, sodium 
current density, various 
electrophysiological 
measures of excitability 
62 
2013 1x SCN1A F1415I, 1x SCN1A Q1923R, 1x wt 
Primarily 
glutamatergic 
neurons, some 
GABAergic; co-
cultured with 
astrocytes 
Various 
electrophysiological 
measures of excitability 
63 
2013 1x SCN1A R1645X GABAergic neurons  
SCN1A expression, various 
electrophysiological 
measures of excitability 
64 
Fragile X syndrome 
2010 3x FXS (FMR1 >200 CGG), 2x wt 
No neurons 
created 
CpG methlyation in the 
FMR1 promoter region, 
FMR1 expression 
65 
2011 
3x FXS (FMR1 > 200 CGG, 
1x FMR1 142 CGG derived 
from mosaic FXS patient), 
1x wt 
NPCs, neurons 
CpG methlyation in the 
FMR1 promoter region, 
FMR1 expression, neuronal 
differentiation 
66 
Table 1.2 (Continued) 
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2012 
1x pre-FXS (F) with 
derivation of isoautosomal 
lines containing either FMR1 
94 CGG- or FMR1 30 CGG-
active chrX 
Neurons, 
astrocytes 
FMR1 mRNA expression, 
PSD95 expression, 
synaptic density, neurite 
length, spontaneous Ca++ 
transient frequency and 
amplitude, altered response 
to glutamate uptake 
67 
Lesch-Nyhan syndrome    
2013 
1x HPRT1 -/Y (M), 1x 
HPRT1 +/- (F) with 
derivation of isoautosomal 
lines containing either wt- or 
mutation-active chrX (both M 
& F lines: complex HPRT1 
rearrangement involving 
ex6-9 inv & del), 1x wt (M), 
1x wt (F) 
Neurons 
HGPRT activity, X-
inactivation status, 
neuronal differentiation, 
neurite length 
68 
Phelan-McDermid syndrome 
2013 2x 22q13 del (1x 825 kb del, 1x 871 kb del) 
Mature forebrain 
neurons 
SHANK3 expression, action 
potential characteristics, 
sE/IPSCs, presence of 
structural and functional 
synapses 
69 
Microcephaly    
2013 1x CDK5RAP2 compound het E1516X;R1558X 
Cerebral 
organoids 
Neuroepithelial and 
progenitor region sizes, 
neuronal outgrowth, RG 
and neuronal number, 
neurogenic divisions, RG 
spindle orientation 
70 
Rett syndrome 
2009 1x MeCP2 R306C (F) No neurons created ND 71 
2010 
1x MeCP2 T158M (F), 1x 
MeCP2 Q244X (F), 1x 
MeCP2 R306C (F), 1x 
MeCP2 c.1155del32 (F), 3x 
wt (M), 2x wt (F) 
Neurons 
MeCP2 expression, X-
inactivation, glutamatergic 
synapse number, spine 
density, soma size, Ca2+ 
oscillations, sE/IPSP 
frequency 
72 
2011 
1x MeCP2 ex3-4 del (F), 
isoautosomal lines with 
either wt- or mutation-active 
chrX 
Neurons 
MeCP2 RNA and protein 
expression, soma size, X-
inactivation 
73 
2011 
1x CDKL5 T288I (M), 1x 
CDKL5 Q347X (F) with 
isoautosomal lines with 
either wt- or mutation-active 
chrX 
Neurons X-inactivation 74 
2011 
1x MeCP2 T158M (F), 1x 
MeCP2 Q244X (F), 1x 
MeCP2 R306C (F), 1x 
MeCP2 X487W (F), 1x 
Neurons X-inactivation, neuronal maturation  75 
Table 1.2 (Continued) 
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MeCP2 c.705delG, 
isoautosomal lines with 
either wt- or mutation-active 
chrX 
2011 
1x MeCP2 T158M (F), 1x 
MeCP2 V247X (F), 1x 
MeCP2 R306C (F), 1x 
MeCP2 R294X (F), 
isoautosomal lines with 
either wt- or mutation-active 
chrX 
Neurons Nuclear size, X-inactivation 76 
Schizophrenia 
2011, 
2014 
2x SCZ, 1x major 
depression (DISC1 
c.2420_2423del) with gene 
correction of 2 lines, 2x wt, 
2x wt edited to DISC1 
c.2420_2423del mutation 
Glutamatergic 
forebrain neurons 
DISC1 expression, synaptic 
puncta density, 
spontaneous synaptic 
current amplitude & 
frequency, vesicle release, 
presynaptic protein 
expression levels 
77,78 
2011 
1x childhood onset-SCZ, 2x 
SCZ/SCZoid, 1x SCZ-
affective, 5x wt 
NPCs, neurons 
Connectivity, neurite 
number, PSD95 and 
glutamate receptor levels 
79 
2011 
1x SCZ 22q11.2 del, 1x 
childhood-onset SCZ, 1x 
SCZ, 2x wt 
Glutamatergic 
neurons ND 80 
2012 4x SCZ, 4x wt No neurons created ND 81 
2012 1x SCZ, 1x wt NPCs 
Extramitochondrial oxygen 
consumption, ROS 
generation 
82 
2013 3x SCZ, 2x wt 
NPCs, 
glutamatergic 
neurons, 
dopaminergic 
neurons 
Differentiation capacity, cell 
area, neurite length & 
number, monoamine levels, 
mitochondrial distribution 
83 
2014 3x 15q11.2 del, 3x wt NPCs 
Neural rosette polarity, 
reversed with CYFIP 
expression 
84 
Timothy syndrome 
2011 2x CACNA1C c.1216G>A, 3x wt Cortical neurons 
Ca2+ signaling, activity-
dependent gene 
expression, cell fate and 
differentiation to lower 
cortical layer and callosal 
projection neurons 
85 
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Figure 1.2. Schematic of biological causes of observed phenotypes. Given the study of 
any particular mutation, several genuine phenotypes attributable to biological (rather than 
technical) causes may exist. This diagram depicts a subset of meaningful biological causes 
of phenotypes, which each should be considered when interpreting an observed phenotype. 
On the bottom from left to right: patients with a particular disease-causing mutation (mutation 
1, purple), those with a distinct disease-causing mutation (mutation 2, orange), others with 
sporadic disease (green), patients experiencing a disease process that encompasses the 
disease in question (blue), and finally unaffected individuals. Above, hypothetical phenotypes 
altered in iPSC-derived cells from the individual directly below are shown in boxes. In the 
given set of individuals, some phenotypes will be common among certain sets of iPSCs, 
whereas others will be unique. Combinations of lines with similar and distinct origins help to 
parse out how the phenotype relates to the mutation of interest (e.g. phenotypes b, d, h), the 
disease of interest (e.g. phenotype c), an overarching disease process (e.g. phenotype e), or 
that particular individual’s genetic background (e.g. all other phenotypes listed above). 
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even obscure true phenotypes resulting from mutation at the desired site. One proposed 
method to improve ZFN and TALEN specificity is to use a mutated FokI nuclease, making it an 
obligate heterodimer87-92. The obligate heterodimer approach ensures that FokI dimerization and 
nuclease activity can only occur if both the forward and reverse TALENs/ZFNs bind to 
neighboring sites. Other FokI mutations have been engineered to reduce toxicity, enhance 
nuclease activity, or restrict activity to single-stranded cutting (“nickases”)93-97. Fortunately, 
TALENs and ZFNs have not been found to induce off-target genomic mutations with 
appreciable frequency thus far45,89,98. The recently-discovered CRISPR-Cas9 system (an RNA-
guided nuclease) demonstrates higher genome editing efficiency than TALENs99, but also has 
increased potential for initiating off-target cleavage events100-103. Similar strategies to those used 
with ZFNs and TALENs have recently been employed to improve CRISPR-Cas9 specificity, by 
employing a mutant Cas9 “nickase,” which requires two guide RNA sites in close proximity to 
create a double-stranded DNA break101,102,104-106. Although there has been concern for off-target 
mutation events using CRISPR-Cas9 in screening-based systems, those studies that have 
examined CRISPR-Cas9 editing in human stem cells have found minimal evidence of off-target 
effects, reducing concern for widespread mutagenesis using this system4,5,107,108. The various 
nuclease activities, specificities, and target site requirements of each system should be 
examined before attempting genomic editing in hiPSCs. Additional information thoroughly 
outlining the advantages and disadvantages of ZFNs, TALENs, and CRISPR-Cas9 methods is 
provided in other reviews86,109,110. 
 In addition to the widespread genetic variability between lines from different individuals, it 
is also important to consider the impact of epigenetic variation on iPSC studies. The parental 
cell from which iPSCs are derived impacts the resulting epigenome, altering gene expression 
and potentially cellular functions111-113. This epigenetic “memory” can impact the study of certain 
disease loci, which may remain silenced after reprogramming61,65,67,68,73-76,114,115. The 
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reprogramming and differentiation processes can themselves affect genomic and epigenetic 
stability in ways that affect phenotypes of interest. A 2010 report showed that reprogramming 
iPSCs derived from patients with CGG repeat expansion in the FMR1 gene (causing fragile X 
syndrome, or FXS) fails to reactivate FMR1 expression65. This contrasted with results from FXS 
mutation ESCs, which did express the mutant FMR1 in the ESC state but silenced it during 
differentiation. Notably, iPSCs reprogrammed from FXS-ESC-derived differentiated cells also 
failed to rescue FMR1 expression, indicating that this disease-associated locus is resistant to 
reprogramming. 
 Furthermore, different groups have come to variable conclusions regarding repeat 
instability during reprogramming and differentiation of iPSCs from patients with repeat 
expansion disorders. In one study of Huntington’s disease, a repeat-expanded HTT line showed 
stable repeat numbers in fibroblasts, iPSCs, and iPSC-derived neurons, with occasional repeat 
contraction seen with increasing iPSC passage number (loss of 2 out of 44 repeats)39. A model 
of frontotemporal dementia (FTD) using C9ORF72 repeat expansion lines found differential 
repeat stability in iPSC reprogramming from fibroblasts of a single patient (≥200 repeat loss or 
no loss), as well as repeat contraction with neuronal differentiation32. Generation of iPSCs from 
Friedreich’s ataxia FXN GAA-repeat fibroblasts showed repeat expansion as well as 
contraction28. Finally, iPSCs derived from FXS patients showed FMR1 repeat instability during 
reprogramming in one study66 but relative repeat stability in two others65,67. The divergence 
between studies may arise due to various reasons that are both biological (e.g. differences 
between patient cells) or technical (e.g. differences in reprogramming or culture methods). 
Repeat instability may introduce artifactual genomic variation during iPSC culture, or could 
alternatively recapitulate mosaicism seen in certain disease states32,66,72. 
 The X inactivation status of reprogrammed female iPSCs and iPSC-derived differentiated 
cells introduces another layer of epigenetic variability. Lines derived from the same individual 
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may not be functionally “isogenic” if they each maintain a different inactivated X chromosome. 
X-inactivation is of particular importance when the disease-causing mutation occurs on a single 
X chromosome (e.g. MeCP2 mutation in Rett syndrome, FMR1 mutation in fragile X syndrome, 
HPRT mutation in Lesch-Nyhan syndrome). When modeling X-linked disorders with female 
iPSCs, the specific X chromosome that is inactivated is crucial for the presentation of a 
mutation-dependent phenotype, as only the mutant gene is expressed when one X 
chromosome is inactivated, and only the wild-type gene is expressed when the other is 
inactivated, drastically impacting resulting neuronal characteristics67,68,72-76,114,115. It is important 
to note that in any female iPSC lines, X-inactivation status can impact neuronal phenotypes, as 
several neuronal genes are present on the X chromosome, where significant allele-biased 
expression occurs during neuronal differentiation116. X-inactivation may thus have broad, though 
subtle, confounding effects on a variety of neuronal phenotypes in any model. This could 
potentially minimize a genuine disease-associated phenotype or lead to variable results from 
studies of the same mutation in different lines or labs, such as studies of the same autosomal 
mutation in a male- vs. a female-derived iPSC line. 
CHOOSING A CELL FATE: EXPLORING CELL TYPE-SPECIFIC PHENOTYPES 
 In addition to deriving cells from patients with mutations or diseases of interest, pluripotent 
stem cells are an exciting tool because of their ability to generate a multitude of cell types from 
an identical genetic background. This property of iPSCs provides an opportunity for 
investigating the nature and causes of selective cellular vulnerability seen in neurological 
diseases using human cells. Differentiating to distinct neuronal or glial subtypes may reveal 
phenotypes only in a subset of cell fates, and/or cell autonomous vs. non-autonomous 
phenotypes. A number of reports have investigated cell type-specificity of phenotypes in 
fibroblasts vs. iPSCs vs. differentiated cells20,26,43, but fewer have examined phenotypes across 
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distinct neuronal subtypes18,43,117. This underutilized power of iPSCs represents a missed 
opportunity (but potential future strength) to investigate the molecular mechanisms underlying 
selective vulnerability in neurological diseases. 
 The ability to make a specific cell fate is of particular interest in the study of diseases with 
well-characterized and limited affected cell populations. A 2011 paper utilized dopaminergic 
neuron-directed differentiation to study effects of the Parkinson’s disease-predisposing LRRK2 
G2019S mutation43. LRRK2 G2019S-homozygous dopaminergic (DA) neurons were more 
susceptible to H2O2-induced cell death than wild-type DA neurons. However, both wild-type and 
LRRK2 G2019S tyrosine hydroxylase (TH)-negative neurons were less susceptible to peroxide-
induced cell death than TH-positive neurons. LRRK2 G2019S DA neuron-enriched cultures also 
showed increased α-synuclein protein levels and increased expression of oxidative stress 
pathway genes (the latter phenotype seen in day 35, but not day 50 or 55, neurons). A 2010 
study examined cellular phenotypes of amyotrophic lateral sclerosis (ALS), a motor neuron 
disorder, in motor neurons from sporadic and familial ALS patient-derived iPSCs. Burkhardt, et 
al. reported TDP-43 aggregates in select sporadic ALS iPSC-derived motor neurons. These 
aggregates were less commonly found in other types of neurons in the same cultures (neurons 
lacking ISLET1/HB9 expression) and were absent in wild-type and SOD1-mutant iPSC-derived 
motor neurons18. Neural crest-directed differentiation was used by the Studer lab to investigate 
the molecular basis of familial dysautonomia, a fatal peripheral neuropathy, in IKBKAP-mutant 
iPSCs26. IKBKAP mutant iPSC-derived neural crest precursors (the progenitor cells of the 
peripheral nervous system) displayed abnormal IKBKAP splicing, decreased ASCL1 
expression, and reduced neuronal differentiation and migratory capacity. These studies and 
others (Tables 1.1 and 1.2) demonstrate the capacity of iPSC disease models to recapitulate 
cell-type specific phenotypes.  
 Cell-type-specific directed differentiation is of limited utility when studying diseases 
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without a clear fate-restricted cellular origin, as is the case with many developmental and 
neuropsychiatric diseases. In these instances, it may be possible to identify alterations present 
in broad groups of neurons (e.g. altered spine density), which may only noticeably affect specific 
circuits in vivo. In some cases, it is valuable to study specific neuronal subtypes in the context of 
a milieu of cell types. The differentiation protocols currently available produce cultures that are 
heterogeneous to variable extents, whether they contain a wide variety of neural cell types or 
cells of more fate-restricted neural lineages (Table 1.3). 
As alluded to above, the cellular context of the cells to be studied may significantly affect 
the phenotype of interest. For example, the presence of a pool of neural progenitor cells in a 
neuronal culture could mask disease-associated phenotypes by continuing to produce newborn 
neurons (discussed here5). This will particularly confound analyses of phenotypes that 
dramatically change over the course of neuronal maturation, such as neurite architecture, soma 
size, synaptic density, electrophysiological activity, and gene expression118-120, and could in 
theory conceal a cell death phenotype by replenishing viable neurons. Alternatively, some 
phenotypes may only be discernible in a heterogeneous culture. Non-cell autonomous effects 
have been carefully studied in models of ALS, which have revealed cytotoxicity of SOD1-mutant 
astrocytes on motor neurons117,121,122. The Eggan lab found that wild-type hESC-derived motor 
neurons displayed increased cell death when cultured with SOD1 G93A-overexpressing human 
astrocytes relative to wild-type astrocytes. Interestingly, SOD1 wt-overexpressing astrocytes did 
not cause motor neuron death, interneurons were not susceptible to SOD1 G93A astrocyte-
induced cytotoxicity, and SOD1 G93A-overexpressing fibroblasts did not induce motor neuron 
death117. In parallel, the Gage lab showed similar cytotoxic effects of SOD1 G37R- (but not wild-
type SOD1-) overexpressing human astrocytes on hESC-derived motor neurons, whereas 
GABAergic neurons were unaffected122. These studies highlight the importance of choice of cell 
type when studying a human disease process. The predicted pathogenic and/or affected cell 
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Table 1.3. Protocols for human ES or iPS cell differentiation 
Dozens of protocols have been published for the production of various types of neurons from 
human ESCs and iPSCs. As many hESC differentiation protocols have been successfully used 
in hiPSCs, protocols using both cell types are included here. Readers should refer to the papers 
listed for further information on the efficiency of directed differentiation to each cell fate listed. 
*For GABAergic neuron generation, only protocols that specifically direct differentiation to an 
inhibitory fate (rather than observation of inhibitory neuron generation) are listed. In contrast, 
studies that reported generation of astrocytes or oligodendrocytes are included whether they 
intentionally biased cells toward these cell fates, or if these cells were observed as a by-product 
of another differentiation method. 
**Protocols listed include studies that performed direct conversion of human somatic cells (non-
stem cells) to neurons. 
Cell type References 
Forebrain neuronal precursors or neurons 
 38,70,72,118,120,125,128-145 
Motor neuron precursors or neurons 125,132,133,135,137,139,146-152 
Dopaminergic neurons 130,132-135,138,139,143,153-165 
GABAergic neuronal precursors or neurons (enriched*) 136,166-170 
Medium spiny neurons 171-174 
Forebrain cholinergic neurons 175-177 
Serotonergic neurons 133 
Hippocampal neurons 178 
Hypothalamic neurons 179,180 
Caudal neurons 129,143 
Cerebellar neurons 181,182 
Astrocytes (observed or enriched*) 38,118,128,133,134,139,140,142,163,183-185 
Oligodendrocytes (observed or enriched*) 128,133,134,163,184-189 
Neural crest precursors or derivatives (including peripheral 
neurons, nociceptors, melanocytes, Schwann cells) 28,30,190-200 
Cranial placode derivatives 201 
Retinal cells 34,56,57,124,202-210 
Lineage reprogramming** 
Neural progenitors 211,212 
Mixed neurons or uncharacterized 213-219 
Glutamatergic neurons (predominantly) 220-223 
GABAergic neurons 222,224 
Dopaminergic neurons 225-228 
Motor neurons 152,229 
Medium spiny neurons 230 
Peripheral sensory neurons 231 
Cholinergic neurons 232 
Serotonergic neurons 233 
Astrocytes 234 
Oligodendrocytes or oligodendrocyte precursors 235 
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subtypes should be carefully evaluated when deciding what cell types will be used to interrogate 
disease-relevant processes. 
 The development of lineage reprogramming as a differentiation method has yielded a 
plethora of protocols with accelerated timescales and, depending on the protocol, relatively 
homogenous cell fates (Table 1.3). These methods employ forced expression of critical 
regulators of cell fate, driving differentiation toward specific cell types. Specific transcription 
factors and miRNA “cocktails” have been identified by multiple groups that enable direct 
reprogramming of human cells into multiple types of brain cells (Table 1.3). Interestingly, these 
methods can facilitate transdifferentiation, allowing use of multiple initial cell types to make 
neurons, including fibroblasts, pericytes, astrocytes, and adipocytes (Table 1.3, reviewed 
here25). In comparison to the embryoid-aggregate-based method, transdifferentiation protocols 
often result in cells that mature more quickly, and which may circumvent the protracted 
differentiation of aggregate-based methods. Lineage reprogramming can provide an opportunity 
to examine more mature neuronal fates, which may be more relevant to some disease 
processes. Increased culture homogeneity also reduces differentiation variability, which may 
reveal otherwise obscured subtle cell-type-specific effects of disease mutations. 
 While these “induced neurons” open many possibilities for screening and disease 
modeling, this approach has yet to be used to successfully identify disease-associated 
phenotypes in human neural cells. In addition, there are potential pitfalls of transdifferentiation 
methods related to the introduction of strong genetic drivers that bypass normal differentiation. 
As lineage-reprogrammed cells are directly converted to a final cell type, it may be difficult to 
study neurodevelopmental processes using these cells. A few protocols exist to directly convert 
cells to human neural progenitor cells (Table 1.3), which may allow study of particular neural 
progenitor cell subtypes. Overexpression of strong transcription factors or miRNAs could also 
mask effects of disease mutations by overpowering a subtle mutation-associated effect on cell 
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fate or gene expression. Furthermore, while the potential uniformity of resulting cultures 
presents an opportunity to study effects of disease-associated mutations in one cell type, this 
assumes prior knowledge that the particular cell type is implicated in disease pathophysiology. 
As previously discussed, the exact cell types affected by certain disease processes are 
unknown, making less biased and more “endogenous” differentiation methods an attractive way 
to examine neurodevelopment and to study multiple cell types simultaneously. 
 Studying selective neuronal vulnerability or cell fate-specific phenotypes is limited to 
those cell fates that can be generated using available protocols (Table 1.3). The breadth of 
neuronal and glial cell fate protocols is constantly expanding, and these are continually being 
improved to yield higher efficiencies at lower cost. However, this perpetual refinement of 
protocols also presents a challenge to researchers - how do we compare similar cell fates 
generated by distinct protocols? Differences in differentiation methods (e.g. use of small 
molecules or genes, monolayer vs. aggregate, small molecule/growth factor concentrations and 
sources, differentiation time, cell purification by MACS/FACS, lab environment) could 
considerably alter the population of resulting neurons. In addition, different iPSC lines have 
incredibly variable neuronal differentiation capacities74,113,117,123-127, which can complicate 
analyses of presumed neuronal differentiation-impairment resulting from mutation75,80,83. As a 
result, it is essential that as a research community we thoroughly characterize the cell 
populations we study (by gene expression studies, immunostaining, electrophysiological 
characterization, etc.) and maintain a high level of transparency in data reporting (recording 
number of lines used, number of differentiations, and number of cells/wells studied for each 
experiment). 
SPECIFICITY OF PHENOTYPE 
There are many factors that may contribute to the presence or absence of any particular 
  24 
phenotype in iPSC-derived cells. Technical variables can be a prominent source of phenotypic 
variation between iPSC lines or within one iPSC line used in multiple laboratories. Each step 
from somatic cell harvesting to phenotypic assay introduces multiple variables that may differ 
between lines, differentiation rounds, and labs. Included among the many technical variables 
are: somatic cell source and age at harvest, reprogramming method, iPSC culture conditions, 
differentiation method (including use of small molecules and exogenous transcripts and/or 
proteins), and phenotypic assay protocol. These factors can influence the epigenome and 
genome, potentially altering specific cellular phenotypes, including the capacity to differentiate 
to a particular cell lineage. Indeed, recent studies have shown that different iPSC lines each 
have their own propensities to differentiate to particular cell lineages (addressed above), 
although this can be partially overcome by modified protocols, such as extended iPSC 
passaging236, DMSO treatment prior to differentiation237, and FGF2 and/or dual SMAD inhibition 
during differentiation125,126. This is a vital concern when studying a potential phenotype of altered 
differentiation potential, and requires that multiple distinct lines and/or isogenic lines be used. 
 Of equal importance to technical variables are the biological causes of phenotypic 
variation between iPSC lines (Fig 1.2). These biologically-significant variable phenotypes can be 
grouped as follows: (1) a phenotype that is unique to cell lines from that particular person, (2) a 
phenotype specific for a mutation of interest, and (3) a phenotype of a pathological process. A 
person-specific phenotype would likely result from genomic or epigenomic variation other than 
the mutation of interest. In contrast, a phenotype could be a biological result of a certain 
mutation, but may not result from other mutations linked to the same disease. For example, the 
SOD1 G93A mutation causing ALS could result in a specific biochemical phenotype that does 
not occur with other ALS-causing mutations in SOD1 or ALS-causing mutations in other genes, 
such as TDP-43 or C9ORF72. Findings such as these reveal interesting aspects of the basic 
molecular and cell biology of the proteins implicated in disease, but may reduce the possibility 
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that the unique phenotype is absolutely required for disease pathogenesis. Finally, a phenotype 
may be characteristic of a specific disease, such as ALS, or a disease spectrum, such as 
neurodegeneration. 
 Although it would be time- and resource-intensive to tease out each of these possibilities 
in any one study, compilation of data from multiple studies can reveal patterns that indicate into 
which group a specific phenotype falls. Targeted strategies can be revealing, including using 
multiple iPSC lines with the same mutation, iPSC lines with different disease-causing mutations, 
and iPSCs derived from patients with sporadic disease. When possible, rescue experiments in 
which the suspected disease cause is corrected can demonstrate the dependence of an 
observed phenotype on a mutation or other characteristic. Complementary methods are also 
critical for determining the relevance of any iPSC-derived finding. This can include non-iPSC 
cell culture, postmortem human tissue studies, and animal models, each of which provide a 
distinct set of advantages and disadvantages when compared to iPSCs. For example, disease 
processes characterized by loss of a developmentally- and regionally-restricted cell type can be 
studied using xenografting of hiPSC-derived cells into rodent disease models, followed by 
examination for symptomatic alleviation. Examples of this sort have been carried out in the 
literature in the study of spinal muscular atrophy (SMA)59, Huntington’s disease37,238, 
Parkinson’s disease164, and congenital hypomyelination185. 
 One such report generated iPSCs from SMN1 mutation-homozygous SMA patients (SMA-
iPSCs) and gene-corrected one copy of the SMN2 gene to an SMN1-like sequence by single-
stranded oligonucleotide treatment (TR-iPSCs), enabling expression of a functional homolog of 
SMN1 from one SMN2 allele59. SMA-iPSC-derived, but not isogenic TR-iPSC-derived, spinal 
motor neurons displayed degenerative phenotypes in vitro. Corti, et al. subsequently 
transplanted SMA-iPSC- or TR-iPSC-derived motor neurons into SMA transgenic mice, and 
found that TR-neurons engrafted with higher efficiency than SMA-neurons, while both rescued 
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deficits in SMA transgenic mice in proportion to motor neuron engraftment59. These types of 
iPSC-based studies that incorporate non-iPSC methods will expand our knowledge of the 
characteristics and potential applications of iPSC-derived cells. 
LIMITATIONS OF THE DISH: BRINGING IN VITRO CLOSER TO IN VIVO 
 Although iPSCs are an exciting and appealing tool for studying the molecular and cellular 
phenotypes underlying human disease states, we must recognize the many caveats and 
limitations that accompany this method. As iPSCs are an in vitro system, they lack many of the 
characteristics of a developing and mature brain. The microenvironment of the developing brain 
cannot yet be fully recapitulated, but certainly affects the extracellular cues presented to 
differentiating cells. The lack of physically disparate regional identities also obfuscates area-
specific phenotypes. For example, it is difficult to study neuronal circuitry using iPSCs, 
particularly when investigating phenotypes unique to specific neuronal circuits of the adult brain. 
However, it may be possible to reproduce inter-regional cellular connections using co-culture of 
cells resulting from distinct directed differentiation methods. Adding to the challenge of 
recapitulating the endogenous nervous system, the cell types that can be made using iPSCs 
have intrinsic limitations. No matter the extent of characterization of gene expression, protein 
expression, morphology, and electrophysiology, it is nearly impossible to map an iPSC-derived 
cell to a corresponding in vivo cell fate. Although a cell may express a set of proteins and 
display firing characteristics of a layer V excitatory pyramidal neuron, it is impossible to know if 
this neuron is a faithful representation of a neuron that exists in vivo at any time over the life of a 
human. This theoretically insurmountable obstacle is minimized with detailed phenotypic 
examination of the cell types to be studied, but must always be acknowledged when interpreting 
data. 
 One strategy to bring more in vivo relevance to iPSC use is xenografting of iPSC-derived 
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neurons into the developing or mature rodent CNS environment. Transplantation has been 
utilized by several groups to characterize the differentiation and functional capacity of neural cell 
types resulting from differentiation38,119,120,143,163,164,166,167,169,170,173,182,185,188,239-242. In addition, a 
handful of studies have used xenografting of wild-type or gene-corrected iPSC-derived cells into 
disease-model rodent brains to observe resulting engraftment and behavioral 
rescue37,59,164,185,238. If would be of interest to extend these studies to examine cellular defects 
relating to processes such as neuronal migration and maturation, axon guidance, and synapse 
formation in mutant vs. wild-type iPSC-derived cells. 
 The developmental timeline of human stem cells in vitro is restrictive, as iPSC/ESC 
neuronal differentiation recapitulates early in vivo neurodevelopment, producing embryonic-like 
neurons that proceed through the neurodevelopmental stages of neural progenitor cell 
proliferation, neuronal migration, and neurite outgrowth and arborization70,131,144,169,170,243-247. 
However, using currently available methods, these cells lack many characteristics of adult 
neurons248, complicating the study of adult-onset diseases using stem cell-derived neurons. 
Human neurodevelopment continues for decades postnatally, with continuing changes in 
synapse number, myelination of axons, and neuronal maturation249-251. In contrast, hiPSC-
derived neurons used to study mechanisms of disease are often differentiated for anywhere 
from 14 to greater than 100 days118,135,139. These differentiation times fall far short of the delayed 
onset of symptoms that accompanies many neurological diseases studied with iPSCs (fragile X 
syndrome: neonatal 252, Rett syndrome: 6-18 months253,254, schizophrenia: 15-30 years255, 
Huntington’s disease: average ~40 years256,257, ALS: average ~60 years258,259, Parkinson’s 
disease: ≥ 60 years260, Alzheimer’s disease: ≥ 65 years261), calling into question whether cellular 
phenotypes of these disorders could be observed in vitro in a matter of weeks or months. The in 
vitro differentiation process is more relevant for neurodevelopmental and neuropsychiatric 
disorders, which are often hypothesized to stem (at least in part) from defects in early brain 
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development (Table 1.2)251,262-264. However, even late-onset neurological diseases can have 
early cellular endophenotypes that manifest before clinically-observed symptoms. For example, 
neurons derived from patients with late-onset disorders can reveal early mechanisms underlying 
disease pathophysiology prior to the development of overt pathology, such as altered gene 
expression and protein processing (Table 1.1). 
 While certain molecular phenotypes may be observable in neurons at early developmental 
stages, other downstream phenotypes may only be observed in fully-mature, “aged” neurons. 
To this end, a number of methods are currently being developed to accelerate the aging and 
maturation process of hiPSC-derived neurons. Xenografting stem cell-derived neurons into 
rodent brain stimulates neuronal maturation120,265, and could be used to ‘age‘ neurons prior to 
assaying for a phenotype of interest. In addition, neurons may be artificially aged in culture by 
presenting cells with exogenous stressors (see Table 1.1). Aging could also be accelerated by 
introducing mutations in genes implicated in cellular aging regulation, such as LMNA, which is 
mutated in the premature aging disorder Hutchinson-Gilford progeria syndrome (HGPS). HGPS 
iPSC-derived cells display premature senescence, dysmorphic nuclei, DNA damage, increased 
mitochondrial reactive oxygen species, and reduced telomere length, thus recapitulating 
aspects of accelerated cellular aging in vitro55,266,267. Such ‘aging’ mutations could theoretically 
be manipulated to hasten neuronal aging in culture. Indeed, a recent study was able to 
recapitulate aspects of neuronal aging in vitro by overexpressing progerin (the truncated 
transcript resulting from HGPS-associated LMNA mutations) in control and Parkinson’s disease 
(PD) iPS-derived cells. In this report, progerin-induced aging was able to reveal PD-specific 
phenotypes that were previously unobservable in wild-type and PD-derived neurons55. These 
strategies facilitate the study of late-onset disorders in vitro on a more practical timescale. 
 The ability to produce cerebral “organoids” presents the possibility of studying a disease 
phenotype in a specific cell type or group of cell fates in the context of a three-dimensional (3D) 
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model of human neurodevelopment 26. These organoids also facilitate the study of phenotypes 
which may only manifest in a 3D system, or which are easier to study in a 3D context, such as 
alterations in neural progenitor proliferation, neuronal migration, cortical layering, and axon 
guidance. While these processes can occur to varying extents in two-dimensional culture 
systems, they are likely more ordered and closer to their in vivo counterparts when occurring in 
3D. This is of interest especially when studying common neurodevelopmental and 
neuropsychiatric disorders, which often do not display striking neuroanatomical phenotypes, but 
are characterized by subtle perturbations in cortical organization27. Cerebral organoids do 
recapitulate some area-restricted neuronal identities (e.g. prefrontal lobe, hippocampal, and 
ventral cortical neuron marker expression), indicating the possibility of using organoids to study 
inter-regional phenotypes. No current method can exactly replicate the in vivo ratios of relevant 
cell fates, extra-cerebral influences on disease processes (e.g. immune cells, blood-brain 
barrier), or the 3D structure of neurodevelopment, preventing the study of human disease-
associated states in a precise human in vivo environment. However, further characterization of 
this recent technique compared to more traditional differentiation protocols and in vivo 
neurodevelopment will help identify those phenotypes that are better studied in this 3D 
environment. 
 Another approach to make in vitro systems more physiological involves tissue engineering 
to mimic in vivo structures “on a chip”. Microfluidic devices can be used to improve nutrient 
delivery and waste removal in tissues or cultures in vitro 28, simulate the blood-brain barrier268, 
model a neurovascular unit269, and manipulate neuronal connectivity270 or organization271. These 
devices could be used to characterize the behavior of iPSC-derived vs. rodent brain-derived 
neurons, as well as provide opportunities to investigate disease-associated phenotypic 
alterations that may not be accessible in traditional culture systems. Although these have yet to 
be widely used in the field, tissue engineering presents many exciting possible avenues for 
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future applications with iPSC-derived neurons272. 
CONCLUDING REMARKS 
 Since the first descriptions of human iPSC methodologies, hundreds of laboratories in 
academia and industry have adopted the technology for the study of neurological and 
psychiatric disorders. Lines from over one hundred patients with brain diseases have been 
published (Tables 1.1 and 1.2), but thousands more are in the process of being characterized. 
As the number of iPSC lines developed goes through exponential expansion, it is crucial that 
the iPSC community develop a standard format for sharing information about these 
lines. The format used should allow the information to be described using a consistent 
vocabulary and to be easily discovered online. There are already several repositories that share 
information on their individual websites (coriell.org, atcc.org, wicell.org, hsci.harvard.edu, and 
nyscf.org), and informational sites that share data about existing lines (umassmed.edu/iscr, 
nimhstemcells.org, and eagle-i.net). While the number of lines is still manageable, these groups 
should work together to drive the standardization of cell line description and of the format for 
sharing iPS cell information. 
 While many have embraced the potential of this technology, others remain skeptical that 
hiPSCs will reveal significant insights into the mechanisms of and treatments for neurological 
diseases. As with any new technology, the early years of adoption have resulted in a wave of 
studies of varying caliber. Several important initial studies with hiPSCs confirmed known effects 
of certain genetic variants, but for the first time in human neurons, while others where able to 
reveal novel insights into the effects of such variants on neuronal function. In some studies 
reporting novel phenotypes in patient-derived lines, concerns have been raised about the 
specificity of the phenotype for the disease state or even for the genetic alteration being studied. 
For example, it has been described that first-generation neuronal differentiation protocols show 
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variable efficiencies, even between multiple lines derived from the same subject125 (also see 
Tables 1.1 and 1.2). Therefore, phenotypes relating to neuronal differentiation (such as neurite 
outgrowth, neuronal marker expression, electrophysiology) must be carefully interpreted in the 
context of appropriate controls.  
 Despite the concerns mentioned above, human iPSCs allow unprecedented investigation 
into the causative events in disease progression. In addition, for the first time, this technology 
allows neuroscientists to test therapeutics in the cell types of interest derived from the patients 
to be treated. As differentiation protocols become more efficient and reliable, and novel 
strategies are optimized to make the in vitro environment more physiological, the insights 
garnered from studies using hiPSCs will be broadened. 
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ABSTRACT  
Several protocols have been developed for human induced pluripotent stem cell 
neuronal differentiation. We compare several methods for forebrain cortical neuronal 
differentiation by assessing cell morphology, immunostaining and gene expression. We 
evaluate embryoid aggregate vs. monolayer with dual SMAD inhibition differentiation protocols, 
manual vs. AggreWell aggregate formation, plating substrates, neural progenitor cell (NPC) 
isolation methods, NPC maintenance and expansion, and astrocyte co-culture. The embryoid 
aggregate protocol, using a Matrigel substrate, consistently generates a high yield and purity of 
neurons. NPC isolation by manual selection, enzymatic rosette selection, or FACS all are 
efficient, but exhibit some differences in resulting cell populations. Expansion of NPCs as neural 
aggregates yields higher cell purity than expansion in a monolayer. Finally, co-culture of iPSC-
derived neurons with astrocytes increases neuronal maturity by day 40. This study directly 
compares commonly employed methods for neuronal differentiation of iPSCs, and can be used 
as a resource for choosing between various differentiation protocols. 
INTRODUCTION 
Since the advent of human induced pluripotent stem cell (hiPSC) technology, numerous 
studies have utilized these cells for neuronal differentiation. Several groups have independently 
developed hiPSC neuronal differentiation protocols, often adapted from existing protocols for 
human embryonic stem cells (ESCs) or mouse iPSCs/ESCs1-10. These protocols are constantly 
being improved and revised, creating a plethora of techniques to differentiate hiPSCs to 
neuronal fates. The ability to differentiate, culture, and manipulate human neurons is of 
tremendous interest to labs seeking to study human neurodevelopment and neurological 
diseases. For a group that is new to stem cell culture and differentiation, the multitude of 
available neuronal differentiation protocols can be overwhelming. Here, we aim to directly 
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compare some of the most commonly used techniques in human neuronal differentiation, using 
gene expression, cell morphology, and immunostaining to benchmark efficiency. We hope this 
study may provide useful information to aid in other groups’ future decisions regarding iPSC 
differentiation methods and reagents. 
Many groups have taken advantage of somatic cell reprogramming technology to 
generate patient-specific iPSC lines in order to model neurodegenerative and 
neurodevelopmental disorders (reviewed here11). Furthermore, there have been many 
advancements in protocols to create neurons of a particular identity (e.g. motor neurons, 
dopaminergic neurons or interneurons)12-18. There are often multiple protocols to differentiate 
stem cells to a particular neuronal fate of interest. While a comparison of neuronal patterning 
protocols would certainly be informative, it is outside the scope of this study.  Here, we focus on 
methods for differentiating iPSCs to a “default” forebrain cortical neuronal fate. 
For the differentiation of iPSCs to forebrain neurons, two base protocols are often 
utilized: an embryoid aggregate-based technique and a monolayer dual SMAD inhibition 
method8,19. In the embryoid aggregate procedure, iPSC colonies in iPSC media are allowed to 
form aggregates in suspension in the absence of exogenous growth factors or small molecules. 
The media is then changed at day 5 to a neural induction media with a DMEM/F12 base, 
containing non-essential amino acids, heparin, and N2 supplement, which supplies transferrin 
and insulin, among other components (“N2 neural induction media”). The primitive 
neuroectodermal aggregates are plated at day 7 onto an adherence-promoting substrate, and 
cultured for 10 days, promoting formation of definitive neuroectoderm. At day 17, neural 
progenitor cells, organized into neural “rosette” structures, are selectively removed from the 
plate and cultured in suspension. These neural aggregates are cultured in a similar neural 
induction medium, but with the addition of B27 supplement (containing biotin, DL alpha 
tocopherol, vitamin A, BSA, catalase, insulin, transferrin, and superoxide dismutase, among 
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other components), cyclic AMP (cAMP), and insulin growth factor-1 (IGF-1) (“N2/B27 neural 
induction media”). After being cultured in suspension for 7 days, the neural aggregates are 
plated on an adherent substrate in a differentiation-promoting media. This “neural differentiation 
media” is made with a neurobasal base media supplemented with non-essential amino acids, 
N2, B27, cAMP, IGF-1, brain-derived neurotrophic factor (BDNF), and glial cell-derived 
neurotrophic factor (GDNF). Differentiated neurons are visible from day 25 onwards, and can be 
cultured as long as is desired for experimental purposes19. There exist multiple variations on this 
protocol, including aggregate formation techniques, the use of different plating substrates, 
neural progenitor cell isolation methods, and co-culture of neuronal cells with astrocytes. 
The monolayer dual SMAD inhibition protocol8 involves dissociating iPSCs and plating 
them as a feeder-free adherent monolayer before rapidly inducing neuroectoderm formation by 
antagonizing the bone-morphogenetic protein (BMP) and transforming growth factor beta (TGF-
beta) signaling pathways (e.g. by using Noggin and SB431542, respectively). The morphogen 
Noggin and small molecule SB431542 induce conversion of hiPSCs or hESCs to a neural 
progenitor cell fate by day 7, in a neural induction media made with a DMEM/F12 base and 
insulin, N2, and B27 (“3N neural induction media”)10. At day 11, cells are dissociated and re-
plated in neural differentiation-promoting media (“neural differentiation media,” defined above). 
Thus the media used by the dual SMAD inhibition protocol is largely similar to those utilized in 
the embryoid aggregate method. Two main differences exist between these two protocols: 1) 
morphogens/small molecules block the BMP and TGF-beta pathways in the dual SMAD 
inhibition protocol, and 2) the monolayer (dual SMAD inhibition protocol) versus the three-
dimensional aggregate (embryoid aggregate technique) culture. The resulting timelines of these 
methods are also distinct, with neuroectoderm at day 17 vs. day 7, and neurons at day 25 vs. 
day 12 in the embryoid aggregate vs. dual SMAD inhibition protocols, respectively. 
Multiple studies have utilized each of these methods, often with modifications, to 
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generate human iPSC-derived neurons. These variations involve the use of different reagents at 
multiple stages of differentiation to achieve a common goal: culture of human neurons. It is not 
always clear from a published study why a particular method was chosen and how the method 
employed compares to other available protocols. Here we examine both the embryoid 
aggregate and dual SMAD inhibition protocols and compare commonly used experimental 
paradigms for aggregate formation, plating substrates, NPC isolation and expansion, and 
neuronal maturation. We evaluate these various techniques through the use of common metrics 
such as morphology, immunostaining and gene expression.  
RESULTS 
Differentiation of human iPSCs into neurons using an aggregate method 
To examine various differentiation strategies, we first utilized an embryoid aggregate 
protocol19 originally based on methods developed for hESCs20. Fig 2.1A shows the timeline 
schematic for the protocol, in which human iPSCs are differentiated to neuronal fates over the 
course of ~40 days. Aggregates were formed by dissociating iPSCs as large clusters at day 1, 
followed by suspension in culture for five days in serum-free iPS media (without FGF2). At day 
5, aggregate media was changed to N2 neural induction media. Aggregates then were plated on 
Matrigel for the formation of primitive neuroepithelial cells (Fig 2.1B, day 10) in N2 neural 
induction media. At day 17, neural rosette structures were manually selected from plates and 
suspended in flasks for another week in N2/B27 neural induction media. This step aims to select 
for definitive neuroepithelial cells since many non-neuroepithelial cell types adhere to the flask. 
At day 24, aggregates were plated on Matrigel and allowed to mature for an additional 15-30 
days in neural differentiation media.  
In order to qualitatively assess the progression of differentiation, we performed 
immunostaining for various markers indicative of the differentiation process (Fig 2.1C). 
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Figure 2.1. Embryoid body differentiation of hiPSCs. (A) Time course of differentiation for 
embryoid aggregates. iPSC colonies were dissociated from mouse embryonic fibroblasts at 
day 1 (D1) and cultured as aggregates in suspension. Aggregates were plated onto culture 
dishes at day 7 (D7), forming primitive neuroepithelial (NE) structures. By day 17 (D17), 
definitive NE structures were present; NE structures were manually isolated and further 
cultured in suspension. Cells were plated for final differentiation at day 24 (D24). Arrows 
indicate media changes across differentiation. Boxes indicate differentiation state. This 
protocol was performed in 11 independent lines, with all lines performing similarly; 
representative images are shown. (B) Bright-field microscopy images showing morphological 
changes spanning differentiation from the earliest time-point (iPSCs) to day 40 (D40) 
neurons. Scale bars from left to right: 100, 200, 200, 500, 500 µm. (C) Cells were 
immunostained at various time-points during neuronal differentiation. Confocal microscopy 
images at days 0 (iPS colony), 18, 26, and 40. Scale bars=100 µm. TOPRO3, nuclear 
marker. D) qPCR analysis of markers over differentiation. Ct data normalized to GAPDH. For 
Oct4: iPS n=14, D17 n=23, D40-50 n=19 with data points all normalized to iPS; MAP2: iPS 
n=15, D17 n=25, D40-50 n=26 with data points all normalized to D40-50; Tbr1: iPS n=14, 
D17 n=25, D40-50 n=26 with data points all normalized to D40-50, from 6 independent 
differentiations. Data are represented as mean ± SEM. 
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Undifferentiated iPSC colonies expressed the pluripotent marker Oct4 (POU5F1), but lacked 
expression of neuronal cytoskeletal markers such as MAP2. The intermediate time-point day 18 
shows the expression of neural progenitor markers Sox1 and Nestin. Neurons differentiated for 
40 days express neuronal proteins such as MAP2, TuJ1, and Tau, the cortical marker Tbr1, and 
synaptic markers such as synaptophysin (SYP) (Fig 2.1C, bottom row). Functional analyses 
were performed using a microelectrode array platform. Spontaneous potentials were observed 
at around 50 days of differentiation, as previously reported using this protocol 21. In order to 
quantitatively assess and compare differentiation progression across multiple wells, qPCR was 
performed for multiple cell-fate markers (Fig 2.1D). Data show that with an increase in 
differentiation time, mRNA expression of Oct4 (POU5F1) decreases, while neuronal markers 
such as MAP2 and Tbr1 increase, and this expression pattern is consistent between wells of the 
same experiment and between differentiation rounds. To complement the qPCR data and 
determine the absolute percentage of neuronal cells derived using this method, the percentage 
of cells expressing MAP2 was quantified from immunostained wells, with 93% (±1.5 SEM) of 
cells expressing MAP2 by day 40. 
Generation of neurons utilizing dual SMAD inhibition in monolayer culture 
We next sought to compare a monolayer-based protocol to this aggregate method. Fig 
2.2A illustrates the timeline schematic that was utilized, based on the technique of dual SMAD 
inhibition8. At the start of differentiation (day 0), iPSCs were dissociated to single cells and re-
plated as a monolayer with a concentration of 20,000 cells/cm2 in MEF conditioned media, 
supplemented with FGF2. After cells reached 90% confluency, media was changed to 3N neural 
induction media supplemented with Noggin (200 ng/mL) and SB431542 (10 µM)10. Cells were 
split at day 11 using dispase and re-plated in neural differentiation media onto 96-well plates 
coated with Matrigel. The bright-field images in Fig 2.2B illustrate the morphological changes 
over the course of differentiation. At day 7, the cells begin to form early rosette structures. After  
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Figure 2.2. Monolayer differentiation of hiPSCs. (A) Time course of differentiation using 
dual-SMAD inhibition. iPSC colonies were dissociated from mouse embryonic fibroblasts at 
day 1 (D1) and plated as a monolayer. Small molecules and growth factors were added as 
indicated. This protocol was performed in at least 6 independent lines; representative images 
from the most efficient differentiations are shown. (B) Bright-field images spanning 
differentiation from the earliest time-point day 0 (D0) to day 40 (D40). Scale bars=50 µm. (C) 
Cells were immunostained at various time-points during neuronal differentiation. Confocal 
images at days 0, 7, 11, 27 and 40. Scale bars=100 µm. TOPRO, nuclear marker. (D) qPCR 
analysis of markers over differentiation. Ct data normalized to GAPDH. For Oct 4: iPS n=3, 
D1 n=3, D7 n=3, D11 n=6, D40 n=5; MAP2: iPS n=3, D1 n=4, D7 n=4, D11 n=6, D40 n=5; 
Tbr1: n=2, D1 n=3, D7 n=3, D11 n=5, D40 n=5. Data are represented as mean ± SEM. 
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Figure 2.2 (Continued)
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re-plating the cells at day 11, small processes begin to emerge (day 14), followed by more 
mature neuronal morphology at day 40 (Fig 2.2B, last panel).  
Both immunostaining and qPCR were employed to examine differentiation efficiency 
over time. Cells begin to express progenitor markers Sox2 and Pax6 at day 7 and Nestin and 
Tbr2 at day 11. From its maximal expression at day 0, Oct4 expression is markedly decreased 
at day 11 (Fig 2.2C). From day 27 through day 40, neuronal markers Tau, MAP2, Tbr1 and 
TuJ1 are expressed. Based on quantification of immunostaining, approximately 45% (±4.6 
SEM) of cells expressed MAP2. Similarly to the aggregate method, when we probed mRNA 
from harvested cells, Oct4 (POU5F1) decreased over differentiation time while MAP2 and Tbr1 
increased up to day 40 (Fig 2.2D). However, this method often resulted in “failed” 
differentiations due to high levels of cell death between days 10-17 of differentiation. Neuronal 
differentiation using the dual-SMAD inhibition protocol without splitting led to cultures that either 
died or did not produce MAP2+ neurons (10/10 differentiation rounds), due to over-confluent  
cultures between days 10-17. However with a revision in the protocol that included splitting the 
cultures at day 11 (Chambers and Studer, personal communication), we observed MAP2+ cells  
in 3/5 differentiation rounds. Based on these initial results, we chose to focus upon optimizing 
the embryoid aggregate differentiation protocol. 
Comparison of embryoid aggregate formation: manual versus AggreWell 
We hypothesized that differentiation efficiency could be improved by creating embryoid 
aggregates of a more uniform size, using AggreWell plates. At day 0, iPSCs were dissociated 
manually using dispase and either resuspended in flasks or triturated and plated in AggreWell 
plates. With AggreWell plates, cells were force-pelleted into microwells by centrifugation. After 
24 hours, dissociated cells formed aggregate structures and were further cultured following the 
protocol outlined in Fig 2.1A. We made aggregates of two different types: 3,000 and 8,000 
cells/aggregate. Manually formed aggregates consisted of varying shapes and sizes (Fig 2.3A),  
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Figure 2.3. Comparison of embryoid body formation. (A,B) Embryoid bodies were either 
formed by dissociating iPSCs (using dispase and trituration) or by AggreWell plate 
technology, followed by culture in non-adherent flasks. (B) Quantification of aggregate size 
from manually-formed or 3,000- or 8,000-cell aggregates. Mean diameter for manually 
formed aggregates=118.3 µm; mean diameter for 3,000 cells/aggregate=183.1 µm; mean 
diameter for 8,000 cells/aggregate=195.2 µm. Scale bars=200 µm.  Data are represented as 
mean ± SEM, from 3 independent differentiations, n=21-43. Significance determined by one-
way ANOVA with a Tukey’s post-test: ***, p<0.0001. F-tests between groups showed 
significantly different variances, with p<0.05 between manual vs. 3,000 cells/aggregate and 
manual vs. 8,000 cells/aggregate. Data are represented as mean ± SEM. (C) 
Immunostaining of day 40 (D40) neurons, following differentiation using either manual 
formation or AggreWell plates. TOPRO, nuclear marker. Scale bars=100 µm. Representative 
images are shown. (D) qPCR was performed using RNA harvested from day 40 cultures. 
Data normalized to GAPDH expression. Manual n=10, AggreWell n=10. Error bars represent 
SEM. Significance was determined by student's t-test: ***, p<0.0001. 
*** 
*** 
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whereas aggregates formed using AggreWell were visually more uniform in size and shape. 
These size differences were quantified by measuring the diameter of aggregates (Fig 2.3B). The 
mean diameter for manually formed aggregates was 118.3 µm (±6.0 SEM), whereas the mean 
diameter was 183.1 µm (±3.6 SEM) for 3,000 cells/aggregate and 195.2 µm (±5.5 SEM)  
for 8,000 cells/aggregate. Both sizes of AggreWell aggregates were significantly larger than 
manually formed aggregates, and although there was a trend for an increased aggregate 
diameter between 3,000 and 8,000 cells/aggregate, it did not reach statistical significance. As 
the AggreWell system is designed to incorporate 3,000 versus 8,000 cells into each aggregate,  
the insignificant difference in aggregate size may reflect a difference in aggregate density, with 
8,000 cells/aggregate being more densely packed than 3,000 cells/aggregate. Not surprisingly, 
the variance of aggregate size distribution was significantly greater with manual aggregate 
formation than with either AggreWell size. Immunostaining for MAP2 in cells following aggregate 
formation with the use of AggreWell is shown in Fig 2.3C (right). Immunostaining at day 40 
showed that approximately 46% (±1.6 SEM) of AggreWell-differentiated cells were MAP2+, 
compared to 93% MAP2+ cells with manually formed aggregate differentiation. Quantification of 
MAP2 mRNA from day 40 neurons that were cultured in the AggreWell format also showed a 
corresponding significant decrease in MAP2 mRNA levels (Fig 2.3D). 
Comparison of plating substrates: Matrigel vs. poly-o-laminin 
The choice of plating substrates for differentiation varies among labs and protocols. By 
far, the two most commonly used substrates are Matrigel and a poly-ornithine/laminin 
combination (POL). We sought to compare the results of using Matrigel versus POL substrate at 
the two plating steps of the embryoid aggregate technique (Fig 2.1A). We found that using 
Matrigel for the first aggregate plating (day 7) was sufficient to direct differentiation to a 
neuroepithelial fate (Fig 2.4A). However, when we attempted to plate aggregates on POL at the  
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Figure 2.4. Comparison of plating substrates. Aggregates were plated on either Matrigel 
or poly-o/laminin (POL) coated plates at days 7 or 24. (A,D) Aggregates plated at day 7 (D7) 
and imaged at day 10 (D10) on Matrigel (A) formed typical neuroepithelial structures, while 
aggregates plates on POL (D) failed to adhere after two days. (B,E) Aggregates were plated 
on either Matrigel or POL coated plates for final differentiation on day 24 (D24) and imaged 
at day 40 (D40). Aggregates plated on Matrigel (B) exhibited an increased density of 
processes, while aggregates plates on POL (E) displayed increased cell body migration from 
the plated aggregate. (C,F) Neural aggregates were dissociated at day 24 and plated on 
either Matrigel (C) or POL (F). (G) Aggregates were plated on either Matrigel (top row) or 
POL (bottom row) at day 24 and allowed to mature until day 40, followed by immunostaining 
and confocal microscopy for neuronal markers. Scale bars=100 µm. Representative images 
are shown. (H) qPCR was performed using RNA harvested from day 40 cultures. Data 
normalized to GAPDH expression. Matrigel n=10, POL n=10. Error bars represent SEM. (I) 
Aggregates were single-cell dissociated and plated on either Matrigel (top row) or POL 
(bottom row) at day 24 and allowed to mature until day 40, followed by immunostaining and 
confocal microscopy for neuronal markers. Scale bars=100 µm. Representative images are 
shown. (J) qPCR was performed using RNA harvested from day 40 cultures. Data 
normalized to GAPDH expression. Matrigel n=22, POL n=22. Significance determined by 
student’s t-test: **, p<0.01; ***, p<0.001.  Data are represented as mean ± SEM. 
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same time-point, aggregates did not reliably adhere to the plate (Fig 2.4D). For the second 
plating of neural aggregates at day 24, cells were plated on either Matrigel (Fig 2.4B) or POL 
(Fig 2.4E). For both plating substrates, aggregates were able to adhere to the plate, and cells 
with neuronal morphology were visible. However, aggregates plated on POL displayed sparser 
distribution of cell processes and more migration of cell bodies away from aggregates (Fig 2.4E) 
compared to aggregates plated on Matrigel (Fig 2.4B). Immunostaining of day 40 differentiated 
neurons showed decreased MAP2 staining (Fig 2.4G, bottom row) as well as low levels of Tau 
staining, in POL versus Matrigel-plated neurons (Fig 2.4G, top row). TuJ1 staining appeared to 
be consistent between the two plating conditions. MAP2 mRNA levels from day 40 differentiated 
neurons, plated on either Matrigel or POL, were quantified using qPCR (Fig 2.4H). Cells from 
POL-plated aggregates expressed significantly less MAP2 mRNA than cells plated on Matrigel. 
Based on immunostaining, approximately 56% (±3.5 SEM) of differentiated neurons expressed 
MAP2 on POL, compared to 93% MAP2+ cells with Matrigel plating. 
While plating aggregates for final differentiation induces efficient neuron generation, for 
some purposes it may be desirable to have a culture that is more monolayer in nature. For 
example, aggregates can interfere with imaging as it is difficult to visualize cells in or near large 
aggregates. In an effort to create a monolayer cell culture, aggregates were dissociated with 
Accutase at day 24 and plated on either Matrigel or POL (Fig 2.4C,F). Immunostaining revealed 
similar results to those seen in Fig 2.4G. Dissociated single cells plated on POL exhibited less 
dense cultures than neurons plated on Matrigel, with less overall staining of neuronal processes 
(MAP2, Tau, TuJ1) (Fig 2.4I, bottom row). MAP2 mRNA from day 40 dissociated/single-cell 
neurons, plated on either Matrigel or POL, was quantified using qPCR. Dissociated cells plated 
on POL had significantly lower MAP2 mRNA expression than cells plated on Matrigel (Fig 2.4J). 
Comparison of neural progenitor cell (NPC) isolation by multiple methods 
There are a number of ways to select desirable day 17 neuroepithelial rosette structures 
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for further differentiation. We next sought to compare different NPC isolation methods at day 17 
of differentiation (Fig 2.5A). First, manual neural rosette selection was compared to enzymatic 
neural rosette selection. Manual rosette selection involved manually scraping away the large, 
clear cells (neural crest morphology) that surround neural rosette structures to remove these 
contaminating cell types. For enzymatic rosette selection, the StemCell Technologies STEMdiff 
Neural Rosette Selection Reagent was used to selectively detach neural rosettes from the dish 
(Fig 2.5B). Immunostaining at day 18 (one day after selection) shows that both manual and 
enzymatic rosette selection enrich for Pax6+ (Fig 2.5C, top row), Nestin+ (Fig 2.5C, top and 
bottom rows) and Oct4- (Fig 2.5C, middle row) cells, compared to cells that were not subjected 
to any NPC selection. Manual selection resulted in fewer Oct4+ cells than rosette selection (Fig 
2.5C, middle row). Sox2 expression was similar between the three conditions, but there were 
several Sox2+/Nestin- cells without NPC selection, and a few Sox2+/Nestin- cells after rosette 
selection (Fig 2.5C, bottom row, asterisks). Immunostaining of differentiated neurons at day 40 
(after enzymatic rosette selection) shows that 85% (±5.1 SEM) are MAP2+, similar to the 93% 
MAP2+ neurons resulting from manual selection. 
We hypothesized that employing a cell-sorting technique would help decrease non-
neuronal cell contamination in our cultures. To test this, we sorted day 17 cells using magnetic 
affinity cell sort (MACS) technology with a PSA-NCAM antibody. Manually selected NPCs and 
PSA-NCAM+ cells were plated on Matrigel in neural differentiation media for 23 days and 
immunostained for various neuronal markers (Fig 2.5D). Both conditions (manual selection and 
PSA-NCAM+) expressed neuronal markers TuJ1, MAP2 and Tau. However, sorted cells (Fig 
2.5D, right column) had high background levels of non-neuronal cells, indicated by non-neuronal 
morphology and absence of neuronal markers. Additionally, Tbr1 immunoreactivity was less 
abundant in MACS preparations compared to manually selected cells (Fig 2.5D, middle row). 
Quantification following PSA-NCAM sorting from these experiments showed 47% (±2.3 SEM)   
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Figure 2.5. Comparison of NPC isolation methods. (A) Schematic indicating the time 
course of differentiation and the techniques used to isolate neural progenitor cells (NPCs). 
Human iPSCs were differentiated for 17 days. NPCs were isolated by manual scraping of 
non-NPCs under a microscope (manual selection), using a proprietary neural rosette 
selection reagent (rosette selection), or by FACS for CD184+/CD44-/CD271-/CD24+ cells 
(FACS). (B) Representative bright field images are shown for selection of rosettes using 
rosette selection reagent. White arrows indicate rosette structures to be isolated. After use of 
the reagent, rosettes are isolated. Scale bars=100 µm. (C) Immunostaining for various cell 
fate markers at day 18 after isolation at day 17. Asterisks in the bottom panel show 
Sox2+Nestin- cells. Scale bars=100 µm. (D) Day 17 NPCs were either manually selected or 
dissociated using accutase and processed for cell sorting. Manually selected or PSANCAM+ 
cells were plated on Matrigel for 23 days in neural differentiation media and immunostained 
at day 40 for neuronal markers. Scale bars=100 µm. (E) Day 17 cells were dissociated and 
subjected to FACS. CD184+/CD44-/CD271-/CD24+ cells (“NPCs”) and all other cells (“non-
NPCs”) were plated on Matrigel and maintained in neural progenitor media for 20 days prior 
to immunostaining. Scale bar = 50 um. (F,G) RNA was harvested from cells at day 17 after 
isolation and used in the NanoString assay. Expression profiles of selected NPC fate 
markers (F) or other cell fate markers (G) are shown. Gene expression was normalized to 
the geometric mean of seven housekeeping genes. Data are represented as mean ± SEM. 
Data are from 5-6 independent differentiations and 3 lines, n=6-30. Significance is shown 
compared to “manual selection.” Statistics were calculated using two-way ANOVA with 
Holm-Sidak multiple comparisons correction: *, p < 0.05; **, p < 0.01; ***, p < 0.001.  
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Figure 2.5 (Continued)
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 MAP2+ cells. 
Because MACS did not improve neuronal purity above other NPC selection strategies, 
we then tested the ability of FACS to enrich for NPCs by isolating CD184+/CD44-/CD271-
/CD24+ cells using the BD Stemflow Human Neural Cell Sorting Kit (based largely on a 
published study22), wherein day 17 cells are dissociated and labeled with these antibodies that 
mark specific cell populations. CD184+/CD44-/CD271-/CD24+ cells (“NPCs”) and flow-through 
cells (“non-NPCs”) were maintained in neural progenitor media for 20 days after sorting, 
followed by immunostaining for Nestin and MAP2 (Fig 2.5E). This media, consisting of a 
DMEM/F12 base with B27, FGF2, EGF, and heparin, supports culture of adherent neural 
progenitor cells23. Fig 2.5E shows that FACS reduced the number of Nestin-/MAP2- cells 
present (asterisks), but was highly stringent and also excluded some cells expressing neuronal 
markers (arrowheads). 
Finally, we compared the gene expression profiles of manual-, rosette-, and FACS-
isolated NPCs at day 17 by NanoString (Fig 2.5F,G). Gene expression analyses show that 
enzymatic rosette selection appeared to be most permissive to other cell types, with decreased 
expression of NPC markers FoxG1, HES1, Pax6, Vimentin (VIM), and MAP2 (Fig 2.5F), and 
higher expression of non-NPC cell fate markers, including the endodermal marker AFP (Fig 
2.5G). There was also a trend for increased expression of pluripotent cell markers nanog and 
Oct4 (POU5F1), but this did not achieve significance. FACS-isolated NPCs showed similar 
overall gene expression to manually isolated NPCs with a few differences, including increased 
HES1 and decreased Tbr2 expression (Fig 2.5F). Overall, these three NPC isolation methods 
each enrich for neural progenitors, with slight differences in NPC purity and identity. 
Consequences of Neural Progenitor Expansion on Neuronal Identity  
Differentiation protocols are time-consuming and costly; thus, we hoped to establish a 
protocol in which we could generate neuronal cells from an expandable NPC pool. This would 
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allow for neuronal differentiation without differentiating cells for 17 days prior to the NPC stage, 
and for expansion of neural progenitors for increased neuronal yield. Fig 2.6A shows the 
differentiation schematic that was used to culture NPCs. Differentiation was performed using the 
embryoid aggregate protocol (Fig 2.1A) until day 17. At day 17, neural rosettes were selected 
and isolated using the Neural Rosette Selection Reagent from StemCell Technologies. 
Harvested cells were either maintained in suspension as neural aggregates in N2/B27 neural 
induction media, plated for expandable monolayer culture in neural progenitor media, or plated 
on Matrigel in 96-well plates for final differentiation in neural differentiation media. We first 
compared neurons resulting from aggregates to neurons differentiated from monolayer NPCs. 
Rosette-selected NPCs were maintained on POL-coated plates in neural progenitor media with 
EGF, FGF2, and heparin. Cells were plated for final neuronal differentiation from a pool of 
monolayer-maintained NPCs after the first or second passage (~3-5 days per passage) or 
directly from day 24 aggregates without passaging. Cells were subsequently maintained in 
neural differentiation media for 16 days (Fig 2.6A). 
Differentiation of monolayer-maintained NPCs from two subsequent passages showed a 
trend for decreased MAP2 mRNA expression after the first passage and significantly lower 
MAP2 expression after the second passage compared to neurons derived directly from day 24 
aggregates (Fig 2.6B). These data indicate decreased potential for neuronal identity with 
extended monolayer NPC expansion, which could result from expansion of contaminating 
adherent non-neuronal cells. We also observed a corresponding decrease in MAP2 
immunostaining in day 40 neurons derived from NPC monolayer passage 2 compared to 
neurons derived from day 24 aggregates (Fig 2.6C). 
We then examined effects of suspension neural aggregate progenitor expansion on 
resulting neuronal identity. NPCs were maintained in suspension as neural aggregates for 2 
days after selection (day 19) or 18 days after selection (day 35) before plating for final neuronal  
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Figure 2.6. Effects of neural progenitor cell maintenance and expansion on 
differentiation efficiency. (A) Schematic indicating the time course of differentiation and the 
techniques used to maintain/differentiate neural progenitor cells (NPCs) after NPC isolation 
with neural rosette selection reagent at day 17. (B) qPCR analysis of MAP2 expression after 
16 days of differentiation of day 24 aggregates or passage 1 or 2 monolayer NPCs. Data 
normalized to GAPDH. (C) Immunostaining of day 40 (D40) neurons, following differentiation 
from either day 24 aggregates or passage 2 NPCs. Scale bars = 100 µm. Representative 
images are shown. (D) NanoString analysis of cell fate markers of neural aggregates plated 
at day 19 or 35, after 16 days of plating in neural differentiation media, normalized to the 
geometric mean of seven housekeeping genes. Data are represented as mean ± SEM, n=6. 
Significance was determined by student's t-test: *, p < 0.05; **, p < 0.01; ***, p<0.001. 
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 differentiation. These cells were cultured in neural differentiation media for 16 days before 
analysis of mRNA expression by NanoString (Fig 2.6D). Prolonged neural aggregate culture did 
not appreciably alter resulting neuronal identity, as demonstrated by comparable expression of 
cortical markers Satb1, Tbr1, and Cux1 (Fig 2.6D). However, the NPC/neural purity of the 
cultures appeared to be improved with longer neural aggregate culture, shown by higher nestin 
(Nes), Pax6, MAP2, and synapsin I (SYN) expression, as well as a trend for lower nanog and 
Oct4 (POU5F1) expression (Fig 2.6D). Thus, if long-term culture and/or expansion of NPCs is 
desired, maintenance in aggregates may be superior to maintenance as a monolayer. 
The emergence of endogenous astrocytes 
 Neuronal markers change over the course of differentiation, such that over time there is 
an upregulation of synaptic markers. We also were interested in whether endogenous 
astrocytes emerged in our cultures within 100 days of differentiation (Fig 2.7A, green arm). 
Immunostaining and confocal microscopy of day 42 and day 100 neuronal cultures showed an 
increase in expression of glial fibrillary acidic protein (GFAP), a marker of astrocytes, at day 100 
(Fig 2.7B). Additionally, using the NanoString platform, we evaluated RNA harvested from either 
day 40 or day 100 neuronal cultures for a subset of neuron and astrocyte markers (Fig 2.7C) 
and synaptic markers (Fig 2.7D). Day 100 cultures showed a significant increase in expression 
of the astrocytic markers GFAP and S100B (Fig 2.7C), as well as in markers of mature neurons, 
VLGUT1 (SLC17A7), NMDAR (GRIN1) and KCC2 (Fig 2.7D). There was no significant 
difference in MAP2, Tbr1, Tau, SYN, PSD95, or VGAT between day 40 and day 100 cultures.  
Neuronal maturation with astrocyte co-culture 
Lastly, we aimed to address the possible benefits of astrocyte co-culture on 
differentiation, i.e. if we could accelerate maturation of neuronal cultures before day 100. 
Differentiated neurons were cultured alone or co-cultured with mouse astrocytes (Sciencell) 
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Figure 2.7. Astrocyte co-culture increases neuronal maturation and endogenous 
astrocytes arise at later time-points in differentiation. (A) Schematic of differentiation up 
to 100 days. For astrocyte co-culture, astrocytes were added to neuronal cultures at ~day 24 
of differentiation. Endogenous astrocytes gradually emerged over the course of 100 days, 
after day 40. (B) Day 42 and day 100 neuronal cultures were immunostained and imaged for 
GFAP. Scale bars=50 µm. (C) After 40-50 (D40) or 100 days (D100), cells were lysed, RNA 
extracted, and expression of 150 genes analyzed using the NanoString platform. A subset of 
neuronal markers (C) and synaptic markers (D) are shown. Data are from at least 6 
independent differentiations (3 lines). For day 40-50 n=29-38, for day 100 n=15-19. (E) 
Neuron cultures with or without astrocytes were immunostained and imaged using confocal 
microscopy at day 40. Insets in right column show VGLUT1 staining along the length of a 
neuronal process. Representative images are shown. Scale bars=50 µm. (F) qPCR was 
performed using RNA harvested from day 40 cultures. Data normalized to GAPDH 
expression. For neurons alone n=20 for MAP2, TBR1, CUX1, GAD1, n= 37 for SYP, n=38 for 
VGLUT1; for astrocyte co-culture n=17 for GAD1, n=18 for MAP2, TBR1, CUX1, n=27 for 
SYP, n=25 for VGLUT1. Data are represented as mean ± SEM. Significance determined by 
student’s t-test: **, p<0.01; ***, p<0.001; ****, p<0.0001. 
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Figure 2.7 (Continued)
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after plating at day 24 (Fig 2.7A, purple arm). Samples were harvested at day 40, before the 
emergence of endogenous astrocytes. By immunostaining, there were no qualitative differences 
in MAP2 or SYP expression between culture conditions (Fig 2.7E). However, we were able to 
visualize protein expression of VGLUT1 at day 40 only when differentiated neurons were co-
cultured with exogenous astrocytes (Fig 2.7E, bottom row). qPCR analysis showed no changes 
in MAP2, Tbr1, CUX1, GAD1 or SYP expression, but significantly increased VGLUT1 
(SLC17A7) expression at day 40 with astrocyte co-culture (Fig 2.7F). 
DISCUSSION 
With advancements in iPSC neuronal differentiation, it has been possible to examine 
human neural development and consequences of neurological disease-associated mutations at 
the cellular level. However, there exist a multitude of techniques to get from point A (iPSCs) to 
point B (differentiated neurons). Here, we evaluated several methods that are regularly used to 
generate forebrain cortical neurons, the “default” neuronal fate generated in the absence of 
exogenously provided patterning factors. We compared the outcomes of these protocols using 
gene expression, cell morphology, and protein expression by immunostaining (Table 2.1). 
Notably, these protocols resulted in robust expression of forebrain cortical transcription factors 
with negligible expression of midbrain and hindbrain transcription factors, as assessed by 
NanoString counts (Fig 2.8). 
The percentage of cells expressing MAP2 was quantified following immunostaining from 
many of the various differentiation schemes employed here. The manual embryoid aggregate 
method with manual rosette selection as well as enzymatic rosette selection, generated the 
highest percentage of MAP2+ cells at day 40 of differentiation (~93% and ~85%, respectively). 
Other differentiation methods resulted in significantly fewer MAP2+ cells, such as monolayer 
dual SMAD inhibition differentiation (~45%), AggreWell embryoid aggregate differentiation  
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Table 2.1: Key comparisons of methods tested 
Optimization 
Parameter Key Benchmarks Results Notes 
Differentiation Protocols 
Embryoid 
Aggregate vs. 
Monolayer Dual 
SMAD Inhibition 
MAP2 %, qPCR of 
neuronal markers 
Consistent neuronal yield with over 
90% MAP2+ neurons using 
embryoid aggregate protocol. 
Decreased MAP2 % with dual SMAD 
inhibition method. 
Zeng et al., 201019; 
Chambers et al., 
20098 
Aggregate Formation 
Manual vs. 
AggreWell 
MAP2 %, qPCR of 
neuronal markers, 
brightfield 
microscopy 
Manual formation more variable in 
aggregate size than Aggrewell. More 
consistent aggregate size and 
decreased MAP2 % using Aggrewell 
Zeng et al., 201019; 
StemCell 
Technologies 
Plating Substrates 
Matrigel vs. POL 
MAP2 %, qPCR of 
neuronal markers, 
immunostaining of 
NPC and iPSC 
markers 
Matrigel promotes aggregate 
adherence better than POL at D7. 
Matrigel generates higher 
percentage of cortical neurons than 
POL at D40. 
Matrigel from BD 
Biosciences. Lot-to-
lot variations in 
protein content may 
affect outcome. 
Progenitor Selection  
Manual/Cell 
Sort/Rosette 
Selection 
MAP2 %, 
immunostaining of 
neuronal markers, 
Nanostring of NPC 
and non-neuronal 
markers 
Rosette Selection is rapid and 
efficient but most permissive to non-
neural cells. FACS and manual 
selection are equally effective for 
eliminating non-neural cells, but 
FACS is more time-consuming, has 
a lower yield, and selects NPCs with 
slightly different marker expression. 
Manual: Zeng et 
al., 201019; Hu et 
al. 20109; FACS: 
BD Biosciences, 
Yuan et al., 201122; 
Rosette Selection: 
StemCell 
Technologies 
Co-culture 
None vs. 
Astrocytes 
qPCR of neuronal 
markers, 
Nanostring of 
neuronal and 
astrocyte markers, 
immunostaining of 
neuronal markers 
Astrocyte-free cultures express 
neuronal markers, but express less 
VGLUT1 than co-culture with 
astrocytes or cultures containing 
endogenous astrocytes 
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Figure 2.8. Expression of forebrain cortical vs. mid- or hindbrain transcription factors. 
Day 17 (NPC) or day 40 (neuron) RNA (same samples as used in Figures 2.5 or 2.6D, 
respectively). Nanostring counts show robust cortical transcription factor expression (FoxG1, 
Sox1, Sox2, Tbr1, Tbr2, HES1, HES5) and negligible expression of non-cortical transcription 
factors (EN-1, HB9, HOXB6, HOXB13). 
  79 
(~46%), and PSA-NCAM sorting (~47%). It has been reported that different iPSC lines can vary 
in their ability to differentiate into neural cells9,24-31. For the embryoid aggregate-based 
differentiation variations examined herein, we did not observe obvious differences in efficiency 
of final neuronal differentiation or cell isolation method across cell lines. As this protocol 
includes steps to minimize or exclude undesirable cell types (e.g. selection of NPCs at day 17 
and subsequent NPC culture in suspension), differences in differentiation capacity of different 
lines are minimized. However, we did note that certain lines differentiated better than others 
using the dual-SMAD inhibition protocol, with the most promising neuronal differentiations 
shown here. 
At both plating steps of the embryoid aggregate protocol, Matrigel appears to be a 
superior substrate for promoting cell adherence and acquisition of neuronal identity. Use of 
Matrigel in the second plating generates >90% MAP2+ cells at day 40 of differentiation, 
compared to 56% MAP2+ cells using POL for the second plating. Plating cells on Matrigel at the 
second step leads to higher MAP2 mRNA expression compared to the POL plating, despite 
whether the cells are plated as aggregates or dissociated and plated as a monolayer. 
Matrigel likely serves as a better substrate due to its complex composition, which 
includes laminin, collagen IV and entactin, as well as a variety of growth factors that may 
promote neuronal differentiation. Notably, we have found that the lot-to-lot variability in Matrigel 
protein concentration is important for its differentiation- and adherence-promoting capability in 
the second plating step. Matrigel lots with higher initial protein concentrations are often more 
suitable for neuronal differentiation, even when plated at the same final protein concentration as 
lower protein concentration lots. 
Isolation of NPCs may be done by a variety of methods, four of which we compared 
here: manual selection, enzymatic rosette selection, PSA-NCAM MACS, and FACS. PSA-
NCAM sorting was less effective than manual NPC selection, with decreased neuronal purity in 
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PSA-NCAM+ sorted populations. Each of the remaining methods serves to enrich for NPCs, 
with some differences. Rosette selection appears to be more permissive to undesirable cell 
types, including pluripotent cells and endodermal cells, than manual selection or FACS. 
However, this method still generates neurons with high purity. The increased HES1 expression 
with FACS could reflect increased purity of proliferative, undifferentiated neuroepithelial cells 
with FACS isolation32,33. Decreased Tbr2 expression with FACS isolation suggests that this 
method may enrich for earlier neural progenitors at the expense of decreased enrichment for 
intermediate progenitors34. 
The less selective nature of the neural rosette selection reagent should be balanced with 
the cost (in both time and money) of each method. The manual selection method can be the 
most time-consuming and requires an experienced user, but requires no additional reagents 
and thus has the lowest reagent cost. The rosette selection method is fastest, but requires use 
of a proprietary reagent and so comes with a moderate cost. Finally, FACS selection is 
somewhat time-consuming and is the most expensive method. FACS also greatly reduces the 
total yield of viable cells, as there is significant cell loss due to prolonged dissociation and 
sorting time. The decision to choose one of these methods should be determined by the 
experimental setup and subsequent use of the isolated NPCs. If a highly sensitive and/or 
expensive method will be used on the isolated NPCs and purity is of the utmost importance, 
FACS isolation may be optimal. For experiments with few cell lines, manual selection is the 
cheapest and most effective method. If many different hiPSC lines are being differentiated, 
manual rosette selection would be time-prohibitive and rosette selection may be a better option. 
For an experiment in which NPCs will be further purified as neural aggregates (where many 
non-NPC fates will adhere while NPCs float as aggregates), rosette selection should be 
acceptable. 
Culturing cells as NPCs has the advantage of expanding the neural progenitor pool for 
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subsequent neuronal differentiation without having to repeat days 1-17 of differentiation. This 
can save time and resources while increasing neuronal yield per differentiation experiment. If 
expansion of cells at the NPC stage is desired, our data suggest that maintenance as neural 
aggregates is superior to maintenance in a monolayer. Differentiation of later passage cells from 
aggregates show increased purity without obvious alterations in neuronal identity (as assayed 
by our 150-probe NanoString profile), whereas extended culture in monolayer decreased 
neuronal identity of the resulting cells. This may be related to the suspension nature of 
aggregate culture, wherein many contaminating cell types (e.g. neural crest cells) will 
preferentially adhere to the flask, whereas desirable cell types (e.g. NPCs) will be maintained as 
suspended aggregates. There also is a possibility that the slightly different media formulations 
of N2/B27 neural induction media versus neural progenitor media may alter cell fate and 
differentiation capacity (e.g. N2, cAMP, IGF-1 only in the former and FGF2, EGF only in the 
latter). Of note, neural aggregate size increases as cells proliferate, which eventually limits 
nutrient access for cells inside the aggregate. To allow cells to continue proliferating while 
maximizing access of cells to nutrients, neural aggregates can be broken up by gentle 
trituration12. Other groups have reported the establishment of NPC lines from hESCs or hiPSCs, 
often using more than one purification strategy to generate a highly pure and homogenous NPC 
population23,35-41. These strategies could be considered to generate NPC lines for longer-term 
use, but it is less sustainable to execute multiple purification techniques for many lines over 
multiple differentiations. 
We also sought to study the emergence of endogenous astrocytes from neuronal 
cultures and examine the effect of exogenous astrocytes on iPSC-derived neurons. Over 
differentiation time, remaining neural progenitor cells begin to produce astrocytes, shown by 
increasing astrocyte marker expression and immunostaining by day 100. This confirms data 
presented by other groups showing emergence of astrocytes with long-term differentiation of 
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hiPSC-derived neural progenitors42-44. Concurrently, there is an increase in the excitatory 
neuronal marker VGLUT1 (SLC17A7) (but not SYN) expression. Co-culture of human iPSC-
derived neurons with mouse astrocytes promoted increased expression of VGLUT1 (SLC17A7) 
at day 40, without affecting other neuronal subtype and synaptic markers. This suggests that 
exogenous astrocyte co-culture promotes the maturation of iPS-derived neurons without altering 
cell fate. These data are consistent with reports of accelerated hESC- and hiPSC-derived 
neuronal maturity with astrocyte co-culture45,46. Addition of exogenous astrocytes has the 
advantage of accelerating neuronal maturation, which may be desirable depending on the 
phenotype to be studied. 
Achieving a “standard” protocol for neural differentiation across laboratories is 
unrealistic, due to the wide range of studied phenotypes and continual development of new 
protocols. Because small variations in methods can have dramatic effects on the resulting cells 
(and studied cellular properties), it is imperative that groups utilizing iPSC-derived neural cells 
carefully report how differentiation was performed and thoroughly characterize the resulting cell 
populations. The data included here provide a framework upon which researchers can base 
decisions regarding differentiation protocols. We hope this may aid in selection of optimal 
protocols, promote awareness of the many variables that can affect differentiation, and 
encourage detailed reporting of differentiation methods in published studies. 
EXPERIMENTAL PROCEDURES 
iPSC reprogramming and generation 
Human iPSCs were obtained from the UCONN Stem Cell Core. Lines YK26, YZ1 and 
TZ1 were generated by retroviral vectors containing the reprogramming factors OCT4, SOX2, 
NANOG and LIN28 or c-Myc and KLF419. Additional lines were reprogrammed by retroviral 
vectors containing the reprogramming factors OCT4, SOX2, c-Myc and KLF4 in conjunction with 
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the Harvard Stem Cell Institute as previously described21.  
iPSC karyotype analysis and characterization 
The NanoString nCounter Human Karyotype Panel CNV CodeSet was used to assay 
iPSC genomic DNA every ~10 passages in order to ensure a stable chromosome number over 
time. 
iPSC culture 
iPSCs were cultured in iPSC media as previously described21. FGF2 (Millipore) was 
added fresh daily at 10 ng/ml. Cells were maintained at 37°C/5% CO2 and were split as 
necessary based on colony growth (~6 days). iPSCs were manually groomed by removing any 
colonies with irregular borders, spontaneous differentiation or transparent centers, prior to 
splitting. iPSCs were maintained on a mouse embryonic fibroblast (MEF) feeder layer at 1.7-2.0 
x105 cells/well of a 6-well plate (Globalstem).  
Embryoid aggregate differentiation protocol 
For the induction of forebrain neurons, iPSCs were differentiated using an embryoid 
body-based protocol19, further optimized here. Colonies with irregular borders, spontaneous 
differentiation or transparent centers were removed prior to splitting. iPSC colonies were 
dissociated from MEFs at day 1 with collagenase (StemCell Technologies) and cultured as 
aggregates for 4 days in suspension with iPSC media (no FGF2), with media changes every 
day. At day 5, aggregates were washed 1X with N2 Neural Induction media and then fed with 
N2 Neural Induction media. On day 7, aggregates were plated on either Matrigel-coated culture 
dishes (used per the manufacturer’s instructions, BD Biosciences) or poly-ornithine (4 µg/cm2) 
and laminin-coated plates (1 µg/cm2), at about 20-30 aggregates/well. Cells were fed every 2 
days with N2 Neural Induction media. Over the course of 10 days, primitive neuroepithelial (NE) 
structures were formed. By day 17 definitive NE structures were present and rosettes selected. 
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Neural rosette selection 
Neural rosettes were selected manually, selected with STEMDiff Neural Rosette 
Selection reagent (used per the manufacturer’s instructions, StemCell Technologies), or purified 
by MACS/FACS (further information below). For manual selection, cells with non-rosette 
morphology were scratched off culture plates using either sterile glass pipettes or sterile plastic 
pipette tips, followed by aspiration of undesirable material. Remaining rosettes were then 
scraped from the plate for further use. For each selection method, neural progenitor cells 
(NPCs) were either dissociated and plated for further differentiation or re-cultured in non-
adherent culture flasks. Alternatively, NPCs were cultured as an adherent monolayer.  
Neural progenitor cell monolayer culture 
NPCs were maintained in neural progenitor media (+FGF2, EGF, heparin) and passaged 
1:3 every 3-5 days or as necessary when confluent. Cells were split onto poly-ornithine 
(4µg/cm2) and laminin (1µg/cm2) coated plates. Plates were coated overnight in a humidified 
37oC incubator. 
Neural aggregate culture 
After NPC selection, cells were cultured in suspension and fed with N2/B27 neural 
induction media with cAMP and IGF-1. At day 24 (or as otherwise noted) cells maintained as 
aggregates were either plated as aggregates (3-5 aggregates/well of 96 well plate) or 
dissociated to single cells with Accutase (Invitrogen) (40,000-50,000 cells/well of 96 well plate) 
and plated on Matrigel for final differentiation in Neural Differentiation media with ROCK inhibitor 
(Stem RD, 10 µM). Cells plated at day 17 were also switched to neural differentiation media at 
day 24 for the remainder of the experiment. A full media change was performed every 2-3 days. 
Astrocyte co-culture 
Mouse astrocytes (Sciencell) were plated on top of differentiated human neurons at day 
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26 in a 1:1 media mix of Neural Differentiation media and Astrocyte media (Sciencell). 
Approximately 120,000 cells/cm2 were plated. Prior to plating, mouse astrocytes were 
maintained per the manufacturer’s directions.  
Monolayer differentiation protocol 
Using an alternate method for the induction of forebrain neurons, iPSCs were 
differentiated using a monolayer protocol8,10. iPSCs were manually groomed by removing any 
colonies with irregular borders, spontaneous differentiation or transparent centers. To initiate 
differentiation, cells were dissociated with Accutase (Invitrogen) for 30 minutes at room 
temperature. The cells were then triturated to form a single cell suspension and subsequently 
filtered through a 0.45 µm cell strainer to remove any cell clumps. Remaining cells on the plate 
were rinsed with additional iPSC media. Cells were washed and centrifuged (200g, 5 minutes) 
2x and then resuspended in 10 mL iPSC media with ROCK inhibitor (StemRD, 10 µM). The cell 
suspension was then plated on a pre-coated gelatin 10cm plate, with a density of less than 
200,000 cells/cm2. 10 cm dishes were then incubated at 37°C for 30 minutes to allow MEFS 
time to adhere to the gelatin, without substantial adherence of iPSCs. After 30 minutes, 
suspended cells were washed with iPSC media + 10 µM ROCK inhibitor and centrifuged (200g, 
5 minutes). Collected cells were resuspended with MEF conditioned media + 10 µM ROCK 
inhibitor. Cells were re-plated as a monolayer with a concentration of 20,000 cells/cm2 in MEF 
conditioned media, supplemented with FGF2 (10 ng/mL). After cells reached 90% confluency, 
media was changed to 3N neural induction media (defined below) supplemented with Noggin 
(200ng/mL) and SB431542 (10 µM) [10]. Cells were split at day 11 using dispase and re-plated 
in neural differentiation media onto 96-well plates coated with Matrigel. 
Aggregate formation using AggreWell 
Aggregates were formed using either 400 or 800 µm well plates. Plates were used per 
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the manufacturer’s instructions to form aggregates of either 3,000 or 8,000 cells/aggregate. 24 
hours after AggreWell plating (day 2), aggregates were resuspended in low-adherence flasks 
and cultured in the appropriate medias listed above. 
Medias 
MEF Medium- 435 mL DMEM (Invitrogen), 5 mL 100x Penicillin/Streptomycin (Invitrogen), 5 mL 
100x L-glutamine (Invitrogen), 50 mL FBS (Invitrogen) 
iPS Medium- 390 mL DMEM/F12, 100 mL KOSR (Invitrogen), 5 mL 100x 
Penicillin/Streptomycin/Glutamine (Invitrogen), 5 mL 100x MEM-NEAA (Invitrogen), 50 µM b-
mercaptoethanol (Invitrogen), with the addition of fresh FGF2 (Millipore, 10 ng/mL) to the 
medium 
N2 Neural Induction Medium- 490 mL DMEM/F12 (Invitrogen), 5 mL N2 supplement 
(Invitrogen), 5 mL 100x MEM-NEAA (Invitrogen), and Heparin (Sigma-Aldrich, 2 µg/mL). 
N2/B27 Neural Induction Medium- 480 mL DMEM/F12, 5 mL N2 supplement (Invitrogen), 10 mL 
B27 supplement (Invitrogen), 5 mL MEM-NEAA (Gibco) and 2 µg/ml Heparin (Sigma-Aldrich), 
with the addition of fresh cAMP (1 µM) (Sigma) and IGF1 (PeproTech, 10 ng/mL) to the 
medium. 
Neural Differentiation Medium- 490 mL Neurobasal medium (Invitrogen), 5 mL N2 supplement 
(Invitrogen), 5 mL 100x MEM-NEAA (Invitrogen), and 10 mL B27 supplement (Invitrogen), with 
the addition of fresh cAMP (Sigma, 1 µM), BDNF, GDNF, and IGF-1 (all PeproTech, 10 ng/mL) 
to the medium. 
Neural Progenitor Medium: 350 mL DMEM (Invitrogen), 150 mL F12 (Invitrogen), 5 mL 100x 
sodium pyruvate (Invitrogen, only if not included in DMEM formulation), 5 mL 100x 
Penicillin/Streptomycin/Glutamine (Invitrogen), 10 mL B27 supplement (Invitrogen) with the 
addition of fresh EGF (Sigma, 20 ng/mL), FGF2 (Millipore, 20 ng/ml), and heparin (Sigma, 5 
µg/ml) to the medium. 
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MEF Conditioned Medium- 2.8x10^6 mouse embryonic fibroblasts (GlobalStem) were plated on 
a gelatin-coated dish (1 hour at room temperature) in MEF media. 24 hours later, cells were 
washed 1X with iPS media and fed with fresh iPS media. Media was incubated for 24 hours and 
then collected. Additional iPS media was conditioned every 24 hours for up to 2 weeks. All 
media was pooled and sterile-filtered before use. 10 ng/mL of FGF2 was added fresh before 
use. 
3N Neural Induction Medium- 485 mL DMEM/F12, 5 ml 100x MEM-NEAA (5 µg/mL), 5 mL N2 
supplement (Invitrogen), 10 mL B27 supplement (Invitrogen), insulin (Sigma, 5 µg/mL), 50 µM 
b-mercaptoethanol (5 µg/mL), 5 mL 100x Penicillin/Streptomycin/Glutamine (5 µg/mL). 
qPCR 
RNA was purified from individual samples and processed through a PureLink RNA Mini 
Kit (Ambion), followed by reverse transcription using SuperScript II (Invitrogen). qPCR was 
performed using Fast SYBR Green Master Mix (Applied Biosystems) and run on a ViiA 7 
System (Applied Biosystems). Samples were assayed with 3 technical replicates. Data was 
analyzed using the ΔΔCT method and expression was normalized to GAPDH expression47. 
Primer efficiency was calculated for each pair of primers and the slope of the dilution line was 
found to be within the appropriate range. Dissociation curves also showed single peak traces, 
indicating template-specific products. 
Primers 
Oct4- Forward: TGGGCTCGAGAAGGATGTG; Reverse: GCATAGTCGCTGCTTGATCG 
MAP2- Forward: AACCGAGGAAGCATTGATTG; Reverse: TTCGTTGTGTCGTGTTCTCA 
Tbr1- Forward: TCACCGCCTACCAGAACAC; Reverse: GTCCATGTCACAGCCGGT 
GAPDH- Forward: GGGAGCCAAAAGGGTCATCA; Reverse: TGGTTCACACCCATGACGAA 
CUX1- Forward: GATGCCACCGCAACGGTAT; Reverse: GGACTGCTCACTTTCATCCTG 
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VGLUT1- Forward: ACTCAGCTCCAGCGTCTCC; Reverse: GAGTTTCGGAAGCTAGCGG 
GAD1- Forward: AGGAGAGGCAATCCTCCAAGA; Reverse: ATCCCGGTCGCTGTTTTCAC 
SYP- Forward: AGGGAACACATGCAAGGAG; Reverse: CTTAAACACGAACCACAGG 
NanoString analysis 
We utilized a custom 150 gene probe set designed by NanoString Technologies 
(nCounter Gene Expression Assay, see Table 2.2) to analyze gene expression for a large 
number of genes from an individual sample. All assays were performed following NanoString 
protocols. The initial hybridization reactions were carried out with 100-1000 ng RNA. Post-
hybridization samples were processed using the nCounter Prep-station. Following run 
completion, the cartridge was scanned at max resolution (~1000 images/sample) using the 
nCounter Digital Analyzer. Data were analyzed using the nSolver Analysis Software and 
normalized to a set of 7 house-keeping genes (HK) or to the total gene set, as noted. HK genes: 
GAPDH, GUSB, HPRT1, LDHA, POLR2A, RPL13a and RPL27. 
Antibodies 
Immunostaining was performed with the following antibodies: Abcam: [MAP2 (1:5000), 
Oct4 (1:1000), Tbr1 (1:200), Sox2 (1:1000), SYP (1:250), VGLUT1 (1:500), GFAP (1:1000)]; 
Millipore, Tbr2 (1:500); Dako, Tau (1:200); Sigma, TuJ1 (1:1000); R+D, Nestin (1:1000); 
Covance, Pax6 (1:300) and Novus, Sox 1 (1:200). Secondary antibodies were supplied by 
Jackson ImmunoResearch: anti-chicken Cy2/Cy3/Cy5, anti-rabbit Cy2/Cy3, anti-mouse 
Cy2/Cy3. Invitrogen, TOPRO3 & DAPI (nuclear markers, 1:1000). 
Immunocytochemistry and microscopy 
Cultures were fixed with 4% paraformaldehyde, followed by membrane permeabilization 
and blocking with 0.1% Triton X-100 in donkey serum (Jackson ImmunoResearch). Samples 
were incubated with primary and secondary antibodies (see Antibodies) overnight and 1 hour,  
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Table 2.2: Probe sequences for NanoString assay 
NanoString 
genes Probe Sequence 
AFP GGAGCGGCTGACATTATTATCGGACACTTATGTATCAGACATGAAATGACTCCAG
TAAACCCTGGTGTTGGCCAGTGCTGCACTTCTTCATATGCCAACA 
Cux1 ACAAACAGCCCTGGAAAAAACTCGAACAGAATTATTTGACCTGAAAACCAAATAC
GATGAAGAAACTACTGCAAAGGCCGACGAGATTGAAATGATCATG 
EN1 
GCAGCATTTTTGAAAAGGGAGAAAGACTCGGACAGGTGCTATCGAAAAATAAGAT
CCATTCTCTATTCCCAGTATAAGGGACGAAACTGCGAACTCCTTA 
FoxG1 
CTGACAAGTCTATCTCTAAGAGCCGCCAGATTTCCATGTGTGCAGTATTATAAGTT
ATCATGGAACTATATGGTGGACGCAGACCTTGAGAACAACCTAA 
GFAP AAGCAGATGAAGCCACCCTGGCCCGTCTGGATCTGGAGAGGAAGATTGAGTCGC
TGGAGGAGGAGATCCGGTTCTTGAGGAAGATCCACGAGGAGGAGGT 
HES1 
ATCTGAGCACAGAAAGTCATCAAAGCCTATTATGGAGAAAAGACGAAGAGCAAGA
ATAAATGAAAGTCTGAGCCAGCTGAAAACACTGATTTTGGATGCT 
HES5 
CAGCCTGTAGAGGACTTTCTTCAGGGCCCGTAGCTGCTGGGCGTACCCCTGGCA
GGCGGGCTGTGCCGCGGGCACATTTGCCTTTTGTGAAGGCCGAACT 
HNK1 GAGGGAGGCCTGAGCACACTGCTTTGGAAATTATTCTAAACACAAAAAAGGGAAA
GAAAATGTTATTTCTCCCTAAGTCAGGAGCATGCAGAGCTAGCCC 
HB9 CCTGGGCGCTTCCCTTTTAAGCAAGGGCGCCTCACCTGCTCTTCAAGAAACAGC
GAGAGGGAGACCCAGGGGGCTGAAACTTGAACTCTGGTTCTTTTAA 
HOXB6 
CACCCATTCCTTTAAATCCGGAGGGGGAAAAAATCCCAAGGTCTGCAAAGGCGC
GGCGCTCGGACTATAAAACACAACAAATCATAAACCCGGCGGAGCA 
HOXB13 
CCACCAGGGTTCCCAAAGAACCTGGCCCAGTCATAATCATTCATCCTGACAGTGG
CAATAATCACGATAACCAGTACTAGCTGCCATGATCGTTAGCCTC 
KCC2 ATGAGAGCGACATCTCAGCTTACACCTATGAGAAGACGTTGGTGATGGAGCAGC
GTTCCCAGATCCTCAAACAGATGCATTTAACCAAGAATGAGCGGGA 
MAP2 
TACTCTGTATGCTGGGATTCCGAGGTTCCAACACACTGTTACAAATCTGTGGGGG
GTTTCTTTCTTCTGATAATTCTAGAGCCTGTTACCATAGAAAGGC 
MYOD1 
TGTAATCTATTCCTGTAAATAAGAGTTGCTTTGCCAGAGCAGGAGCCCCTGGGGC
TGTATTTATCTCTGAGGCATGGTGTGTGGTGCTACAGGGAATTTG 
Nanog TGCAGGCAACTCACTTTATCCCAATTTCTTGATACTTTTCCTTCTGGAGGTCCTAT
TTCTCTAACATCTTCCAGAAAAGTCTTAAAGCTGCCTTAACCTT 
Nestin CAGAGAATCACAAATCACTGAGGTCTTTAGAAGAACAGGACCAAGAGACATTGAG
AACTCTTGAAAAAGAGACTCAACAGCGACGGAGGTCTCTAGGGGA 
NMDAR 
TTCAAGAGAGTGCTGATGTCTTCCAAGTATGCGGATGGGGTGACTGGTCGCGTG
GAGTTCAATGAGGATGGGGACCGGAAGTTCGCCAACTACAGCATCA 
Oct4 
AAGTTCTTCATTCACTAAGGAAGGAATTGGGAACACAAAGGGTGGGGGCAGGGG
AGTTTGGGGCAACTGGTTGGAGGGAAGGTGAAGTTCAATGATGCTC 
Pax6 GGGAATTAAAGGCCTTCAGTCATTGGCAGCTTAAGCCAAACATTCCCAAATCTAT
GAAGCAGGGCCCATTGTTGGTCAGTTGTTATTTGCAATGAAGCAC 
PSD95 TGCCCTGAAGAATGCGGGTCAGACGGTCACGATCATCGCTCAGTATAAACCAGA
AGAGTACAGCCGATTCGAGGCCAAGATCCACGACCTTCGGGAACAG 
S100B 
AGAAGGCCATGGTGGCCCTCATCGACGTTTTCCACCAATATTCTGGAAGGGAGG
GAGACAAGCACAAGCTGAAGAAATCCGAACTCAAGGAGCTCATCAA 
Satb1 
TTCCGAAATCTACCAGTGGGTACGCGATGAACTGAAACGAGCAGGAATCTCCCA
GGCGGTATTTGCACGTGTGGCTTTTAACAGAACTCAGGGCTTGCTT 
Table 2.2 (Continued) 
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Sox1 AAAGCGTTTTCTTTGCTCGAGGGGACAAAAAAGTCAAAACGAGGCGAGAGGCGA
AGCCCACTTTTGTATACCGGCCGGCGCGCTCACTTTCCTCCGCGTT 
Sox2 
AAAGCGTTTTCTTTGCTCGAGGGGACAAAAAAGTCAAAACGAGGCGAGAGGCGA
AGCCCACTTTTGTATACCGGCCGGCGCGCTCACTTTCCTCCGCGTT 
Synapsin I 
GGATCTACTTCTGTTTTAGAACCTCCACATTCCTGAAGACCTCCGCCCCTGGTTT
CCCCAGAGGGCGTTTTCCTTCCTGGAAGTGCCCAAATACCAGGCA 
Tau ATTGGGTCCCTGGACAATATCACCCACGTCCCTGGCGGAGGAAATAAAAAGATTG
AAACCCACAAGCTGACCTTCCGCGAGAACGCCAAAGCCAAGACAG 
Tbr1 GCCGTCTGCAGCGAATAAGTGCAGGTCTCCGAGCGTGATTTTAACCTTTTTTGCA
CAGCAGTCTCTGCAATTAGCTCACCGACCTTCAACTTTGCTGTAA 
Tbr2 
TCTCTAGATTCCAATGATTCAGGAGTATACACCAGTGCTTGTAAGCGAAGGCGGC
TGTCTCCTAGCAACTCCAGTAATGAAAATTCACCCTCCATAAAGT 
TWIST1 
CAACTCCCAGACACCTCGCGGGCTCTGCAGCACCGGCACCGTTTCCAGGAGGC
CTGGCGGGGTGTGCGTCCAGCCGTTGGGCGCTTTCTTTTTGGACCTC 
VGAT CAGGCTGGAACGTGACCAACGCCATCCAGGGCATGTTCGTGCTGGGCCTACCCT
ACGCCATCCTGCACGGCGGCTACCTGGGGTTGTTTCTCATCATCTT 
VGLUT1 
TCGGCTACTCGCACTCCAAGGGCGTGGCCATCTCCTTCCTGGTCCTAGCCGTGG
GCTTCAGCGGCTTCGCCATCTCTGGGTTCAACGTGAACCACCTGGA 
Vimentin 
GAGGAGATGCTTCAGAGAGAGGAAGCCGAAAACACCCTGCAATCTTTCAGACAG
GATGTTGACAATGCGTCTCTGGCACGTCTTGACCTTGAACGCAAAG 
Housekeeping genes: 
B2M 
CGGGCATTCCTGAAGCTGACAGCATTCGGGCCGAGATGTCTCGCTCCGTGGCCT
TAGCTGTGCTCGCGCTACTCTCTCTTTCTGGCCTGGAGGCTATCCA 
GAPDH 
TCCTCCTGTTCGACAGTCAGCCGCATCTTCTTTTGCGTCGCCAGCCGAGCCACAT
CGCTCAGACACCATGGGGAAGGTGAAGGTCGGAGTCAACGGATTT 
GUSB CGGTCGTGATGTGGTCTGTGGCCAACGAGCCTGCGTCCCACCTAGAATCTGCTG
GCTACTACTTGAAGATGGTGATCGCTCACACCAAATCCTTGGACCC 
HPRT1 
TGTGATGAAGGAGATGGGAGGCCATCACATTGTAGCCCTCTGTGTGCTCAAGGG
GGGCTATAAATTCTTTGCTGACCTGCTGGATTACATCAAAGCACTG 
LDHA 
AACTTCCTGGCTCCTTCACTGAACATGCCTAGTCCAACATTTTTTCCCAGTGAGTC
ACATCCTGGGATCCAGTGTATAAATCCAATATCATGTCTTGTGC 
POLR2A TTCCAAGAAGCCAAAGACTCCTTCGCTTACTGTCTTCCTGTTGGGCCAGTCCGCT
CGAGATGCTGAGAGAGCCAAGGATATTCTGTGCCGTCTGGAGCAT 
RPL13a AGTCCAGGTGCCACAGGCAGCCCTGGGACATAGGAAGCTGGGAGCAAGGAAAG
GGTCTTAGTCACTGCCTCCCGAAGTTGCTTGAAAGCACTCGGAGAAT 
RPL27 
GGGCCGGGTGGTTGCTGCCGAAATGGGCAAGTTCATGAAACCTGGGAAGGTGG
TGCTTGTCCTGGCTGGACGCTACTCCGGACGCAAAGCTGTCATCGTG 
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respectively. Imaging was performed using a Zeiss LSM710 confocal microscope and images 
were acquired using ZEN black software. Software was used to pseudo-color images and add 
scale bars. Quantified MAP2 immunostaining was performed blind on at least 3 images per 
condition, with at least 200 cells counted per image, using ImageJ software (NIH).  
MACS 
Day 17 embryoid aggregate-differentiated cells were utilized for MACS. Cells were dissociated 
to single cells using Accutase (Invitrogen) + 10 µM ROCK inhibitor (StemRD) for 30-45 minutes. 
Cell clumps were removed using a 70 µm strainer (Pre-separation filter, Miltenyi). Cells were 
sorted per the manufacturer’s instructions using Anti-PSA-NCAM Microbeads (Miltenyi) and 
related equipment (MS columns and MACS Separator, Miltenyi).  
FACS 
Day 17 embryoid aggregate-differentiated cells were utilized for FACS. Cells were dissociated 
using Accutase (Invitrogen) for 25 minutes and treated per the manufacturer’s protocol (Human 
Neural Cell Sorting Kit, BD Biosciences). The kit was used to isolate CD184+/CD44-/CD271-
/CD24+ neural stem cells, which were separated from neural crest and other non-neuronal cells 
using a BD FACSAria cell sorter. Cells were either harvested after sorting for RNA analysis or 
plated on Matrigel for immunostaining and confocal microscopy analysis.  
Statistics 
Data was analyzed using GraphPad PRISM 5/6 software. Values are expressed as means 
±S.D. or ±SEM, as indicated by figure legend text. See Table 2.3 for experimental details. 
Statistical significance was tested by either an unpaired Student's t-test (two-tailed), by one-way 
ANOVA with a Tukey’s post-test, or by two-way ANOVA with Holm-Sidak multiple comparisons 
correction (as indicated by figure legend text). Statistically significant differences were 
determined by P values less than 0.05.
  92 
 
 
 
 
 
 
Table 2.3: Number of iPSC lines, differentiations and well numbers contributing to 
each figure 
Figure Lines used 
Independent 
differentiations 
n 
Figure 2.1 
YZ1, TZ1, 
YK26, fAD 2a 
1D: 6 
1D: iPS n=14-15, D17 n=23-25, D40-50 
n=19-26 
Figure 2.2 YZ1, YK26 *2D: 2 
*2D: iPS n=2-3, D1 n=3-4, D7 n=3-4, D11 
n=5-6, D40 n=5 
Figure 2.3 YZ1, YK26 3B: 4, 3D: 2 
3B: manual n=43, AG3000 n=21, AG8000 
n=26; 3D: Manual/Aggrewell n=10 
Figure 2.4 YZ1, YK26 4H/J: 2 
4H: Matrigel and POL n=10; 4J: Matrigel 
and POL n=22 
Figure 2.5 YZ1, YK26 
5F,G: manual: 5; 
rosette: 18; 
FACS: 6 
5F,G: Manual n=15; Rosette n=30; FACS 
n=6 
Figure 2.6 
YZ1, YK26, 
fAD 2a,b 
6B/D: 2 6B: n=11-26; 6D: n=6, both time-points 
Figure 2.7 YZ1, YK26 7C,D: 6; 7F: 5 
7C,D: D40-50 n=29-38, D100 n=15-19; 
7F: Neurons alone n=20 for MAP2, TBR1, 
CUX1, GAD1, n= 37 for SYP, n=38 for 
VGLUT1; Astrocyte Co-culture n=17 for 
GAD1, n=18 for MAP2, TBR1, CUX1, 
n=27 for SYP, n=25 for VGLUT1 
* 10/10 differentiations without dissociation failed. 3/5 differentiations with dissociation yielded 
MAP2+ cells. 
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ABSTRACT 
Genetic and clinical association studies have identified disrupted-in-schizophrenia 1 
(DISC1) as a strong candidate risk gene for major mental illness. DISC1 is interrupted by a 
balanced chr(1;11) translocation in a Scottish family, in which the translocation predisposes to 
the development of psychiatric disorders. We investigate the consequences of DISC1 
interruption in human neural cells using TALENs or CRISPR-Cas9 to target the DISC1 locus. 
We show that disease-relevant DISC1 targeting results in decreased DISC1 protein expression, 
increased canonical Wnt signaling activity, and a shift in neural cell fate. DISC1-dependent Wnt 
signaling and cell fate changes can be reversed by antagonizing the Wnt pathway during a 
critical window in neural progenitor development. These experiments suggest that DISC1-
disruption increases Wnt signaling, which alters the identity of neural progenitors, thereby 
modifying Wnt responsiveness and cell fate. These studies shed light on the roles of DISC1 
during human brain development, and further our understanding of the pathogenesis of major 
mental illness. 
INTRODUCTION 
Schizophrenia is a debilitating psychiatric disorder that affects ~1% of the world’s 
population. Schizophrenia and other major mental illnesses (MMIs) are widely regarded to result 
from a combination of genetic susceptibility and environmental insults1-3. A diagnosis of 
schizophrenia is marked by clinical and neurobiological heterogeneity, without striking universal 
pathological hallmarks4. However, clinical and genetic studies indicate that schizophrenia and 
other MMIs are likely diseases of altered circuitry resulting from disruptions in 
neurodevelopment5-8.  The precise developmental step(s) and affected cell type(s) that lead to 
altered circuitry are not known, but are also likely to be heterogeneous. The recent expansion of 
GWAS studies has identified many interesting but generally weak genetic linkages9-14. There are 
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also rare strong genetic variants that have been associated with mental illness, including 
various CNVs and a balanced translocation interrupting the gene disrupted in schizophrenia 1 
(DISC1)1,15,16. DISC1 was initially associated with mental illness upon the discovery that its 
coding sequence is interrupted by a balanced chr(1;11) translocation in a Scottish family, in 
which the translocation cosegregates with schizophrenia, bipolar disorder and major 
depression17-19. The diversity of phenotypes in subjects harboring the translocation suggests 
that a subtle underlying disruption in development may exist, which predisposes subjects to 
MMI by increasing vulnerability to other environmental and genetic risk factors. While such rare 
variants are not likely to contribute significantly to the incidence of sporadic disease, they offer 
valuable opportunities for investigation. Studying biological effects of known rare mutations with 
high penetrance has the potential to illuminate cellular and molecular processes implicated in 
disease pathophysiology, as has been demonstrated with familial mutations in 
neurodegenerative diseases20. 
Though the genetics of major mental illness are incredibly complex, genetic association 
studies have implicated DISC1 as a candidate risk gene for schizophrenia, schizoaffective 
disorder, bipolar disorder, major depression, and autism spectrum disorders (ASD)21-29. The 
involvement of DISC1 and other susceptibility genes in both adult-onset major mental illnesses 
and childhood-onset ASD indicate that a disturbance of proper neurodevelopment may 
contribute to each of these disorders30-32. This hypothesis is further strengthened by involvement 
of mental illness risk-associated proteins in neurodevelopmental processes, such as neural 
progenitor proliferation, neuronal migration, neurite outgrowth, neuron maturation, and 
myelination (reviewed here30,33-35). DISC1 has been implicated in several neurodevelopmental 
processes, including proliferation, Wnt signaling, synaptic maturation, neurite outgrowth, and 
neuronal migration (reviewed here30). In addition, many known DISC1 interacting proteins have 
independently been associated with neuropsychiatric diseases, further implicating this network 
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of proteins in the pathophysiology of mental illness (reviewed here30). In order to understand 
how DISC1 mutations increase susceptibility to mental illness, intensive study is necessary to 
elucidate the pathways by which it normally functions in the human brain and how disease-
predisposing DISC1 variants affect neurodevelopment.  
The discovery of the Scottish chr(1;11) translocation stimulated several hypotheses 
regarding the pathological mechanisms of this abnormality. The balanced translocation could 
lead to a C-terminally-truncated DISC1 protein, a DISC1 fusion protein, or loss of protein 
production from one allele via nonsense-mediated decay. Several rodent models have been 
developed to address these possibilities, using mutations in endogenous DISC1, 
overexpression of truncated DISC1, or DISC1 knockdown. These models have identified 
interesting effects of DISC1 perturbation on cell signaling, neuronal migration, morphology, 
physiology, and in some instances, behavior36-45. Without brain tissue from human t(1;11) 
carriers, it is difficult to know which (if any) of these models mimic the human disease state.  
DISC1 has a very complex splicing pattern, with over 50 splice variants identified to date 
in human brain46. Given the complexities of DISC1 splicing, a detailed study examining the 
consequences of DISC1 interruption is best accomplished in human brain cells. The advent of 
human induced pluripotent stem cells (iPSCs) that can be differentiated to many somatic 
lineages, including neurons, has allowed a dramatic expansion in the investigation of cellular 
mechanisms of human disease47-49. The ability to recapitulate aspects of corticogenesis by 
differentiating iPSCs makes these cells a particularly powerful tool for studying disorders of 
human neurodevelopment, including major mental illnesses50-54. While somatic cell-derived 
iPSCs from multiple subjects can be used to study disease processes, there exist wide 
variations in genomic content and epigenetic modifications across cell lines that alter gene 
expression and cellular phenotypes55. When using iPSCs to model a subtle disease phenotype 
in vitro, the effects of background genetic variation between control and patient samples can 
  101 
obscure or falsely identify differences between these groups. In the study of a known disease-
predisposing mutation, one way to avoid this problem is to use “isogenic” lines, which differ only 
at a single locus. Here, we study the consequences of DISC1 disruption in isogenic stem cell 
lines generated using transcription activator-like effector nucleases (TALENs) or clustered 
regularly interspaced short palindromic repeats (CRISPR)-Cas9 to interrupt DISC1 near the site 
of the balanced translocation or else in an exon common to all isoforms. In these studies, 
multiple isogenic clonal lines are compared for each genotype, allowing for careful study of the 
effects of genomic DISC1 interruption on gene expression and neuronal development. 
Recent models of mental illness using human iPSCs have utilized sporadic disease 
lines56-60 as well as rare variants61,62. These studies have implicated multiple 
neurodevelopmental steps that may be disrupted in the pathophysiology of mental illness. Here, 
we investigate the effects of disease-relevant genomic DISC1 disruption on DISC1 expression 
and human cortical neurodevelopment. We explore the functional consequences of genomic 
DISC1-interruption in human iPSC-derived human cortical neural progenitor cells (NPCs) and 
neurons. We find that disease-relevant DISC1-interruption decreases DISC1 expression due to 
nonsense-mediated decay and increases NPC Wnt signaling, which subtly alters cell fate in 
NPCs and neurons. This study further clarifies the functions of DISC1 and identifies how these 
functions are perturbed in a human disease model, providing insights into a form of 
neurodevelopmental disruption that may contribute to the pathophysiology of mental illness. 
RESULTS 
Genomic DISC1 exon 8 interruption results in loss of DISC1 expression due to 
nonsense-mediated decay 
 In order to investigate the effects of DISC1 interruption at the site of the Scottish 
translocation in human neurons, we introduced DISC1 frameshift mutations into control iPSCs. 
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Mutations were introduced either into exon 8 (near the site of the translocation) or exon 2  
(intended to disrupt all known coding isoforms) (Fig 3.1). This strategy allowed us to examine in 
detail the effects of genomic DISC1 interruption on DISC1 expression and neural progenitor and 
neuronal phenotypes in the absence of other genetic variation. Using either TALEN or CRISPR-
Cas9 technology, we generated isogenic human iPSC lines that are wild-type (wt) or have 
frameshift mutations in either exon 8 (monoallelic: exon 8 wt/mut or “ex8wm”, biallelic: “exon 8 
mut/mut” or “ex8mm”) or exon 2 (biallelic: exon 2 mut/mut or “ex2mm”). Exon 8 mutations were 
generated using a TALEN pair (constructed using a hierarchical ligation procedure63), while 
exon 2 mutations were generated by CRISPR-Cas9 targeting. Using these techniques, multiple 
DISC1 mutant genotypes were attained at each locus. Exon 8 targeting resulted in 2 distinct 
heterozygous 1 bp deletions and 1 heterozygous 1 bp insertion, as well as a 1 bp deletion/1 bp 
insertion compound heterozygous genotype (Fig 3.1C). These indels result in the introduction of 
a premature termination codon (PTC) within 3 codons (exon 8 ins 1 bp) or 27 codons (exon 8 
del 1 bp). Exon 2 targeting resulted in two distinct biallelic mutation genotypes: a 1 bp/2 bp 
insertion compound heterozygote and a 1 bp insertion homozygote (Fig 3.1D), resulting in a 
PTC within 12 codons (exon 2 ins 1 bp) or 65 codons (exon 2 ins 2 bp). Targeted cells 
maintained iPSC colony morphology, expressed iPSC markers Nanog, Oct4, SSEA4, Sox2, and 
TRA-1-60 (Fig 3.1E; Fig 3.2), and maintained a euploid karyotype (Fig 3.3). No predicted off-
target cleavage events were detected using RNA-sequencing data (data not shown, see 
Experimental Procedures). Multiple iPSC clones of each genotype were used for the studies 
described herein to minimize the potential effects of clonal variability and off-target cleavage 
events (Table 3.1). 
Genomic DISC1 interruption has been hypothesized to cause expression of a truncated 
or mutant DISC1 or to decrease DISC1 expression from the mutated allele30. The limited 
evidence that exists from t(1;11) patients suggests that the translocation lowers DISC1  
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Figure 3.1. Targeting the human DISC1 locus. (A) Diagram of the coding sequence of 
DISC1, with the sites of induced frame shifts and the Scottish chr(1;11) translocation 
indicated. (B) Diagram of the DISC1 genomic locus, with exons shown on the top line and 
sample transcripts shown below. A selection of alternatively spliced isoforms are shown in 
red. (C,D) Wild-type and mutant sequences around the exon 8 (C) or exon 2 (D) targeting 
sites, obtained by Sanger sequencing of targeted iPS colonies. Mutation sites are indicated 
with black arrowheads. (E) Immunostaining for pluripotent cell markers Nanog, Oct4, SSEA4, 
Sox2, and TRA-1-60 following genome-editing. Scale bar = 50 um. 
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Figure 3.3. Genomic stability analyses. Genomic DNA was harvested from each iPSC line 
and assayed using the NanoString human CNV assay codeset. Representative CNV 
analyses are shown for wt/wt lines (A), exon 8 wt/mut lines (B), exon 8 mut/mut lines (C), 
and exon 2 mut/mut lines (D). Examples of abnormal CNV profiles that resulted in discarding 
iPSC lines are shown in (E-G), with abnormalities in red boxes. Karyotyping was performed 
routinely on all lines to examine genomic stability. 
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Table 3.1. Summary of lines used to generate data. (x) indicates data not shown. 
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transcript and protein levels in patient-derived cell lines64. However, the effects of t(1;11) have 
not yet been studied in human neurons. Based on the genomic structure surrounding the 
t(1;11)breakpoints, if splicing occurs between DISC1 exon 8 and the next available exon on 
chr11, the resulting transcript would contain a premature stop codon. The introduction of a PTC 
into a coding RNA often results in nonsense-mediated decay (NMD) if the PTC occurs prior to 
the last exon-exon junction of the transcript65. Thus, we hypothesized that genomic DISC1 
interruption would cause decay of those PTC-containing mRNAs that extended at least one 
exon past the interruption (i.e. beyond exon 8 for exon 8 targeting; beyond exon 2 for exon 2 
targeting). Given the complexity of DISC1 splicing, we chose to analyze transcription at multiple 
DISC1 coding regions to assess levels of distinct groups of isoforms. For example, exons 12 
and 13 are only present in the longest DISC1 transcripts (L and Lv), whereas exon 2 is present 
in all identified DISC1 coding transcripts46. We therefore predicted that exon 8 targeting would 
decrease expression of longer splice variants from the mutant allele(s), whereas biallelic exon 2 
targeting would ablate DISC1 expression, due to degradation of all coding RNAs. 
To examine the effects of genomic DISC1 interruption on DISC1 RNA expression, RNA 
was harvested from NPCs and/or differentiated neurons. Wild-type and DISC1-targeted iPSCs 
were differentiated to neural fates using an embryoid aggregate-based protocol66, which results 
in definitive neuroepithelium by day 17 and expression of neuronal makers past day 25. We 
sought to characterize the expression of multiple isoforms of DISC1 by examining RNA 
expression of distinct exons or exon junctions. Initial qPCR analyses of day 40 neuronal 
samples revealed that the presence of a single exon 8 mutant allele (exon 8 wt/mut) does not 
significantly decrease total DISC1 expression (assessed by qPCR of DISC1 exon 2) but does 
significantly decrease expression of the longest DISC1 isoforms (DISC1 exon 12/13) (Fig 
3.4A,B). Biallelic exon 8 interruption (exon 8 mut/mut) significantly decreased total DISC1 and 
long DISC1 transcripts (Fig 3.4A,B). Surprisingly, the biallelic exon 2 mutation did not reduce 
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Figure 3.4. DISC1 exon 8-disruption causes loss of full length DISC1 expression via 
NMD. (A,B) Wild-type and DISC1-disrupted iPSCs were differentiated to day 40 neural fates 
and RNA was harvested for qRT-PCR of DISC1 exon 2 (A) or exons 12/13 (B). Expression 
is normalized to GAPDH and wt/wt levels. (C) iPSCs were differentiated to NPCs (day 17) 
and neurons (day 50) and RNA was harvested for NanoString. DISC1 probe expression is 
normalized to expression of 8 housekeeping genes & average wt/wt d17 levels. Statistics 
shown versus wt of corresponding differentiation day. (D) Representative Western blot of 
DISC1 in day 40 neuronal lysates.  Full length DISC1 is indicated with blue arrows; novel 
truncated DISC1 is indicated by red arrows. The red asterisks denote a nonspecific band. 
(E,F) Quantification of full-length (E) or all (F) DISC1 from Western blots of day 40 neuronal 
lysates, normalized to GAPDH and wt/wt levels. (G,H) Day 40 neurons were treated with 100 
ug/ml cycloheximide (CHX) or vehicle (DMSO) for 3 hrs, followed by RNA harvest and qRT-
PCR for exon 2 (G) or the exon 12/13 junction (H) of DISC1. Expression normalized to 
GAPDH and average DMSO expression within genotype. All data derived from at least 5 
independent differentiations. Stats: (C) 2-way ANOVA, (A,B,E-H) 1-way ANOVA. Mean ± 
SEM shown. ns = not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
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DISC1 expression, but instead modestly increased total DISC1 (exon 2) RNA levels and did not 
alter expression of long isoforms (Fig 3.4A). We further investigated levels of various DISC1 
isoforms in NPCs (day 17) and neurons (day 50) using a custom NanoString probeset which 
included probes targeting multiple DISC1 exons. The NanoString analyses confirmed the qPCR 
data, showing isoform-specific effects of genomic DISC1 disruption, where introduction of a 
PTC into exon 8 decreased expression of longer (extending beyond exon 8) but not shorter 
DISC1 transcripts at day 17 (NPC) and day 50 (neuron) (Fig 3.4C). Unexpectedly, exon 2 
targeting appeared to decrease DISC1 expression at day 17 (Fig 3.4C), but either did not 
change or increased expression of various DISC1 isoforms at days 40-50 (Fig 3.4A-C). 
 To investigate the effects of DISC1 interruption at the protein level, we performed 
Western blots of day 40 neuronal lysates and analyzed DISC1 expression using a monoclonal 
antibody we generated against the C-terminus of DISC1. Single allelic DISC1 exon 8 mutation 
resulted in a ~55% decrease in full-length DISC1 protein expression, while biallelic exon 8 
mutation led to total loss of full length protein, consistent with a loss of expression from longer 
transcripts (Fig 3.4D-F). Biallelic exon 2 targeting showed a total loss of full length protein, but 
surprisingly led to the expression of a shorter, novel DISC1 protein product in day 40 neural 
cells (Fig 3.4D, red arrows). This truncated protein was expressed at levels nearly identical to 
that of wild-type full-length DISC1 (Fig 3.4F). Although unexpected, the truncated DISC1 protein 
resulting from exon 2 mutation provided an opportunity to include in our analyses the effects of 
an independent DISC1 mutation in a system that was isogenic to our disease-relevant (exon 8-
disruption) DISC1 disruption model. As several prior studies have demonstrated that 
misexpression of a mutant truncated DISC1 can phenocopy DISC1 knockdown30, we used our 
exon 2- and exon 8-targeted cells to explore whether these observations would hold true in a 
human neuronal context. 
To determine whether the observed changes in DISC1 expression in the exon 2- and 
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exon 8-targeted cells were due to NMD of RNAs containing a PTC, we treated day 40 neurons 
with cycloheximide (CHX), which inhibits NMD by interfering with the “pioneer” round of 
translation required to detect the PTC67. Analysis of DISC1 expression after CHX treatment 
revealed significantly increased NMD of exon 2- and exon 12/13-containing mRNAs in exon 8- 
but not exon 2-targeted cells (Fig 3.4G,H). These data suggest that introduction of a PTC into 
DISC1 exon 8, but not exon 2, results in NMD of PTC-containing transcripts. This result 
supports a loss-of-function (LOF) model, whereby genomic DISC1 interruption at exon 8 causes 
loss of DISC1 expression from the disrupted allele. In the chr(1;11) balanced translocation, 
splicing of exon 8 to the next available exon (in chromosome 11) results in a premature 
termination codon within 2 or 61 codons (depending on usage of 2 different predicted exons), 
prior to the last exon of the chr11 gene. This fusion transcript should therefore also recruit the 
NMD pathway, as observed in our model. The common effect of 1 bp insertion or deletion on 
decreasing DISC1 expression suggests that the number of codons (3 or 27) preceding the PTC 
does not alter targeting of the transcript for NMD. 
 We further explored the effects of DISC1 genomic disruption on DISC1 protein stability, 
using cycloheximide (CHX) to prevent translation in day 40 neurons. DISC1 protein was 
remarkably refractory to turnover under these conditions, showing very little or no degradation 
over 24 hours (Fig 3.5). These data contrast with a recent report of a 1-4 hr DISC1 half-life in 
PC12 cells68. Efficacy of the CHX treatment was confirmed by detecting APP levels, which 
showed a half life of ~4 hr for this protein, in agreement with measurements of APP half life in 
the literature69-73. There was no indication from these studies that DISC1 mutation resulted in an 
unstable DISC1 protein product. 
Genomic DISC1 interruption alters expression of NPC fate markers 
To examine the effects of DISC1 disruption in NPC and neuronal cell populations, we 
characterized broader gene expression profiles and cell fate in wild-type and DISC1-targeted 
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Figure 3.5. DISC1 mutations do not destabilize DISC1 protein. Day 40 neurons were 
treated with DMSO (vehicle) or 100 ug/ml cycloheximide (CHX) for the indicated time 
periods. Cells were then lysed and equal protein amounts were used for Western blotting. 
(A) Quantification of protein levels over time with CHX treatment. Mean ± SEM shown. 
Statistics: two-way ANOVA, **** p < 0.0001. Sample number shown in white within bars. (B) 
Representative Western blot showing DISC1, APP, and GAPDH protein levels. Blue arrows 
indicate full-length DISC1, red arrows indicate exon 2 truncated DISC1, grey arrows indicate 
APP, asterisks indicate nonspecific bands. Data derived from at least 3 independent 
differentiations. 
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cells. Neural differentiation resulted in dorsal forebrain NPC fates across all genotypes (Fig 
3.6A, expressing Nestin, Pax6, Brn2, Ngn2, FoxG1, Tbr2). In order to quantitatively measure 
expression of a broad selection of neural markers, we used a custom NanoString codeset to 
assay RNA expression in rosette-selected day 17 NPCs. NanoString analyses showed that 
DISC1 exon 8 and exon 2 interruption significantly decreased FoxG1 and Tbr2 expression (Fig 
3.6B). There also was decreased Sox1 and increased Pax6 expression in exon 2-targeted 
NPCs, suggesting that exon 2 mutation causes more dramatic cell fate changes than exon 8 
interruption (Fig 3.6B,C). DISC1 interruption did not alter expression of other broad progenitor 
markers, such as Sox2, HES1, Nestin, or Vimentin (Fig 3.6B,C). The decrease in FoxG1 and 
Tbr2 RNA in the absence of decreased expression of other cortical progenitor markers argued 
against a deficit in telencephalic differentiation. Furthermore, immunostaining did not reveal any 
qualitative changes in the proportion of FoxG1+ cells, suggesting that FoxG1 levels were 
decreased on an individual cell basis (Fig 3.6A). 
DISC1 interruption subtly alters neuronal fate but not neuronal maturity 
We further investigated effects of DISC1 disruption on cell fate in iPSC-derived neurons. 
Differentiation for 40 days resulted in neurons of mixed layer identity (lower layer: CTIP2, Tbr1; 
upper layer: Cux1, Brn2, Satb2) that expressed neuronal markers MAP2, Tau, SYP, PSD-95, 
and VGLUT2 (Fig 3.7A). A population of neural progenitors persisted in these cultures (Nestin, 
Tbr2; Fig 3.7A). Neurons demonstrated spontaneous action potentials by day 42 when co-
cultured with astrocytes (Fig 3.7B, Fig 3.8A). Gene expression was assayed in day 50 neurons 
by NanoString, revealing a persistent decrease in Tbr2 expression across all genotypes and 
decreased FoxG1 in exon 8 wt/mut and exon 2 mut/mut neurons (Fig 3.7C). There were no 
significant expression changes of general neuronal markers (including TUJ1, Tau, PSD-95, Syn 
I, and SYP; Fig 3.7D). Exon 2 mut/mut neurons expressed lower levels of select mature 
neuronal genes VGLUT1, GRIN1, and MAP2 (Fig 3.7D). Exon 8 interruption did not significantly  
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Figure 3.6. DISC1 disruption causes subtle alterations in NPC fate. (A) iPSCs were 
differentiated to day 17 NPCs, rosette selected, and immunostained for the NPC markers as 
shown. Scale bar = 50 um. (B,C) iPSCs were differentiated to day 17 NPCs, rosette 
selected, and RNA was harvested for NanoString. Gene expression is normalized to 
expression of 8 housekeeping genes and wt/wt levels. Data derived from at least 8 
independent differentiations. Statistics: 2-way ANOVA. Mean ± SEM shown. * p < 0.05, ** p 
< 0.01, **** p < 0.0001. 
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Figure 3.7. DISC1 disruption does not alter neuronal differentiation capacity or 
maturity but causes subtle alterations in cell fate. (A) iPSCs were differentiated to day 40 
neurons and immunostained for the markers labeled. Scale bar = 50 um top 8 rows, 25 um 
bottom 3 rows. (B) Day 24 cells were dissociated and plated with human astrocytes on 
microelectrode arrays. Day 42 single unit waveforms are shown. (C-E) iPSCs were 
differentiated to day 50 neurons and RNA was harvested for NanoString. Gene expression is 
normalized to expression of 8 housekeeping genes and wt/wt levels. (F,G) Quantification of 
SYP (F) and SYN I (G) protein expression in day 40 neuronal lysates, normalized to Tau. (H) 
Representative Western blot of neuronal markers SYN I, SYP, MAP2, Tau, and loading 
control GAPDH in day 40 neuronal lysates. Same membrane as shown in Fig 3.4D. Data 
derived from at least 8 independent differentiations. Statistics: (C-E) 2-way ANOVA, (F,G) 1-
way ANOVA. Mean ± SEM shown. ns = not significant, * p < 0.05, ** p < 0.01, *** p < 0.001, 
**** p < 0.0001. 
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Figure 3.7 (Continued)
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Figure 3.8. Microelectrode array (MEA) recordings show spontaneous activity from 
embryoid aggregate and Ngn2-transduced iPSC-derived neurons. Example raster plots 
from embryoid aggregate day 47 neurons (A) and Ngn2-transduced day 29 induced neurons 
(B). Each row represents one electrode; 8 representative electrodes were selected from 1 
recording of each of the genotypes as shown. 
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alter neuronal layer marker expression, while exon 2 interruption significantly decreased lower 
layer neuron markers CTIP2, FezF2, and Tbr1, with a trend for decreased upper layer markers 
Satb1 and Cux1 (Fig 3.7E). These gene expression changes support the day 17 NPC data, 
where exon 8 interruption subtly shifts cell fate without impairing neuronal differentiation, and 
exon 2 interruption causes a broader dysregulation of neurogenesis. We further investigated 
neuronal maturity by assessing expression of presynaptic proteins. Western blot analyses 
revealed no significant alterations in SYP or Syn I expression with DISC1 disruption (Fig 3.7F-
H), in contrast to a different clinical DISC1 mutation (exon 12 Δ4bp74), which was found to result 
in a dramatic increase in both62. 
The effects of DISC1 disruption on neuronal cell fate confounded further analyses of 
neuronal phenotypes, as differences in cell fate can affect many neuronal properties. In 
addition, while the embryoid aggregate-based protocol employed here is a valuable tool for 
studying neurodevelopment, iPSC differentiation results in a heterogeneous pool of neurons 
that follows a human developmental timeline54. These factors can complicate analyses requiring 
a homogenous cell population or mature neurons, which may not develop in these cultures for 
months. In order to study gene expression in a more homogenous and mature neuronal 
population, we utilized a single-step induction protocol, wherein Neurogenin2 (Ngn2) viral 
transduction directly converts iPSCs to layer 2/3 excitatory neurons75. For these analyses, we 
narrowed our focus to our disease model, DISC1 exon 8 wt/mut lines, in parallel with wild-type 
lines. Immunostaining confirmed that this protocol induces rapid neuronal fate conversion and 
results in neurons expressing Tau, MAP2, PSD-95, and SYP (Fig 3.9A). These neurons 
expressed upper-layer markers Brn2, Cux1, Cux2, and Satb2, and excitatory neuron markers 
VGLUT1 and VGLUT2 (Fig 3.9A). Ngn2 induced neurons (iNs) demonstrated spontaneous 
action potentials when co-cultured with astrocytes (Fig 3.8B, 3.9B). In order to first compare the 
population of neurons generated by Ngn2 expression to our standard embryoid aggregate- 
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Figure 3.9. Induced neuron differentiation modifies the neurodevelopmental effects of 
DISC1 disruption. (A) iPSCs were transduced with Neurogenin 2 and differentiated for 28 
days to yield a homogenous and mature population of excitatory layer II-III neurons. Day 28 
neurons were immunostained for the markers labeled. Scale bar = 50 um. (B) Day 4 cells 
were dissociated and plated with human astrocytes on microelectrode arrays. Day 24 single 
unit waveforms are shown. (C-F) Ngn2-transduced iPSCs were differentiated to day 28 
neurons and RNA was harvested for NanoString. Gene expression is normalized to all genes 
and day 40 embryoid aggregate-derived neurons (average of 19 samples, shown by red 
dotted line). Data derived from 6 independent differentiations. Statistics: (C-F) 2-way 
ANOVA. Mean ± SEM shown. ns = not significant, ** p < 0.01, **** p < 0.0001. 
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based protocol, we compared gene expression of day 40 aggregate-derived neural cells to day 
28 Ngn2-transduced cells. NanoString showed downregulation of layer I marker Reelin and 
lower layer markers Tbr1 and CTIP2 and upregulation of upper layer marker Satb1 in Ngn2-
transduced neurons relative to aggregate-derived neurons (Fig 3.9C). Decreased Cux1/2 
expression in the iNs may reflect the decrease in the progenitor population, as these markers 
can be expressed in upper-layer precursor cells as well as upper-layer neurons76. Expression of 
some general neuronal markers was increased with Ngn2 transduction, including DCX, 
NeuroD1, Tau, and TUJ1 (Fig 3.9D). Confirming the increased maturity of the induced neuron 
cultures, neural progenitor marker levels were decreased (FoxG1, HES1, Pax6, Sox1; Fig 
3.9E), and mature neuronal markers were increased (PSD-95, SYP, Syn I, VGLUT1/2; Fig 3.9F) 
compared to embryoid aggregate neurons. 
Comparison of wild-type and ex8wm induced neuron cultures revealed comparable 
expression of many neuronal markers in these cultures. However, decreased expression of 
Satb1 and NeuroD1, with increased expression of Sox2 may reflect decreased neuronal 
maturity in exon 8 wt/mut neurons (Fig 3.9C-E)77,78. The decreased levels of neural progenitors 
and low FoxG1 expression obscure the decrease in FoxG1 and Tbr2 expression observed with 
embryoid aggregate differentiation (Fig 3.9 E), making these induced neurons a less attractive 
model in which to study the neurodevelopmental consequences of DISC1 interruption. 
RNA-sequencing shows a dorsal fate shift in DISC1-interrupted NPCs and 
neurons 
 In order to get a genome-wide view of gene expression changes, we performed RNA-
sequencing (RNA-seq) on day 17 NPC samples and day 50 neuronal samples of wild-type and 
DISC1-disrupted cells. These data show that exon 8 interruption did not substantially alter 
global gene expression, whereas exon 2 interruption had a greater effect in disrupting gene 
  120 
expression, including genes crucial for neurogenesis (Fig 3.10 and by DEseq, data not shown). 
Examination of cell fate markers largely confirmed and extended the NanoString findings, 
suggesting a subtle shift in cell fate with DISC1 interruption (Fig 3.10). RNA-seq confirmed the 
decrease in FoxG1 expression in NPCs (Fig 3.10D). To investigate for potential dorsal-ventral 
fate shifts, we evaluated expression of a subset of dorsal and ventral markers. Among 
telencephalic progenitor markers, a selection of dorsal markers were increased (Pax3, Pax7, 
Msx2, NeuroG2, Dbx2, Wnt8B) and ventral markers were decreased (ASCL1, DLX1/2, Gsx2) by 
DISC1 interruption (Fig 3.10A,B). Notably, Pax3, Pax7, NeuroG2, Msx2, Dbx2, Wnt8B, ASCL1, 
DLX1/2, GSX2, FoxG1, and Tbr2 (EOMES) are identified in select DEseq comparisons, 
especially at day 17 (data not shown). While this RNA-seq analysis is limited by low sample 
numbers, it supports a subtle dorsal shift in cell fate with DISC1 interruption. Beyond these cell 
fate changes, a number of other genes were identified by DEseq analysis that are outside the 
scope of the current study, including differential expression of several protocadherin genes 
across all genotypes. This gene family has several roles in neural development and neuronal 
function, and provides interesting candidates for future studies. 
 The observed changes in gene expression suggested that disease-relevant DISC1 exon  
8 interruption did not drastically alter neuronal differentiation capacity or neuronal  
maturation but did cause subtle but significant changes in cell fate, including decreased FoxG1 
and Tbr2 expression. FoxG1 is a marker of telencephalic progenitors79-82, while Tbr2 is 
expressed in intermediate progenitor (IP) cells of the cortex83-85. While FoxG1 is expressed 
broadly in the progenitor cells of the developing neocortex, it is particularly critical for 
differentiation of ventral forebrain neurons82,86,87 and is expressed in a high-ventral to low-dorsal 
gradient in the developing forebrain88. We hypothesized that DISC1-disruption might subtly alter 
neural cell fate via an established patterning pathway. The Wnt proteins are a major family of 
patterning molecules that regulate the dorsal-ventral axis in neurodevelopment89. During
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Figure 3.10. RNA-seq of DISC1-targeted NPCs and neurons. iPSCs were differentiated to 
NPCs (day 17) and neurons (day 50) and RNA was harvested for RNAseq. Counts were 
upper-quartile normalized. (A) Dorsal telencephalic markers, (B) ventral telencephalic 
markers, (C,D) NPC markers, (E,F) neuronal markers. Statistics shown versus wt of 
corresponding differentiation day. Data derived from 2-6 independent differentiations. 
Statistics: 2-way ANOVA. Mean ± SEM shown. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 
0.0001. 
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forebrain development, Wnts are present in a dorsal to ventral gradient and act on neural 
progenitors to create a dorsal neuronal population. In contrast, Shh is present in a ventral to 
dorsal gradient and ventralizes neural progenitors in the developing cortex90-92. Artificially 
elevating Wnt signaling in the developing cortex has been shown to decrease FoxG1 
expression and cause a dorsal shift in neural identity89. Wnts have also been shown to trigger IP 
differentiation and premature neuronal differentiation, thus reducing the abundance of Tbr2-
positive cells in the cortex93,94. As DISC1 has been shown to participate in the Wnt signaling 
pathway, we next sought to investigate the Wnt signaling properties of DISC1-targeted neural 
progenitors. 
DISC1-disrupted NPCs display elevated baseline Wnt signaling activity, 
independent of dorsal identity 
DISC1 has been identified as both a positive and negative regulator of Wnt signaling40,95-
97. Accordingly, we investigated Wnt signaling in NPCs derived from our isogenic wild-type and 
DISC1-disrupted iPSCs. We evaluated Wnt signaling by introducing a TCF/LEF-responsive 
luciferase into cells by Amaxa nucleofection, followed by incubation with control (L) or Wnt3a 
(W) conditioned media (CM) for 24 hrs. Cells were then lysed and used for luciferase assays. 
Analysis of luciferase activity showed that DISC1-disrupted NPCs display decreased Wnt 
responsiveness, with a decreased fold change in luciferase activity with Wnt3a application 
relative to control (Fig 3.11C). However, this decreased Wnt response is driven by increased 
baseline Wnt signaling in DISC1-disrupted cells (wt vs. DISC1 mutant L CM luciferase activity, 
Fig 3.11B). Interestingly, this phenotype is not present in iPSCs (Fig 3.12), highlighting the cell-
fate specificity of this DISC1-mediated alteration in Wnt signaling. These results suggest that 
DISC1 disruption decreases the Wnt response in NPCs by increasing basal Wnt signaling. 
The cell fate changes and increased baseline Wnt signaling observed in DISC1- 
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Figure 3.11. DISC1 interruption increases basal Wnt signaling and decreases Wnt 
responsiveness in NPCs, independent of dorsal identity. (A) Schematic of experimental 
design. iPSC-derived day 24 NPCs were nucleofected with plasmids encoding the 
Super8XTOPFlash luciferase reporter and beta-galactosidase (b-gal) as a marker of 
transfection efficiency. After 18 hr, media were changed to control (L) or Wnt3a (W) 
conditioned media (CM) for 24 hr, followed by cell lysis. Cell lysate luciferase activity (luc) 
was normalized to beta-galactosidase activity (b-gal) and wt/wt L levels (B), L levels within 
genotype (C), wt/wt DMSO L levels (D), or L levels within condition (E). (B,C) DISC1-
disruption causes increased baseline Wnt signaling (B), which drives decreased Wnt 
response (C). (D,E) Wild-type and DISC1-disrupted cells treated with vehicle (DMSO) or 
cyclopamine (cyclop) to dorsalize NPCs for days 5-17 do not show changes in baseline Wnt 
signaling (D) or Wnt response (E). Statistics in (D) versus wt DMSO L; statistics in (E) versus 
wt DMSO W. Sample numbers shown in bars. (F) RNA was harvested from day 40 neurons 
and used for Nanostring. Gene expression was normalized to all genes. Statistics shown 
versus wt DMSO. Mean ± SEM shown. Data derived from at least 3 independent 
differentiations. Stats: (B-E) 1 way ANOVA, (F) 2 way ANOVA. * p < 0.05, ** p < 0.01, *** p < 
0.001, **** p < 0.0001. 
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Figure 3.11 (Continued)
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Figure 3.12. DISC1 disruption does not alter Wnt signaling in iPSCs. iPSCs were 
nucleofected with plasmids encoding the Super8XTOPFlash luciferase reporter (luc) and 
beta-galactosidase (b-gal) as a marker of transfection efficiency. After 18 hr, media were 
changed to control (L) or Wnt3a- (W) conditioned media for 24 hr followed by cell lysis. (A) 
Cell lysate luciferase activity was normalized to beta-galactosidase activity. (B) Wnt3a-
stimulated luc/b-gal was normalized to the average L CM level within each genotype. Mean ± 
SEM shown. Data derived from at least 10 independent sets of samples. Stats: 1 way 
ANOVA. ns = not significant. 
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disrupted cells could be related or independent phenotypes. Altered cell fate could result in 
changes in observed Wnt signaling by changing the pool of cells being assayed. Conversely, 
increased baseline Wnt signaling could alter cell fate. A third possibility is that these phenotypes 
are interrelated, where altered Wnt signaling and cell fate each feed into one another. If dorsal 
NPC fates have different intrinsic Wnt signaling properties than more ventral NPCs, changes in 
Wnt signaling may be observed in dorsal-shifted NPCs. 
To assess whether the observed alteration in Wnt signaling could be induced in wild-
type cells by forcing a dorsal fate, we pushed NPCs to more dorsal fates by antagonizing Shh 
signaling with cyclopamine during days 5-17 of differentiation60,62,98. NPCs were then rosette 
selected and cultured as neural aggregates without cyclopamine for ~13 days prior to Wnt 
signaling assays (schematic in Fig 3.11A). Cyclopamine treatment did not alter baseline levels 
of Wnt signaling or Wnt responsiveness in wild-type or DISC1-disrupted lines (Fig 3.11D,E). 
Dissociated NPCs were also plated and differentiated as neurons for 16 days, followed by RNA 
harvest. NanoString showed that a window of prior cyclopamine exposure did not alter 
expression of many cell fate markers, supporting previous studies demonstrating the “default” 
dorsal fate of NPCs differentiated from human pluripotent cells91,99,100. Cyclopamine treatment 
did decrease FoxG1 expression in wild-type cells (Fig 3.11F), suggesting that decreased FoxG1 
expression in DISC1-disrupted cells can be mimicked in wild-type cells using cyclopamine to 
dorsalize NPCs. However, the increased baseline Wnt signaling and decreased Wnt-
responsiveness of DISC1-disrupted NPCs is not induced in wild-type cells with cyclopamine 
treatment. Thus, the altered Wnt signaling seen in DISC1-disrupted cells does not appear to 
result from altered dorsal identity of these NPCs. 
Wnt signaling and gene expression changes in DISC1-disrupted cells can be 
rescued with Wnt antagonism in a critical window of neurodevelopment 
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 The elevation in baseline Wnt signaling in DISC1-disrupted NPCs suggested a 
mechanism by which DISC1 interruption may alter cell fate. As Wnts act to dorsally pattern 
NPCs during neural development, increased baseline Wnt signaling with DISC1 disruption may 
cause NPCs to attain a slightly more dorsal fate than wild-type cells. In order to test this 
hypothesis, we treated wild-type and DISC1 exon 8 wt/mut NPCs with either a Wnt agonist 
(CHIR99021) or antagonist (XAV939) during days 7-17 of differentiation. Immunostaining of 
NPCs showed dramatic cell fate changes with CHIR99021 treatment, including decreased 
FoxG1 and Tbr2 expression, and increased MAP2 expression (Fig 3.13A). Neural rosettes were 
then cultured in suspension as neural aggregates in the absence of these small molecules prior 
to assaying Wnt signaling.  Previous treatment with Wnt antagonist XAV939 decreased baseline 
Wnt signaling and increased Wnt responsiveness in DISC1 exon 8 wt/mut NPCs (Fig 3.13B,C). 
The altered Wnt response of DISC1-targeted NPCs can thus be rescued by prior Wnt 
antagonism during a 10-day window early in neural development. In contrast, Wnt agonism 
caused wild-type cells to mimic the decreased Wnt responsiveness of DISC1-targeted cells (Fig 
3.13C). CHIR99021 treatment also caused a dramatic decrease in Wnt baseline signaling, likely 
due to the observed decrease in NPCs and increase in neuronal cell fates at early progenitor 
time points (Fig 3.13 A,B). 
In parallel with Wnt signaling assays, NPCs were plated and differentiated as neurons 
for 16 days prior to RNA harvest and cell fate analyses. Antagonizing NPC Wnt signaling with  
XAV939 rescued decreased FoxG1, Brn2, and Tbr2 expression in exon 8 wt/mut neurons (Fig 
3.13D,E). Stimulating Wnt signaling with CHIR99021 pushed NPCs to spontaneously 
differentiate, decreasing expression of progenitor markers and cortical layer markers (Fig 3.13 
D,E). 
CHIR99021 treatment resulted in decreased expression of ventral marker GSX2 and 
increased expression of caudal genes HOXA1/2 and HOXB4, consistent with the effects of Wnt  
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Figure 3.13. Wnt antagonism rescues altered Wnt signaling and cell fate in DISC1-
disrupted cells. iPSCs were differentiated to NPCs and treated with vehicle (DMSO), Wnt 
antagonist XAV939 (XAV), or Wnt agonist CHIR99021 (CHIR) during days 7-17. After rosette 
selection, small molecules were withdrawn. (A) Examples of immunostained NPCs are 
shown. Scale bar = 50 um. (B,C) Prior exposure to Wnt antagonist XAV939 decreases 
baseline Wnt signaling and increases Wnt responsiveness in NPCs, whereas Wnt agonist 
CHIR99021 decreases Wnt responsiveness. iPSC-derived NPCs were nucleofected with 
plasmids encoding the Super8XTOPFlash luciferase reporter and beta-galactosidase as a 
marker of transfection efficiency. After 18 hr, media were changed to control (L) or Wnt3a- 
(W) conditioned media (CM) for 24 hr followed by cell lysis. Cell lysate luciferase activity (luc) 
was normalized to beta-galactosidase activity (b-gal) and wt/wt DMSO L levels (B) or L 
levels within treatment condition (C). Sample numbers shown in bars. (D-F) RNA was 
harvested from day 40 neurons and used for Nanostring. (D,E) Progenitor and neuronal, 
dorsal, ventral, caudal markers. (F) Wnt pathway genes. Gene expression is normalized to 
all genes. Significance asterisks in dark blue are versus wt/wt DMSO; asterisks in light blue 
are versus ex8wm DMSO. All luciferase assay and Nanostring samples are independent of 
samples used in Fig 6.  Mean ± SEM shown. Data derived from at 3 independent 
differentiations. Stats: (B,C) 1 way ANOVA, (D-F) 2 way ANOVA. * p < 0.05, ** p < 0.01, *** p 
< 0.001, **** p < 0.0001. 
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in dorsal and posterior patterning (Fig 3.13E). XAV939 opposed many of these effects in wild-
type and exon 8 wt/mut cells. XAV939 also rescued increased DAB2 expression in exon 8 
wt/mut cells, whereas CHIR99021 increased DAB2 levels in wt and ex8wm neurons. 
Furthermore, prior treatment of NPCs with CHIR99021 altered neuronal expression of Wnt 
pathway genes AXIN2, Irx3 and Six3 (Fig 3.13F). The reversal of gene expression changes in 
exon 8-targeted neurons with Wnt antagonism during NPC development suggests that altered 
cell fate in DISC1-disrupted cells is downstream of increased Wnt signaling. Rescue of cell fate 
changes by Wnt antagonism in DISC1 exon 8 wt/mut cells also rescues increased baseline Wnt 
signaling and decreased Wnt responsiveness in DISC1-targeted NPCs. These studies support a 
model in which altered Wnt signaling and cell fate are interdependent phenotypes in DISC1-
disrupted NPCs and neurons (Fig 3.14). 
DISCUSSION 
The study of genetic predispositions to mental illness, even if found only in a subset of 
patients, will improve our understanding of the pathophysiology of these debilitating disorders. 
Both rare, highly-penetrant and common, weaker DISC1 variants have been associated with 
multiple MMIs (reviewed here30). The Scottish chr(1;11) translocation provides a unique 
opportunity to investigate the pathophysiology of a rare genetic alteration that has been 
rigorously linked to MMI101. Without brain tissue from patients, it has been difficult to identify the 
pathological mechanisms of the Scottish translocation. Even with the study of t(1;11) patient-
derived cells, it would be impossible to attribute findings specifically to DISC1 disruption due to 
the presence of background genetic variability between control and t(1;11) lines and the 
disruption of other genes by the translocation (e.g. the long non-coding RNA (lncRNA) DISC2). 
DISC1 fragment overexpression in mice yields schizophrenia-associated phenotypes36,37,41,44, 
while DISC1 knockdown in embryonic rodent brain impairs neural progenitor cell (NPC)  
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Figure 3.14. Summary of Wnt modulation findings with wild-type and DISC1 ex8wm 
cells. (A) Schematic of neural progenitor populations. (B) Schematic of differentiation. The 
increase in baseline Wnt signaling observed in dissociated neural aggregates appears to be 
interdependent on a subtle fate shift of NPCs and neurons, observed at days 17 and days 
40-50, respectively. (C) The Wnt signaling and gene expression changes observed with 
DISC1 disruption can be rescued with Wnt antagonism and induced with Wnt agonism. 
iPSC: induced pluripotent stem cell, NP: neural precursor, RGC: Radial glial cell, IP: 
intermediate progenitor, XAV: Wnt antagonist XAV939, CHIR: Wnt agonist CHIR99021. 
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proliferation and alters neuronal migration39,43,44. Animal models have thus identified critical 
neurodevelopmental roles for DISC1 that could be perturbed by either loss-of-function (LOF) or 
gain-of-function (GOF) mechanisms. Due to differences in DISC1 splicing between human and 
rodent samples46,102, there is a need to complement animal models with studies of human 
neurons and glia. 
Human induced pluripotent stem cells (iPSCs) provide a tremendous advantage when 
studying otherwise inaccessible human cells and tissues. To investigate the consequences of 
DISC1 interruption in human neurons with a controlled genetic background, we TALEN- and 
CRISPR-Cas9-targeted iPSCs to create isogenic lines, which differ only at a single locus. We 
did not find evidence for off-target mutations with CRISPR-Cas9 or TALEN targeting, in 
agreement with recent reports of the high specificity of genome editing in human iPSCs103-106. 
The model described herein allows investigation of the effects of DISC1 interruption on 
DISC1 expression and neurodevelopment. As the clinical presentation of subjects with t(1;11) is 
relatively modest, in that patients can develop normally for decades before diagnosis of any 
neuropsychiatric disorder, we predicted that phenotypic alterations resulting from DISC1 
interruption in neurons would also be mild. We found that genomic DISC1 interruption near the 
site of the Scottish chr(1;11) translocation causes loss of expression of longer DISC1 transcripts 
from the mutated allele by NMD, which increases baseline Wnt signaling and alters the 
transcriptional profile of NPCs and neurons. These data support a loss-of-function model, 
wherein DISC1 interruption causes decreased full-length DISC1 expression (confirmed by 
Western blotting) and has downstream consequences on DISC1-dependent Wnt signaling, 
which results in a subtle NPC and neuronal fate shift. The exon 2 biallelic mutant lines 
demonstrate that an independent DISC1 mutation can dysregulate many of the same processes 
as our disease-relevant exon 8 disruption, and has even stronger effects on neuronal cell fate. 
These data support studies in the field showing that DISC1 knockdown and overexpression of 
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many different DISC1 mutants share several phenotypic consequences (reviewed here30). As 
exon 2 mutation does not dramatically alter DISC1 transcript structure by RNA-seq (Appendix 
1), we hypothesize that the truncated DISC1 protein may result from forced usage of an 
alternate start codon downstream of the introduced frameshift mutation, resulting in an N-
terminally truncated protein. 
The similarity in effects of heterozygous and biallelic DISC1 exon 8 interruption suggest 
that DISC1 is subject to haploinsufficiency, where loss of long isoform expression from one 
allele is sufficient to alter neurodevelopment. Unexpectedly, biallelic exon 8 mutation did not 
exacerbate the changes in gene expression or Wnt signaling observed in exon 8 wt/mut lines. 
This phenomenon has been demonstrated for other genes important for neural patterning, 
including presenilin 2 (PS2), where loss of a single copy of PS2 on a PS1 null background 
phenocopies the developmental defects of the PS2/PS1 double knockout107. It is also possible 
that our phenotypic assays may not have the resolution to detect subtle differences between 
DISC1-mutant genotypes. Furthermore, other phenotypes related to DISC1-disruption, not 
assayed here, may be stronger in exon 8 biallelic mutant cell lines than in exon 8 wt/mut cells. 
It should be noted that because we have not generated the chr(1;11) translocation, we 
cannot assess for presence of a fusion transcript or evaluate the effects of disruption of the 
antisense lncRNA DISC2. In patients carrying t(1;11), there has been no evidence of expression 
of a truncated DISC1 or a DISC1 fusion protein with the nearest downstream chromosome 11 
gene (DISC1FP1 or Boymaw). Patient lymphoblastoid cell lines showed a decrease in 
detectable DISC1 protein and mRNA without the appearance of any truncated or novel protein 
species64, supporting a loss of DISC1 expression from the mutated allele. PCR from patient cell 
lines has revealed expression of a transcript from the der 1 chromosome, fusing DISC1 exons 
1-8 to DISC1FP1/Boymaw exons 1-4, but there is no evidence that this transcript results in a 
translated protein product108. Indeed, the presence of a PTC in the fusion transcript prior to the 
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last exon of the chr11 gene suggests that this protein would be targeted for NMD. Thus, there is 
little evidence to suggest that a fusion protein plays a large role in the pathophysiology of the 
disease process. However, the role of DISC2, which is also interrupted by t(1;11), cannot be 
addressed here and remains unknown. Disruption of DISC2 in the human chr(1;11) 
translocation could exacerbate or modify our observed phenotypes with DISC1 interruption. 
The ability to identify defects in neurodevelopment with human iPSCs depends on 
recapitulating human corticogenesis in a dish. The advent of newer “induced neuron” 
differentiation methods, which accelerate differentiation by overexpressing master regulators of 
cell fate, may obscure developmental effects of disease mutations. Here we found that Ngn2-
induced neurons were unable to reproduce the developmental phenotype observed in embryoid 
aggregate-derived neurons, but did display distinct gene expression changes suggestive of 
altered development. Therefore, the choice of differentiation protocol can greatly impact the 
ability to detect consequences of disease mutations. Traditional differentiation methods follow a 
developmental timeline of cell fate generation, but result in heterogeneous and immature 
cultures. Induced neuron differentiation results in more homogenous and mature neurons, but 
bypasses critical regulatory processes of neurodevelopment. 
The results described herein reveal a role of DISC1 disruption in disordered 
neurodevelopment. Previous analyses of psychiatric disease with human iPSCs have also 
reported changes in neural development. Studies with sporadic schizophrenic patient-derived 
(SCZ) lines identified decreased neuronal connectivity and synaptic density, normal 
electrophysiological activity, and altered expression of glutamate receptors and Wnt signaling 
pathway genes in schizophrenic patient-derived cortical neurons56. SCZ cortical NPCs and 
immature neurons displayed decreased migration and increased oxidative stress59. Modeling 
hippocampal neurogenesis also revealed a deficit in neurogenesis and reduced neuronal 
activity in these lines60. A model of 15q11.2 deletion, which predisposes to schizophrenia, 
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showed disordered adherens junctions and apical polarity in del15q11.2 cortical NPCs61. 
Another study used iPSCs with a distinct DISC1 mutation found in an American family, in which 
a 4 bp deletion in exon 12 co-segregates with schizophrenia62,74. This mutation resulted in 
dysregulation of presynaptic biology, with decreased synaptic density and synaptic transmission 
and increased presynaptic protein expression in cortical neurons62. 
Our findings differ from the study of the DISC1 Δ4 bp mutation, as we do not observe an 
upregulation of presynaptic proteins62. Because there were insufficient family members in the 
American pedigree to conclusively associate the C-terminal 4 bp deletion with schizophrenia, 
the clinical causality of this mutation in human patients remains unclear74. There exist numerous 
possibilities to explain the distinct phenotypes resulting from different DISC1 mutations. It is 
possible that different genetic backgrounds alter the phenotype of DISC1 disruption, or that the 
mutations used in the present study act through a distinct pathological mechanism from the 4 bp 
deletion. Furthermore, the differentiation methods used in that study were slightly different than 
those utilized here, including the use of dual SMAD inhibition (antagonizing BMP signaling) and 
cyclopamine (antagonizing Shh signaling), which likely results in a different population of neural 
progenitors and neurons, as BMPs and Shh are critical regulators of dorsal-ventral patterning of 
the telencephalon109. Future studies should address whether differentiating these lines in 
parallel illuminates common pathological mechanisms of these distinct disease-associated 
DISC1 mutations. 
Here, we found that disease-relevant DISC1 disruption alters Wnt signaling in human 
NPCs. DISC1 is thought to play a role in the Wnt signaling pathway by binding to and inhibiting 
the action of GSK3β, thus allowing accumulation of beta-catenin and promoting Wnt signaling in 
the cell40,95,110. An alternative role for DISC1 in Wnt signaling has been proposed in rat striatum, 
where a DISC1-D2R complex is important for facilitating GSK3β activity and thus negatively 
regulates Wnt signaling97. Based on these two models, disruption of DISC1 expression might 
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lead to either decreased or increased Wnt signaling in the cell. We observed that decreased 
expression of DISC1 or misexpression of truncated DISC1 increases baseline Wnt signaling 
and decreases Wnt responsiveness in NPCs. Our results are consistent with the decreased Wnt 
response upon DISC1 knockdown in murine NPCs, but do not support a model in which DISC1 
increases Wnt signaling40,96. It is also unlikely that the DISC1-D2R complex plays a significant 
role in cortical NPCs, which differ greatly from striatal neurons. The data described herein do 
support a role of DISC1 in negatively regulating Wnt signaling, such that altered DISC1 
expression increases baseline NPC Wnt signaling. 
The Wnt signaling pathway has been implicated in the pathophysiology of 
neuropsychiatric disorders, making the role of DISC1 in this pathway of particular interest111-113. 
However, we are not aware of any previous studies investigating Wnt signaling in a human 
neuronal model of mental illness. Perturbation of Wnt signaling in animal models supports a role 
of Wnt signaling in positional patterning (on the dorsal-ventral and anterior-posterior axes) as 
well as in regulating the balance of progenitor proliferation vs. differentiation. Artificial 
dysregulation of this system can result in disordered corticogenesis and defects in neural 
progenitor behavior114. 
We found that DISC1 disruption causes altered NPC and neuronal cell fate via increased 
baseline Wnt signaling. The Wnt signaling and gene expression data are consistent with animal 
models in which increased Wnt signaling in the developing brain causes dorsal NPC fate shift, 
decreases FoxG1 expression, and decreases Tbr2 expression by promoting IP differentiation 
89,94,115. Wnt inhibition with XAV939 for a 10 day window in DISC1-targeted NPCs rescued 
neuronal cell fate changes, suggesting that increased Wnt signaling with DISC1-disruption is 
upstream of cell fate alterations. The increase in Tbr2 expression with XAV939 treatment 
upholds previous reports that Wnt antagonism causes expansion of Tbr2+ IPs 94,116,117. The 
ability of prior Wnt antagonism to restore Wnt responsiveness in DISC1-targeted NPCs 
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suggests that the altered DISC1-disrupted neural progenitor population also has different 
intrinsic Wnt signaling properties. Although we found evidence that DISC1-disrupted cells 
displayed a dorsal fate shift, forcing a dorsal fate in wild-type NPCs did not induce the Wnt 
phenotype seen with DISC1 disruption. These studies suggest a model in which DISC1 
interruption increases Wnt signaling, which alters the pool of NPCs, resulting in decreased Wnt 
responsiveness. The inability of cyclopamine to induce altered Wnt signaling in wild-type NPCs 
suggests that the relevant cell fate change in DISC1-disrupted NPCs is a Wnt-stimulated 
dysregulation of progenitor proliferation vs. differentiation, rather than purely a dorsal fate shift. 
The involvement of long DISC1 isoforms in neuronal migration (identified in rodent 
knockdown studies) could also reflect a role of DISC1 in proper acquisition of neuronal cell fate. 
Studies of genetic disorders of neuronal development and migration have found that defects in 
cell fate transitions underlie the migration deficit118,119. Furthermore, expression of FoxG1 has 
been shown to be required for the exit of migrating neurons out of the multipolar phase and for 
entry into the cortical plate120. The observed alterations in cell fate may thus cause defects in 
migration and cortical plate entry with DISC1 disruption, in agreement with in vivo DISC1 
knockdown studies. 
Further work will be required to elucidate the exact mechanism by which DISC1-
disruption alters Wnt signaling in human NPCs. We have also identified other candidate gene 
expression changes that result from DISC1 interruption by RNA-sequencing, which provide 
interesting candidates for future study. This work shows the utility of human iPSCs in modeling 
mental illness-associated defects in human neurodevelopment. Taken together, this study 
strengthens the association between Wnt signaling, neurodevelopment, and major mental 
illness.  
EXPERIMENTAL PROCEDURES 
  138 
Genome editing 
Healthy control human iPSC line YZ1 was obtained from the UCONN Stem Cell Core 
(generated by retroviral vectors containing reprogramming factors OCT4, SOX2, c-Myc, and 
KLF4)121. TALENs were designed and constructed using a hierarchical ligation procedure63. 
TALE monomer plasmids and TALEN backbone plasmids were a generous gift from Feng 
Zhang. Exon 8 TALENs were designed targeting unique genomic sequences in DISC1 exon 8 
(5’-TTAACGATATTGAAACCCAA-CTACCAGCCTTGCTTGAAG-
CCAAAATGCATGCCATATCA-3’) (TALEN sites underlined).  For CRISPR-Cas9 targeting, a 
unique genomic site in DISC1 exon 2 (GAGGAACCTCGGCGCACTTTGGG) was cloned into a 
gRNA cloning vector using Gibson assembly. The pCAG-Cas9-T2A-GFP plasmid was a gift 
from Kiran Musunuru (Addgene plasmid #44719); the gRNA cloning vector was a gift from 
George Church (Addgene plasmid #41824)122. Targeting plasmids (exon 8: TALENs (3 ug each) 
and pCAG-GFP (1 ug) or exon 2: pCAG-Cas9-T2A-GFP (2.5 ug) and gRNA (2.5 ug)) were 
electroporated into dissociated YZ1 iPSCs (~5E6 cells, dissociated in Accutase (Life 
Technologies) supplemented with 10 uM ROCK inhibitor, Y-27632 (Stem RD)) using the Amaxa 
4D-Nucleofector X Unit (Lonza, program DN-100).  Transfected cells were plated onto Matrigel- 
(BD Biosciences) coated plates in mTeSR1 media (Stemcell Technologies) + 10 uM ROCK 
inhibitor. 48 hours after transfection, iPSCs were dissociated and GFP+ cells were collected by 
FACS. GFP+ cells were plated at low density onto irradiated MEFs (GFP+ cells: ~3000 
cells/cm2, MEFs: ~17500 cells/cm2, GlobalStem). Cells were cultured in standard iPS cell 
medium until small, isolated colonies appeared (~7-10 days). Clones were transferred to 
individual wells of a matrigel-coated 96 well plate and expanded in mTeSR1 media. Genomic 
DNA was harvested using QuickExtract DNA Extraction solution (Epicentre). Clones were 
screened for genomic mutation by PCR amplification around the target site, followed by Sanger 
sequencing. 
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Karyotype analysis 
The NanoString nCounter human karyotype panel (NanoString Technologies) was used 
per manufacturer’s instructions to evaluate cell lines for large-scale CNVs. Briefly, 200-600 ng 
genomic DNA (gDNA), extracted using PureLink Genomic DNA Mini Kit (Life Technologies), 
was AluI-digested for 2 hrs at 37°C, denatured for 5 min at 95°C, and cooled on ice for 2 min to 
prevent renaturation. Denatured gDNA was combined with capture and reporter probesets and 
hybridized at 65°C for 16-30 hrs. Hybridized samples were processed using the nCounter Prep 
Station and imaged using the nCounter Digital Analyzer (NanoString Technologies). Sample 
counts were normalized to a reference sample with a normal karyotype.  
iPSC culture 
Human iPSCs were cultured as previously described66. Briefly, cells were cultured on an 
irradiated MEF feeder layer (GlobalStem, ~17500 cells/cm2) in 10 ng/ml FGF2 (PeproTech), 
added fresh daily. Cells were maintained at 37°C/5% CO2 and split every ~6 days. Differentiated 
cells were manually removed prior to splitting. 
Embryoid aggregate neuronal differentiation 
Neuronal differentiation was performed using an embryoid aggregate-based protocol, as 
previously described66. Briefly, iPSC colonies were removed from MEFs and cultured as 
embryoid aggregates in suspension for 4 days in iPSC media (without FGF2), followed by 2 
days in N2 neural induction media. Day 7 aggregates were plated onto Matrigel-coated 6 well 
plates and maintained in N2 neural induction media, forming neuroepithelial structures. For 
dorsal-ventral patterning, cells were treated with 1/1000 DMSO (Sigma) or 2 uM cyclopamine 
(Santa Cruz) as indicated during days 5-17 of differentiation. For Wnt manipulation, cells were 
treated with 1/5000 DMSO (Sigma), 2 uM XAV939 (Stemgent), or 3 uM CHIR99021 (Tocris) as 
indicated during days 7-17 of differentiation.  At day 17, neural rosettes were enzymatically 
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isolated using STEMDiff Neural Rosette Selection Reagent (Stemcell Technologies) and 
cultured in suspension for 7-14 days in N2/B27 neural induction media containing cAMP (1 uM, 
Sigma) and IGF-1 (10 ng/ml, Peprotech). Neural aggregates were dissociated using Accutase in 
the presence of 10 uM ROCK inhibitor and plated for final differentiation at ~85000 cells/cm2 in 
neural differentiation media containing cAMP (10 uM, Sigma), IGF-1, BDNF, and GDNF (10 
ng/ml, Peprotech). The day of neural aggregate dissociation was considered “day 24”. Cells 
were cultured for another 16 days to day 40 or 26 days to day 50. 
Induced neuron differentiation 
Induced neurons were generated as described75, with some modifications. iPSCs were 
cultured on Matrigel-coated plates in mTeSR1 media, infected with lentivirus encoding Ub-rtTA, 
TetO-Ngn2-T2A-puro, and TetO-GFP, and expanded. Viruses were a generous gift from Kevin 
Eggan. Transduced cells were dissociated with Accutase and plated onto Matrigel-coated plates 
at 50000 cells/cm2 in mTeSR1 (day 0). On day 1, media was changed to KSR media with 
SB413542 (10 uM, Tocris), LDN-193189 (100 nM, Stemgent), XAV939 (2 uM, Stemgent), and 
doxycycline (2 ug/ml, Sigma). Doxycycline was maintained in the media for the remainder of the 
differentiation. On day 2, media was changed to 1:1 (KSR + SB413542/LDN-
193189/XAV939):N2B media with puromycin (5 ug/ml, Gibco). Media was changed to N2B 
media + 1:100 B27 supplement (Life Technologies) on day 3. From day 4 on, cells were 
cultured in NBM media + 1:50 B27 + BDNF, GDNF (10 ng/ml, Peprotech), CNTF (10 ng/ml, 
R&D systems). Puromycin was maintained in the media until day 4-6. 
Medias 
MEF media: DMEM, 10% FBS, 100 U/ml Penicillin-Streptomycin, 2 mM L-glutamine (Life 
Technologies). 
iPSC media: DMEM/F12, 20% KOSR, 1x MEM-NEAA, 1x Penicillin-Streptomycin-Glutamine, 55 
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uM beta-mercaptoethanol (Life Technologies). 
N2 neural induction media: DMEM/F12, 1x N2 supplement, 1x MEM-NEAA (Life Technologies), 
2 ug/ml heparin (Sigma). 
N2/B27 neural induction media: DMEM/F12, 1x N2 supplement, 1x B27 supplement, 1x MEM-
NEAA (Life Technologies), 2 ug/ml heparin (Sigma). 
Neural differentiation media: Neurobasal medium, 1x N2 supplement, 1x B27 supplement, 1x 
MEM-NEAA (Life Technologies), 2 ug/ml heparin (Sigma). 
KSR media: Knockout DMEM, 15% KOSR, 1x MEM-NEAA, 55 uM beta-mercaptoethanol, 1x 
GlutaMAX (Life Technologies). 
N2B media: DMEM/F12, 1x GlutaMAX (Life Technologies), 1x N2 supplement B (Stemcell 
Technologies), 0.3% dextrose (D-(+)-glucose, Sigma). 
NBM media: Neurobasal medium, 0.5x MEM-NEAA, 1x GlutaMAX (Life Technologies), 0.3% 
dextrose (D-(+)-glucose, Sigma). 
Cycloheximide treatment 
Day 40 embryoid aggregate differentiated neurons were treated with neural 
differentiation media + 1/500 DMSO (vehicle) or 100 ug/ml cycloheximide (Sigma) for the times 
indicated. Cells were then harvested for RNA and subsequent qRT-PCR analysis or lysed for 
Western blots. 
Microelectrode array recordings 
MEA recordings were performed as previously described66. Sterile single-well MEA 
culture dishes were coated with poly-D-lysine (Sigma) for 1 hr at room temperature, washed 3 
times with sterile water, and dried overnight. The electrode area of each well was coated with 
Matrigel for 1 hr at 37°C. For embryoid aggregate-derived neurons, neural aggregates (day 24) 
were dissociated with Accutase + 10 uM ROCK Inhibitor. For induced neurons, cells were 
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dissociated on day 4 of differentiation with Accutase + 10 uM ROCK Inhibitor + DNase I (5U/ml, 
NEB). Human astrocytes (ScienCell), maintained in Astrocyte Medium (ScienCell), were 
dissociated with 0.25% Trypsin-EDTA (Life Technologies).  Approximately 75000 neurons and 
75000 astrocytes were resuspended in a 3:2 mixture of neural media:astrocyte media in a 50 ul 
volume and plated directly onto the electrode surface. Cells were incubated at 37°C for 30 min 
to allow cells to adhere before adding 500 ul 3:2 neural:astrocyte media to the well. Cells were 
fed with either neural differentiation media (embryoid aggregate neurons) or NBM media 
(induced neurons) for the remainder of the protocol. 
MEA recordings were performed using the Muse system (Axion Biosystems). Each well 
contains 64 nano-porous platinum electrodes arranged in an 8x8 grid. Data were acquired using 
AxIS software (Axion Biosystems) at a sampling rate of 12.5 kHz, filtered using a 200-2500 Hz 
Butterworth band-pass filter. The detection threshold was set to ±5.5x SD baseline electrode 
noise. Raster plots were analyzed using NeuroExplorer (NEX Technologies). Waveform data 
were filtered and plotted using custom MATLAB scripts (The Mathworks). 
qPCR 
RNA was extracted using the Pure Link RNA Mini Kit (Life Technologies) and reverse 
transcribed using SuperScript II (Life Technologies). cDNA was used for qPCR with Fast SYBR 
Green Master Mix (Life Technologies) on a ViiA 7 System (Life Technologies). Samples were 
run using 3 technical replicates (n in figures represent biological replicates only). Data were 
normalized to GAPDH expression using the ΔΔCT method as previously described123. Primer 
efficiency was calculated for each primer pair and the slope of a template dilution curve was 
found to be within an appropriate range. Melting curves after amplification showed single peaks 
at the appropriate temperature for each amplicon, indicating specificity of amplification. Primers 
are listed below. 
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Primers  
Gene Application Primer Sequence 
DISC1 Exon 2 Sanger 
genotyping 
Forward CTACATGAGAAGCTCGACAGGGCCTGGGAT 
Reverse CAAGAGACTGAAGGGCCGAGAGAGACATC 
DISC1 
Exon 8 Sanger 
genotyping 
Forward AAACCCAGAAATCTCTGACCTGGCTGTTCC 
Reverse CCCAAATACGGTACTCACTTAAACACCTTGTGC 
GAPDH qPCR 
Forward GGGAGCCAAAAGGGTCATCA 
Reverse TGGTTCACACCCATGACGAA 
DISC1 qPCR, exon 2 
Forward CCCCTACTGTGACCTCTGTGA 
Reverse AATCTGGTGCCACCTCTGA 
DISC1 
qPCR, exon 
12/13 
Forward AAAGTGTGAAGACATAGGCAAGAA 
Reverse CCCTCCTGAGAGAATGAATGAG 
 
NanoString gene expression analysis 
Two 150-gene nCounter Custom CodeSets were designed by NanoString Technologies 
to facilitate analysis of 150 genes from a single sample. One codeset was used to generate 
initial embryoid aggregate expression data (Appendix 2). Data were analyzed by subtracting 
counts from a blank control and normalizing to 8 housekeeping genes (B2M, GAPDH, GUSB, 
HPRT1, LDHA, POLR2A, RPL13a and RPL27).  After this codeset was depleted, another 
codeset was made, which greatly overlapped with the initial codeset (but with some 
substitutions) – this codeset was used to generate induced neuron and patterning embryoid 
aggregate data (Appendix 2). Data were analyzed with nSolver Analysis Software (NanoString 
Technologies) and normalized to the total gene set. 
 Assays were performed according to the manufacturer’s instructions. Briefly, 200-1000 
ng RNA was hybridized with capture and reporter probesets at 65°C for 12-30 hours. Hybridized 
samples were processed using an nCounter Prep Station and imaged using an nCounter Digital 
Analyzer (NanoString Technologies). 
Immunocytochemistry and microscopy 
Cells were fixed with 4% paraformaldehyde (Sigma), followed by membrane 
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permeabilization and blocking with 0.2% Triton X-100 (Sigma) and 2% donkey serum (Jackson 
Immunoresearch) in PBS for 1 hour at room temperature. Cells were then incubated with 
primary antibodies overnight at 4°C, secondary antibodies for 1 hr at room temperature, and 
1:1000 DAPI (Life Technologies) for 10 minutes, with multiple washes between each step. 
Samples were imaged using a Zeiss LSM710 confocal microscope and Zen black software. Zen 
black and FIJI were used to pseudo-color images and add scale bars. Antibodies are listed 
below. 
Western blots 
Lysates were prepared in a buffer containing 1% NP40, 10 mM EDTA, 150 mM NaCl, 50 
mM Tris, cOmplete Protease Inhibitors and phosSTOP (Roche). BCA protein assays were 
performed on all samples to normalize for protein content (Pierce). Equal protein amounts were 
loaded onto 4-12% Bis-Tris NuPAGE gels (Life Technologies) and transferred to nitrocellulose 
membranes. Blots were either incubated with HRP-conjugated secondary antibodies and 
developed using ECL substrate (for DISC1 only, Pierce) or incubated with fluorophore-
conjugated secondary antibodies and imaged on the Odyssey system (all other antigens, LI-
COR). 
Antibodies 
Antigen Host Application Dilution Vendor Catalog # 
MAP2 Chicken ICC, WB 1/2500, 1/5000 Abcam ab5392 
Brn2 Rabbit ICC 1/300 Abcam ab137469 
Satb2 Mouse ICC 1/100 Abcam ab51502 
Nestin Mouse ICC 1/1000 R&D MAB1259 
PSD-95 Mouse ICC 1/400 Abcam ab2723 
Cux2 Rabbit ICC  Abcam ab130395 
Cux1 Mouse ICC 1/300 Abcam ab54583 
Ngn2 Rabbit ICC 1/200 Abcam ab109236 
VGLUT1 Rabbit ICC 1/300 Synaptic systems 135303 
VGLUT2 Mouse ICC 1/1000 Abcam ab79157 
CTIP2 Rat ICC 1/300 Abcam ab18465 
Tbr2 Rabbit ICC  (gift from Hevner lab) 
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Tbr2 Rabbit ICC 1/250 Abcam ab23345 
FoxG1 Rabbit ICC 1/300 Abcam ab18259 
Pax6 Rabbit ICC 1/300 Covance PRB-278P 
Tau Rabbit ICC, WB 1/200 Dako A0024 
Tbr1 Rabbit ICC 1/250 Abcam ab32454 
SYP Rabbit ICC, WB 1/200, 1/1000 Abcam ab14692 
DISC1 (3G10) Mouse WB 1/1000 (from TYP/DJS labs) 
GAPDH Mouse WB 1/2000 Millipore MAB374 
SYN I Rabbit WB 1/200 Millipore 574777 
APP (C9) Rabbit WB 1/1000 (from DJS lab) 
 
RNA-sequencing 
RNA was extracted from embryoid aggregate differentiated day 17 (NPC) or day 50 
(neuron) samples using the Pure Link RNA Mini Kit (Life Technologies). Total RNA samples 
were converted into cDNA libraries using the TruSeq Stranded Total RNA-RiboZero Gold 
Sample Prep Kit (Illumina). Starting with 100 ng of total RNA, ribosomal RNA was removed by 
hybridization to a biotinylated probe selective for ribosomal RNA species, followed by 
streptavidin bead binding and sample purification.  The resulting rRNA-depleted sample was 
chemically fragmented and converted into single-stranded cDNA using reverse transcriptase 
and random hexamer primers, with the addition of Actinomycin D to suppress DNA-dependent 
synthesis of the second strand. Double-stranded cDNA was created by removing the RNA 
template and synthesizing the second strand in the presence of dUTP in place of dTTP. A single 
A base was added to the 3’ end to facilitate ligation of sequencing adapters, which contain a 
single T base overhang. Adapter-ligated cDNA was amplified by polymerase chain reaction to 
increase the amount of sequence-ready library. During this amplification the polymerase stalls 
when it encounters a U base, rendering the second strand a poor template. Accordingly, 
amplified material used the first strand as a template, thereby preserving the strand information. 
Final cDNA libraries were analyzed for size distribution and using an Agilent Bioanalyzer (DNA 
1000 kit, Agilent), quantitated by qPCR (KAPA Library Quant Kit, KAPA Biosystems), then 
  146 
normalized to 2 nM in preparation for sequencing. RNA was sequenced using stranded paired-
end reads, with ~50 millions reads per sample. 
Differential gene expression analysis 
Reads were mapped to the UCSC Human Reference Genome (hg19) using TopHat 
v2.0.10124. Reads mapping to genes were counted using htseq (v0.6.1)125. Counts were upper 
quartile normalized using SVS (Golden Helix) for limited gene comparisons. Alternatively, 
differential gene expression analysis between lines was performed using the edgeR package in 
R126. To evaluate for differential exon usage across the lines, the DEXSeq package was used127.  
Off-target mutagenesis analysis 
Off-target cleavage sites were predicted for the exon2 CRISPR/Cas9 construct using 
CCTop (http://crispr.cos.uni-heidelberg.de/) and <crispr.mit.edu>128. For the exon 8 TALEN 
constructs, potential off target cleavage sites were predicted using PROGNOS129 and 
TALENoffer130.  Variants in the RNA-seq datasets were called using the GATK Best Practices 
for Variant Discovery131. No indels or SNPs were observed at any of the top 10 overall or top 10 
coding predicted CRISPR/Cas9 or TALEN cleavage sites from each of these prediction tools.   
Luciferase assays 
 Control (“L”) and Wnt3a conditioned media (CM) was produced using Wnt3a-expressing 
and control (“L”) cells (ATCC). Conditioned medias were generated according to the ATCC 
protocol. Neural aggregates (~day 27-31) were dissociated using Accutase + 10 uM ROCK 
Inhibitor. Cells were resuspended in in P3 solution (Lonza) and DNA was added (3 ug 
Super8XTOPFlash, 1.5 ug pMIR-REPORT-beta-galactosidase, 1-5E6 cells). Super8XTOPFlash 
was a gift from Randall Moon132; pMIR-REPORT-b-gal was purchased from Life Technologies. 
Cells were electroporated by the Amaxa 4D-Nucleofector X Unit (Lonza, program CU-133). 
Electroporated cells were recovered in RPMI (Life Technologies) + 10% B27 supplement + 20 
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uM ROCK Inhibitor for 15 minutes and subsequently plated onto poly-ornithine/laminin coated 
96 well plates (4 ug/cm2 poly-ornithine, 1 ug/cm2 laminin, coated overnight at 37°C) containing 
N2/B27 neural induction media + 10 uM ROCK-Inhibitor. 16 hours later, media was changed to 
L or Wnt3a CM for 24 hours. Cells were then lysed in luciferase assay lysis buffer (Biotium) and 
used for a firefly luciferase assay (Biotium) and beta-galactosidase assay (Promega). Luciferase 
and beta-galactosidase activities were assayed using a Synergy H1 reader (BioTek). Luciferase 
activity was normalized to beta-galactosidase activity for each sample. 
Data collection and statistics 
All data represent at least three independent experiments, utilizing the iPSC lines as 
shown in Table 3.1. Data were analyzed using GraphPad PRISM 6 software. Values are 
expressed as means ±SEM. Statistical significance was tested by either one-way or two-way 
ANOVA with Holm-Sidak’s multiple comparisons post-test, as indicated in figure legends. 
Statistical significance was determined by P-values of < 0.05. 
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 The study of human neuropsychiatric diseases is a complex task, due in part to our 
relatively incomplete knowledge of the underlying genetic alterations and molecular pathways 
implicated in these disorders. Only recently have tools been developed and genetic studies 
performed that facilitate investigation of the cellular and molecular pathophysiology of 
neuropsychiatric diseases. It will continue to be essential to combine work in heterologous cell 
lines, animal models, and human iPSCs to carefully model the molecular, cellular, and circuit 
defects that accompany mental illness-associated genetic mutations. When using iPSC-derived 
neurons, rare variants of strong effect will be important for identifying crucial pathways that can 
be dysregulated to contribute to disease. Given the variability inherent to iPSC differentiation 
protocols, stronger variants are more likely to yield reproducible, statistically significant 
phenotypes. The use of isogenic cell lines will be essential to control for effects of genetic 
background, which can greatly impact neuronal differentiation and neuronal phenotypes1,2. 
While off-target effects of genome editing remain a legitimate concern, several studies have 
found that use of genetic engineering technologies in human iPSCs is specific, with very few off-
target mutations identified3-6. 
The studies cited above have nevertheless identified substantial clonal genomic 
variation among “isogenic” lines, which is attributed to somatic mutations that accumulate in 
individual clonal lines during passaging3,6. This somatic variation should be considered a source 
of potential phenotypic variability among lines with “identical” genotypes. Variation can be 
minimized by limiting cell passage number and regularly assaying for large-scale genomic 
variation (e.g. large CNVs). However, some accrual of genetic variation is likely unavoidable 
with extended cell culture. As a result, even with “isogenic” lines, ideally multiple lines of each 
genotype should be used to demonstrate disease phenotypes. Showing that a phenotype is 
reproducible when multiple wild-type and disease lines are used diminishes the chance of false 
phenotype discovery due to clonal variation.  
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Pioneering studies of neuropsychiatric disease in human neurons have identified 
developmental processes altered in different disease contexts, including neural progenitor 
organization, oxidative stress, hippocampal neurogenesis, neuronal migration, neuronal 
connectivity, and neuronal activity. These studies do not overlap much in their study of 
mutations and phenotypes, but differing results do exist between studies and mutations. For 
example, a study of sporadic SCZ lines identified decreased postsynaptic protein expression 
and synaptic density but normal spontaneous electrophysiological activity in neurons, whereas 
DISC1 exon 12 Δ4bp lines showed decreased synaptic density, increased presynaptic protein 
expression, and decreased neuronal activity7,8. The current study does not evaluate synaptic 
density or activity in-depth, but shows unchanged expression of presynaptic proteins in neurons 
with frameshift mutations in exon 2 or exon 8 of DISC1. A recent report identified 
disorganization of NPC polarity with del15q11.2, but not with DISC1 exon 12 Δ4bp9. Differences 
in phenotypes across disease models could result from distinct differentiation protocols, 
variability in the neuronal populations studied, and bona fide differences in the consequences of 
different disease-predisposing mutations. As increasing numbers of iPSC lines become 
available from different patients and with different mutations, future studies can assess 
phenotypes of interest across many disease-associated cell lines. Such studies will be able to 
identify those phenotypes that are unique to specific mutations and which, if any, are common 
across multiple mutations. 
Genetic studies of major mental illnesses have revealed linkage of disease to many 
neurodevelopmental and synaptic genes10-12. It is very unlikely that most or all of these 
mutations, even if they are genuinely linked to development of mental illness, will impact the 
same cellular or developmental pathways. Rather, different mutations will likely impact distinct 
steps in development, and may exhibit phenotypes in distinct neuronal (or non-neuronal) 
subtypes. Different disease-predisposing mutations are likely to converge downstream onto 
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alterations in circuitry. Changes in neural circuitry in the adolescent brain may result from 
alterations in one or more upstream steps in development, including neural progenitor 
proliferation and patterning, neuronal migration and differentiation, and neurotransmission (Fig 
4.1). Refining our knowledge of human neural development and identifying those processes that 
are altered with rare, but strongly penetrant, genetic variants linked to major mental illness will 
expedite the study of common, weaker variants. As technologies expand the possibilities for 
large-scale, high-throughput cell culture and phenotypic assays, mutations may eventually be 
studied in a combinatorial fashion. Introducing combinations of multiple mutations could 
evaluate additive effects on disease-relevant phenotypes, which may be easier to detect than 
the consequences of single, weak variants. 
The ability to directly convert stem cells and somatic cells to specific neuronal 
populations of interest will increase our power to detect phenotypic alterations, but reduce the 
possibility of discovering alterations in unexpected cell types and processes. One example is 
demonstrated here, where DISC1 interruption resulted in a consistent reduction of progenitor 
markers FoxG1 and Tbr2 in cortical NPCs derived from an embryoid aggregate differentiation 
protocol. However, iPSCs that were directly converted to a mature, homogenous population of 
upper layer neurons using Ngn2 transduction did not display these gene expression changes. 
As we show that DISC1-disruption alters Wnt signaling and NPC patterning during a window of 
neural progenitor development, this phenotype cannot be studied with a protocol, like Ngn2 
induction, that largely bypasses this developmental time point. Expression of FoxG1 and Tbr2 is 
dramatically decreased in Ngn2-transduced “induced neurons” (iNs), and the effect of DISC1 
mutation on neurodevelopment is masked. However, iNs would be a more appropriate cell 
population to use to study synaptic biology, as this protocol greatly reduces heterogeneity 
(decreasing experimental noise) and increases maturity (making synaptic studies more  
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Figure 4.1. Schematic of developmental steps that may be affected by schizophrenia-
associated mutations.  
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relevant). Our work demonstrates how selection of a differentiation protocol inherently biases a 
study to the discovery of different phenotypic alterations. 
 Combinations of multiple differentiation strategies will be crucial in narrowing the 
processes and cell types affected in major mental illnesses. As induced and directed 
differentiation protocols are refined and become more efficient, reproducible, and homogenous, 
the arsenal of potential iPSC-derived neuronal and glial subtypes will continually expand. While 
a variety of cell types have been implicated in major mental illness, one cell type of great 
interest in schizophrenia are cortical interneurons13.  As protocols now exist to generate cortical 
interneurons from human iPSCs14,15, these are a particularly appealing target for further study. 
Investigations of the inhibitory-excitatory balance using mixed cultures of excitatory and 
inhibitory neurons will also facilitate the recognition of circuit dysfunction.  
While most studies of psychiatric disease thus far have focused on neurons, iPSCs also 
can be used to investigate the role of disease-associated mutations in glial biology and neuron-
glia interactions. Although investigation into glial dysfunction is less prevalent, there is evidence 
supporting glial abnormalities in schizophrenia16. This may be of interest in the case of DISC1 
mutations, as DISC1 is expressed in microglia, astrocytes, and oligodendrocytes, in addition to 
neurons17. Furthermore, the association of many immunity-related genes in recent 
schizophrenia GWAS makes astrocytes and microglia attractive cell types in which to study 
mutations and variants in these genes12. 
 Three-dimensional models of human neurodevelopment will be crucial in expanding 
current findings by examining human neuronal development in a setting closer to the in vivo 
context. While these “cerebral organoid” protocols currently generate heterogeneous cultures, 
with high inter-organoid variability, they still offer valuable information on cortical development18. 
Future protocols will likely address this variability, making these models more attractive for 
disease modeling. This method would be particularly interesting for further study of the 
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developmental dysregulation that accompanies DISC1 mutation. In three-dimensional 
organoids, one could investigate cell fate and cell position in the “cortex”, refining the phenotype 
observed here (i.e. are cell fate changes accompanied by disruption of proper cell migration or 
positioning?). Organoids also can be used for “in-organoid” electroporation studies, to assay the 
effects of local manipulation of gene expression on human neurons in a developing cortical 
structure. 
The current work opens many doors for future studies of the functions of DISC1 in 
human neurons. DISC1 has been implicated in several distinct neuronal processes, and the 
potential phenotypes available for investigation are abundant19. Given the synaptic deficits 
identified in some other models of mental illness (discussed above), further investigation into 
synaptic biology using DISC1-disrupted neurons is warranted. The involvement of DISC1 in Wnt 
signaling points to neural progenitor cell proliferation as an interesting target for further analysis. 
NPC subtype-specific proliferation and cell cycle analyses would be particularly interesting, in 
light of the data presented here showing alterations in NPC fate with DISC1 disruption. DISC1 
has been linked to neuronal migration by multiple in vivo knockdown studies in rodent cortex, as 
well as through the identification of centrosomal binding partners20-22. Investigation of neuronal 
migration in culture is limited, as the process of neuronal migration in the developing brain is a 
highly regulated and context-dependent process23. Xenografting studies would allow for 
observation of human iPSC-derived neuronal migration in a developing rodent cortex. This 
method is technically challenging but offers an exciting opportunity for studying how DISC1 
disruption affects cell fate and migration in human neurons in an in vivo environment. 
A further advantage of using human iPSCs to model neurological diseases is that these 
cells have the potential to recapitulate species-specific steps of neurodevelopment. Dramatic 
changes in neocortical structure and development have occurred over evolution, with the human 
brain characterized by an expansion of progenitor layer numbers and size and consequent 
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enlargement of the neocortex24,25. The increase in brain size over evolutionary time has been 
attributed in part to an expansion of intermediate progenitors and the presence of non-apical 
radial glial cells in the outer subventricular zone (oSVZ) of the developing primate cortex26,27. A 
recent study profiling human neural progenitors, purified from human fetal brains, identified 
unique transcriptional signatures of apical vs. non-apical radial glia. Using single-cell analyses, 
these cell types were further subdivided based on gene expression. When compared to purified 
mouse neural progenitors, this study found that human NPCs displayed a greater number of 
distinct transcriptional states, often defined by expression of genes that were not present in 
mouse progenitors28. 
The pronounced diversity of neural progenitors in human cortex, defined by unique 
transcriptional signatures, highlights both a challenge and advantage of modeling neurological 
disease using human cells. The vast majority of our knowledge regarding markers of different 
neural progenitor and neuronal states is derived from rodent studies, which harbor a distinct 
developmental program. This can make interpreting data derived from human neuronal 
differentiations challenging, as the relevance of these genes in human neurodevelopment is 
less well-studied. An expansion of studies of human neural development, from primary human 
tissues as well as from human stem cells, will help to address these challenges in the future. 
Furthermore, disease modeling using human cells allows for the discovery of alterations in cell 
types that are not present in rodent cortex, and therefore have not been previously studied. The 
present study identifies alterations in a human neural progenitor population with DISC1 
mutation, including decreased expression of the intermediate progenitor marker Tbr2. Future 
single-cell transcriptional studies of wild-type versus DISC1-disrupted progenitors may identify 
alterations in the balance of primate-specific NPC fates, which could not be identified using 
rodent models. 
Modeling neuropsychiatric disease with human iPSCs has several caveats. Culture and 
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differentiation of neurons in vitro is distinct from in vivo neurodevelopment in many ways, 
making the study of neurodevelopment with iPSCs challenging. However, these cells provide 
novel opportunities for investigating disease processes in otherwise inaccessible human cells. 
When iPSC studies are combined with existing in vivo models of brain development and 
neurological diseases, the potential for investigation and discovery in this field is extraordinary. 
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Figure A1. Exon usage at the DISC1 locus by RNA-sequencing. DEXSeq was used to 
evaluate for differential exon usage in wild-type (wt) and DISC1-disrupted cells at day 17 
(top) and day 50 (bottom). DISC1 exon structure is shown at bottom. There is no evidence 
for alteration of transcript structure with exon 8 or exon 2 mutations. 
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Table A2.1. Nanostring probe sequence for codeset 1. 
CTIP2 GTGAAAAGTAAGGAAATCAGCCTTTCATCCCGGTCCTAAGTAACCGTCAGCCGAAGGTCTCGTGGAACACAGGCAAACCCGTGATTTTGGTGCTCCTTGT 
Cux1 ACAAACAGCCCTGGAAAAAACTCGAACAGAATTATTTGACCTGAAAACCAAATACGATGAAGAAACTACTGCAAAGGCCGACGAGATTGAAATGATCATG 
DISC1 
ex1/2 
CCGGCGGCGGCGGCGTGAGCCACCGCGCAGGCAGCCGGGATTGCTTACCACC
TGCAGCGTGCTTTCGGAGGCGGCGGCTGGCACGGAGGCCGGGCTACAT 
DISC1 
ex11b 
CCCCAGGCTCCACTCCGAGGATAAAAGGAAGACCCCTTTGAAGGAATCTTACAT
CCTTTCTGCAGAACTTGGAGAAAAGTGTGAAGACATAGGCAAGAAG 
DISC1 
ex12/13 
CTTGGAAGATCAACTTCACACAGCAATCCACAGTCATGATGAAGATCTCATTCAG
TCTCTCAGGAGGGAGCTCCAGATGGTGAAGGAAACTCTGCAGGCC 
DISC1 ex2 CCCCAACCCCTCCTGGCTCTCACAGTGCCTTTACCTCAAGCTTTAGCTTTATTCGGCTCTCGCTTGGCTCTGCCGGGGAACGTGGAGAAGCAGAAGGCTG 
DISC1 
ex3a 
GCGTAGATCATGACTTCTTTAGACATCATGAAAAGAAAAAGAGGACCCACGTGGA
AGAATACGCTCATTTATGATCAGGGTAGCATCATATTCCTCTCCC 
DISC1 
ex9a 
TATAAGTACTGTGATGCAGAGTCCTGGACACAGAGAAGTCAGCAACTTGCCTGA
GGACAGCCTGCAGGACACAGCACTGTGATTTGAACCCAGAGAGTCT 
Fezf2 GGGGCAGCCAGTTTTAACCCCAGCCTGTCACCGTGAGCGCCCCAGAAGAGCGCGGCGCCCCTAGCCATCTTTATACAGCCATGTAAATCCTCCTGTACAA 
FoxG1 CTGACAAGTCTATCTCTAAGAGCCGCCAGATTTCCATGTGTGCAGTATTATAAGTTATCATGGAACTATATGGTGGACGCAGACCTTGAGAACAACCTAA 
MAP2 TACTCTGTATGCTGGGATTCCGAGGTTCCAACACACTGTTACAAATCTGTGGGGGGTTTCTTTCTTCTGATAATTCTAGAGCCTGTTACCATAGAAAGGC 
Nestin CAGAGAATCACAAATCACTGAGGTCTTTAGAAGAACAGGACCAAGAGACATTGAGAACTCTTGAAAAAGAGACTCAACAGCGACGGAGGTCTCTAGGGGA 
NeuroD1 GTGCCCAGCTCAATGCCATATTTCATGATTAGAGGCACGCCAGTTTCACCATTTCCGGGAAACGAACCCACTGTGCTTACAGTGACTGTCGTGTTTACAA 
NeuroG1 GCCCCTAGACGGCCTTTCCTTTTGCACTTTCTGAACTCCACAAAACCTCCTTTGTGACTGGCTCAGAACTGACCCCAGCCACCACTTCAGTGTGATTTAG 
Pax6 GGGAATTAAAGGCCTTCAGTCATTGGCAGCTTAAGCCAAACATTCCCAAATCTATGAAGCAGGGCCCATTGTTGGTCAGTTGTTATTTGCAATGAAGCAC 
PSD-95 TGCCCTGAAGAATGCGGGTCAGACGGTCACGATCATCGCTCAGTATAAACCAGAAGAGTACAGCCGATTCGAGGCCAAGATCCACGACCTTCGGGAACAG 
Satb1 TTCCGAAATCTACCAGTGGGTACGCGATGAACTGAAACGAGCAGGAATCTCCCAGGCGGTATTTGCACGTGTGGCTTTTAACAGAACTCAGGGCTTGCTT 
Sox1 AAAGCGTTTTCTTTGCTCGAGGGGACAAAAAAGTCAAAACGAGGCGAGAGGCGAAGCCCACTTTTGTATACCGGCCGGCGCGCTCACTTTCCTCCGCGTT 
Sox2 AGCGCCCTGCAGTACAACTCCATGACCAGCTCGCAGACCTACATGAACGGCTCGCCCACCTACAGCATGTCCTACTCGCAGCAGGGCACCCCTGGCATGG 
Syn I GGATCTACTTCTGTTTTAGAACCTCCACATTCCTGAAGACCTCCGCCCCTGGTTTCCCCAGAGGGCGTTTTCCTTCCTGGAAGTGCCCAAATACCAGGCA 
SYP TAGTGCCTGTGATCGTGTGTTGCCATTTTGTCTGGCTGTGGCCCCTCCTTCTCCCCTCCAGACCCCTACCCTTTCCCAAACCCTTCGGTATTGTTCAAAG 
Tau ATTGGGTCCCTGGACAATATCACCCACGTCCCTGGCGGAGGAAATAAAAAGATTGAAACCCACAAGCTGACCTTCCGCGAGAACGCCAAAGCCAAGACAG 
Tbr1 GCCGTCTGCAGCGAATAAGTGCAGGTCTCCGAGCGTGATTTTAACCTTTTTTGCACAGCAGTCTCTGCAATTAGCTCACCGACCTTCAACTTTGCTGTAA 
Tbr2 TCTCTAGATTCCAATGATTCAGGAGTATACACCAGTGCTTGTAAGCGAAGGCGGCTGTCTCCTAGCAACTCCAGTAATGAAAATTCACCCTCCATAAAGT 
(Table A2.1, continued) 
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TUJ1 GCCGCCCTCCTGCAGTATTTATGGCCTCGTCCTCCCCACCTAGGCCACGTGTGAGCTGCTCCTGTCTCTGTCTTATTGCAGCTCCAGGCCTGACGTTTTA 
VGLUT1 TCGGCTACTCGCACTCCAAGGGCGTGGCCATCTCCTTCCTGGTCCTAGCCGTGGGCTTCAGCGGCTTCGCCATCTCTGGGTTCAACGTGAACCACCTGGA 
Vimentin GAGGAGATGCTTCAGAGAGAGGAAGCCGAAAACACCCTGCAATCTTTCAGACAGGATGTTGACAATGCGTCTCTGGCACGTCTTGACCTTGAACGCAAAG 
 
 
Table A2.2. Nanostring probe sequences for codeset 2. 
AXIN2 CTTGTCCAGCAAAACTCTGAGGGCCACGGCGAGTGTGAGGTCCACGGAAACTGTT
GACAGTGGATACAGGTCCTTCAAGAGGAGCGATCCTGTTAATCCT 
BRN2 GGGCACGGAGCTGCTTCGGGTGCATCACGCTGCTCGTTCCTGAGGTATGGGAACT
GGCCTTTAGTGAAGCTATCCAGAGCAGGGCAAATAGCCACTGGTA 
CCND2 TAGATTGCAAAGCAATGAACTCAAGAAGGAATTGAAATAAGGAGGGACATGATGGG
GAAGGAGTACAAAACAATCTCTCAACATGATTGAACCATTTGGG 
CTIP2 GTGAAAAGTAAGGAAATCAGCCTTTCATCCCGGTCCTAAGTAACCGTCAGCCGAAG
GTCTCGTGGAACACAGGCAAACCCGTGATTTTGGTGCTCCTTGT 
Cux1 ACAAACAGCCCTGGAAAAAACTCGAACAGAATTATTTGACCTGAAAACCAAATACGA
TGAAGAAACTACTGCAAAGGCCGACGAGATTGAAATGATCATG 
Cux2 GATAACAGAATGTCCGTGCCATTGTAAATGTTGTAGAGATGTGGGCCGTGGCCCAA
CCGTCCTATATGAGATGTAGCATGGTACAGAACAAACTGCTTAC 
CyclinD1 TTGAACACTTCCTCTCCAAAATGCCAGAGGCGGAGGAGAACAAACAGATCATCCGC
AAACACGCGCAGACCTTCGTTGCCCTCTGTGCCACAGATGTGAA 
DAB2 TTATTTGAGACTTCTCCATCGGGATCGCCTGGTGTCACCAAGTGTCCACTGGTACTG
AGGTTTGCTGCCTGCCTTCTTGCCATGTCTAACGAAGTAGAAA 
DCX AAAGCTATGTCTGTTCCTCAGACAACTTCTTTAAAAAGGTGGAGTACACCAAGAATG
TCAATCCCAACTGGTCTGTCAACGTAAAAACATCTGCCAATAT 
FoxG1 CTGACAAGTCTATCTCTAAGAGCCGCCAGATTTCCATGTGTGCAGTATTATAAGTTA
TCATGGAACTATATGGTGGACGCAGACCTTGAGAACAACCTAA 
GRIA2 TGACCTATGATGCCGTTCAAGTGATGACTGAAGCCTTCCGCAACCTAAGGAAGCAA
AGAATTGAAATCTCCCGAAGGGGGAATGCAGGAGACTGTCTGGC 
GRIN1 TTCAAGAGAGTGCTGATGTCTTCCAAGTATGCGGATGGGGTGACTGGTCGCGTGGA
GTTCAATGAGGATGGGGACCGGAAGTTCGCCAACTACAGCATCA 
GSX2 TCTATGTCGACTCGCTCATCATCAAGGACACCTCACGGCCTGCGCCCTCGCTGCCT
GAACCGCACCCCGGGCCGGATTTCTTCATCCCGCTTGGCATGCC 
HES1 ATCTGAGCACAGAAAGTCATCAAAGCCTATTATGGAGAAAAGACGAAGAGCAAGAA
TAAATGAAAGTCTGAGCCAGCTGAAAACACTGATTTTGGATGCT 
HES5 CAGCCTGTAGAGGACTTTCTTCAGGGCCCGTAGCTGCTGGGCGTACCCCTGGCAG
GCGGGCTGTGCCGCGGGCACATTTGCCTTTTGTGAAGGCCGAACT 
HOXA1 CAGATAATTCTGGACCAGAGACTTGGTGCGGGGTTAACACCTTCATCCAGATTGGG
TGCCAGCATACATTTTCTGGTGGGCCTTAACATCCCTCCTGCTT 
HOXA2 CCCAAAGTTTCCCAGTCTCGCCTTTAACCAGCAATGAGAAAAATCTGAAACATTTTC
AGCACCAGTCACCCACTGTTCCCAACTGCTTGTCAACAATGGG 
HOXB4 CCTTTTCTCTTTCTGACATTCCAAAACCAGGCCCCTTCCTACCTCTGGGGCTGCTTG
AGTCTAGAACCCTTCGTATGTGTGAATATCTGTGTGCTGTACA 
Irx3 AGTCGCTTCTGTGGCACCCCGCATTCGCTGTGAGGTTTGTTTGTCCGGTTGATTTTG
GGGGGTGGAGTTTCAGTGAGAATAAACGTGTCTGCCTTTGTGT 
MAP2 TACTCTGTATGCTGGGATTCCGAGGTTCCAACACACTGTTACAAATCTGTGGGGGG
TTTCTTTCTTCTGATAATTCTAGAGCCTGTTACCATAGAAAGGC 
(Table A2.2, continued) 
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Nestin CAGAGAATCACAAATCACTGAGGTCTTTAGAAGAACAGGACCAAGAGACATTGAGA
ACTCTTGAAAAAGAGACTCAACAGCGACGGAGGTCTCTAGGGGA 
NeuroD1 GTGCCCAGCTCAATGCCATATTTCATGATTAGAGGCACGCCAGTTTCACCATTTCCG
GGAAACGAACCCACTGTGCTTACAGTGACTGTCGTGTTTACAA 
Pax6 GGGAATTAAAGGCCTTCAGTCATTGGCAGCTTAAGCCAAACATTCCCAAATCTATGA
AGCAGGGCCCATTGTTGGTCAGTTGTTATTTGCAATGAAGCAC 
PSD-95 TGCCCTGAAGAATGCGGGTCAGACGGTCACGATCATCGCTCAGTATAAACCAGAAG
AGTACAGCCGATTCGAGGCCAAGATCCACGACCTTCGGGAACAG 
Reelin TATTCAGACCCCAGCATCATCGTGTTATATGCCAAGAATAACTCTGCGGACTGGATT
CAGCTAGAGAAAATTAGAGCCCCTTCCAATGTCAGCACAATCA 
Satb1 TTCCGAAATCTACCAGTGGGTACGCGATGAACTGAAACGAGCAGGAATCTCCCAGG
CGGTATTTGCACGTGTGGCTTTTAACAGAACTCAGGGCTTGCTT 
Six3 CAGCCTGACGGAGCGCGCGGACACCGGCACCTCCATCCTCTCGGTAACCTCCAGC
GACTCGGAATGTGATGTATGATAGCCAAGGCCGCCCTCCTCCCTC 
Sox1 AAAGCGTTTTCTTTGCTCGAGGGGACAAAAAAGTCAAAACGAGGCGAGAGGCGAAG
CCCACTTTTGTATACCGGCCGGCGCGCTCACTTTCCTCCGCGTT 
Sox2 AGCGCCCTGCAGTACAACTCCATGACCAGCTCGCAGACCTACATGAACGGCTCGC
CCACCTACAGCATGTCCTACTCGCAGCAGGGCACCCCTGGCATGG 
Syn I GGATCTACTTCTGTTTTAGAACCTCCACATTCCTGAAGACCTCCGCCCCTGGTTTCC
CCAGAGGGCGTTTTCCTTCCTGGAAGTGCCCAAATACCAGGCA 
SYP TAGTGCCTGTGATCGTGTGTTGCCATTTTGTCTGGCTGTGGCCCCTCCTTCTCCCCT
CCAGACCCCTACCCTTTCCCAAACCCTTCGGTATTGTTCAAAG 
Tau ATTGGGTCCCTGGACAATATCACCCACGTCCCTGGCGGAGGAAATAAAAAGATTGA
AACCCACAAGCTGACCTTCCGCGAGAACGCCAAAGCCAAGACAG 
Tbr1 GCCGTCTGCAGCGAATAAGTGCAGGTCTCCGAGCGTGATTTTAACCTTTTTTGCACA
GCAGTCTCTGCAATTAGCTCACCGACCTTCAACTTTGCTGTAA 
Tbr2 TCTCTAGATTCCAATGATTCAGGAGTATACACCAGTGCTTGTAAGCGAAGGCGGCT
GTCTCCTAGCAACTCCAGTAATGAAAATTCACCCTCCATAAAGT 
TUJ1 GCCGCCCTCCTGCAGTATTTATGGCCTCGTCCTCCCCACCTAGGCCACGTGTGAGC
TGCTCCTGTCTCTGTCTTATTGCAGCTCCAGGCCTGACGTTTTA 
TWIST1 CAACTCCCAGACACCTCGCGGGCTCTGCAGCACCGGCACCGTTTCCAGGAGGCCT
GGCGGGGTGTGCGTCCAGCCGTTGGGCGCTTTCTTTTTGGACCTC 
VGLUT1 TCGGCTACTCGCACTCCAAGGGCGTGGCCATCTCCTTCCTGGTCCTAGCCGTGGG
CTTCAGCGGCTTCGCCATCTCTGGGTTCAACGTGAACCACCTGGA 
VGLUT2 TACGACAGTGAGAAAGATCATGAATTGTGGTGGTTTTGGCATGGAAGCCACACTGC
TCCTGGTCGTTGGCTATTCTCATACTAGAGGGGTAGCAATCTCA 
Vimentin GAGGAGATGCTTCAGAGAGAGGAAGCCGAAAACACCCTGCAATCTTTCAGACAGGA
TGTTGACAATGCGTCTCTGGCACGTCTTGACCTTGAACGCAAAG 
WNT3A TCTCTCCGCGGGTGGGACTCTTCCCTGGGAACCGCCCTCCTGATTAAGGCGTGGC
TTCTGCAGGAATCCCGGCTCCAGAGCAGGAAATTCAGCCCACCAG 
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  Appendix 3 
 
Neuronal migration and neurite outgrowth of DISC1-
targeted cells 
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Figure A3. DISC1 disruption does not affect neurite outgrowth but increases neuronal 
migration in vitro. In vitro assay: day 24 neural aggregates were plated onto poly-
ornithine/laminin-coated plates and cultured for 72 hr in neural differentiation media. (A) 
Representative image of a neural aggregate, immunostained as shown. Scale bar = 200 µm.  
(B) Quantification of neurite outgrowth (each dot represents avg of 10 longest neurites from 1 
aggregate, n = 21-69), using Simple Neurite Tracer in FIJI. (C) Migration was measured by 
subtracting average aggregate radius from average radius of migrated cells in FIJI. n = 42-86 
Data represent at least 3 independent differentiations. Mean ± SEM shown, statistics: one 
way ANOVA. ns = not significant, * p < 0.05, **** p < 0.0001. 
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Appendix 4 
 
Proliferation of DISC1 targeted NPCs 
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Figure A4. DISC1 exon 2 disruption increases EdU incorporation in NPCs. NPCs from 
dissociated day 24 neural aggregates were plated and cultured in L (control) conditioned 
media for 24 hours, in the presence of 10 uM EdU for hours 16-20. The proportion of 
EdU+/DAPI+ cells was quantified using CellProfiler. Data represent at least 5 independent 
differentiations. Number of images counted shown in bars. Mean ± SEM shown, statistics: 
one way ANOVA. ns = not significant, * p < 0.05, **** p < 0.0001. 
